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ABSTRACT 
Background: Patients with Coronary Heart Disease (CHD) or Tuberculosis (TB) are 
more likely to have Type 2 Diabetes Mellitus (T2DM). Insulin Resistance (IR) in 
patients with normal glucose may also be a risk factor for these conditions.  
Methods: This thesis explored whether T2DM and IR are risk factors for TB 
enrolled patients receiving TB treatment in the previous year and controls. In 
addition, the thesis explores whether T2DM and IR are risk factors for CHD among 
patients with stable CHD and controls. The studies were based in Saudi Arabia and 
used cross sectional surveys and case controls design. Controls were asymptomatic 
adults attending the TB clinics for labour reasons. All participants were screened for 
fasting plasma glucose (FPG), insulin, glycated haemoglobin (HbA1c) and lipids. 
We assessed the severity of the clinical presentation of TB among patients with 
T2DM, IR and normal glucose. Finally, we described the quality of life of patients 
with CHD among patients with T2DM, IR and normal glucose. 
Results: One hundred seventy-five adults with pulmonary TB and 140 controls were 
recruited (36.6% and 40.7% female and 63.4% and 59.3% male, respectively). 
Twenty-nine per cent of TB cases had T2DM and 22% normoglycemic IR. 3.3% of 
patients were unaware of their T2DM diagnosis. TB was associated with prediabetes 
(AOR 5.112, p = 0.032), low level of risky HDL Cholesterol (AOR 0.316, p = 0.001) 
and non-Saudi nationalities (AOR 4.018, p ˂ 0.001). Former TB cases were more 
likely to eat fast foods (1 – 2 times/week, AOR 2.857 and 2 – 3 times/month, AOR 
3.126, p = 0.026, respectively) and to have a fair or poor diet (AOR 13.518, and 
AOR 37.766, respectively) (p ˂ 0.001). Three hundred twenty-five patients with 
stable CHD and were recruited (29.2% and 39.9% female and 70.8% and 60.1% 
male, respectively). Of these 65% had T2DM and 31.3% normoglycemic IR. Almost 
6% of patients were unaware of their T2DM status. CHD were more likely to have 
T2DM (AOR 4.974, p = 0.034), high FPG (AOR 5.034, p = 0.021), to be male (AOR 
9.950, p ˂ 0.001), aged above 50 years old (p ˂ 0.015), Saudi (AOR 6.879, p = 
0.002), to have primary education (AOR 20.315, p = 0.004), hypertension (AOR 
5.920, p = 0.003) and to take lipid lowering medications (AOR 24.516, p ˂ 0.001) 
than controls. Cases were more likely to have high WHR (AOR 33.997, p ˂ 0.001) 
and diastolic BP (AOR 1.080, p = 0.004) than controls. CHD-IR cases had lower 
quality of life and satisfaction scores with bodily appearance (p = 0.003), overall 
perception of satisfaction with themselves (p = 0.041) and score in the psychological 
domains (p = 0.006) than controls. Patients with CHD and T2DM had lower overall 
scores for quality of life (p = 0.002), satisfaction with bodily appearance (p = 0.012), 
overall perception of satisfaction with themselves (p = 0.015), with access to health 
services (p = 0.049) and satisfaction score with transport (p = 0.027) than controls. 
Conclusion: TB was more prevalent among non-Saudi nationals and males. Patients 
with TB were more likely to have T2DM, and to be prediabetic, but not more likely 
to have IR than controls. More efforts are required to upscale the detection of T2DM 
among TB patients. Patients with CHD were more likely to be male and to have 
T2DM and IR than controls. Patients with CHD and IR had a lower quality of life 
than controls. More efforts are required to upscale the management of T2DM and IR 
among CHD patients. 
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Chapter 1 
Introduction 
1.1. Background 
1.1.1. Diabetes mellitus (DM) 
Diabetes mellitus is one of the oldest known diseases to mankind, with the first case 
reported roughly 3000 years ago in an Egyptian manuscript (1). A clear distinction 
between type 2 (T2DM) and type 1 DM was first made in 1936 (2) and in 1988 
T2DM was first described as being part of a complex metabolic syndrome. T2DM, 
previously known as non-insulin dependent DM, is the most common form of 
diabetes, characterized by relative insulin deficiency, insulin resistance (IR) and 
hyperglycaemia (3) and is the result of interactions between behavioural, 
environmental and genetic risk factors (4). 
After World War II, Western hemisphere countries became more affluent and 
experience significant lifestyle changes and this demographic  and epidemiological 
changes led to a shift from communicable to non-communicable diseases (5). 
Developing countries have followed the same pattern, with epidemiological and 
demographical transitions having happened quicker than expected in recent decades 
(6). 
T2DM is a combination of reduced insulin secretion and insulin resistance (IR). The 
latter being the inability of the body to utilize glucose in the presence of insulin. The 
risk of T2DM can be increased by obesity, a family history of T2DM and lifestyle 
and it is more common among some ethnicities. Irregular but increased levels of 
blood glucose that are lower than the T2DM cut-off are is known as pre-diabetes (7). 
Individuals with pre-diabetes have a greater risk of T2DM, but its onset can be 
2 
prevented or delayed by increased physical activity, lowering body weight and a 
controlled diet. Therefore, the global rise in T2DM incidence is impacted by the two 
important factors of a lack of physical exercise and unhealthy dietary habits (8). 
1.1.2. Insulin Resistance (IR) 
Insulin is a hormone produced in the pancreatic islets of Langerhans by the beta 
cells. This peptide hormone is responsible for maintaining the normal levels of blood 
glucose, enabling the cellular uptake of glucose and regulating the metabolism of 
protein, lipids and carbohydrates, using its mitogenic effects to promote cell growth 
and division. In 1889, two German scientists, Minkowski and von Mering, 
discovered insulin in animal experiments and demonstrated that removing the 
pancreas led to the severe development of diabetes (9, 10) through a substance that 
dealt with metabolic control. Their hypothesis was later refined by demonstrating 
that destroying the islet of Langerhans had the same effect associated with diabetes. 
Minkowski and Zuelzer attempted to isolate the missing substance from the islet of 
Langerhans, as did Scott in the United States of America (USA), however, their 
attempts produced inconsistent results. De Meyer of Belgium proposed the name 
‘insulin’ in 1909, and Schaefer also proposed the same name in 1916 (10). 
In 1928 it discovered that insulin was a polypeptide and its amino acid sequence was 
identified in 1952. Insulin is a dipeptide with A and B chains connected by 
disulphide bridges and a total of 51 amino acids with a molecular weight is 5802 and 
an iso-electric point of pH 5.5. There are 21 amino acids in the A chain, while there 
are 30 amino acids in the B chain. The N-terminal helix of the A chain is linked to 
the C-terminal helix that it is anti-parallel and the B chain contains a central helical 
fragment. The A and B chains are joined together by two disulphide bonds that join 
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the helices of the N- and C-terminals in the A chain to the B chain via its central 
helix. In its inactivated form (proinsulin), a connecting peptide forms link between 
the N-terminal of the A chain and the C-terminal of the B chain (10, 11). 
The definition of IR is the presence of an elevated or normal insulin levels that give 
rise to weakened biological reactions indicating that there is sensitivity impairment to 
insulin-mediated glucose disposal (12, 13). In the other words, IR is a physiological 
condition characterized by a reduced cell sensitivity to insulin leading to 
hyperglycaemia and T2DM (12). There are tissue variances regarding sensitivity and 
insulin dependence, and the IR syndrome echo the composite effects of additional 
insulin and mutable resistance to its action (10, 13). IR plays a significant role in 
numerous diseases, such as polycystic ovarian syndrome (PCOS) (14), hypertension 
(15), cardiovascular diseases (CVD) (16), metabolic syndrome (15), obesity (17), 
T2DM (18) and tuberculosis (TB) (19). 
1.1.3. T2DM and TB 
TB and T2DM have co-existed for centuries and share comorbidities. The 
Phthisiologia, written by Richard Morton in 1694, already indicated the link between 
these conditions had been known since Roman times. In the year 600 Common Era 
(CE), (20) the Indian physician Susruta was aware of this link, and in 800 CE, 
Avicenna commented that phthisis often complicated diabetes (21). 
It was also noted by Root (22) that ‘‘in the latter half of the 19th century the diabetic 
patient appeared doomed to die of pulmonary TB if he succeeded in escaping coma’’ 
while Bouchardat (23) mentioned ‘‘at autopsy every case of diabetes had tubercles 
in the lungs’’ (24). 
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Although by the start of the 20th century it was apparent that the connection between 
T2DM and TB was of major concern for clinicians, the effect of T2DM on TB was 
disregarded after the development of treatment programs that were potent for both 
diseases (25, 26). At present, however, there has been a drastic change over recent 
decades with a global re-emergence of the T2DM-TB association due to the 
expansion of T2DM in low and middle income countries (LMIC) (24) in areas where 
TB is still highly prevalent (25). There was an estimated 10 million TB incident 
cases in 2017, resulting in 1.6 million deaths (27), while T2DM, the seventh leading 
cause of death in 2016, affected 422 million in 2014, with an estimated 1.6 million 
deaths in 2016 (27). It is anticipated that by 2035 the number of individuals with 
T2DM will rise to 592 million (28) with 80% of them living in LMICs where TB is 
prevalent (28, 29). 
The risk of TB rises threefold in patients with T2DM (30, 31). Furthermore, it 
enhances an individual’s vulnerability to Mycobacterium tuberculosis (Mtb) 
infection and disease development (31). T2DM impairs the necessary immune 
responses required to fight progression from infection to clinical disease, as the 
adaptive and intrinsic responses are directly compromised. Patients that have T2DM 
can have renal failure, impaired cell-mediated immunity, pulmonary 
microangiopathy and micronutrient deficiency and these factors increase an 
individual’s susceptibility to developing TB (31-33). Studies conducted around the 
world have indicated that 12 - 44% of patients with TB have T2DM (34-39). 
1.1.4. T2DM and CHD 
A major underlying factor in CVD, the highest cause of mortality and morbidity in 
the world, is IR. Margaret Albrink was one of the first researchers to identify a group 
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of factors linked to a higher risk of CHD, which included hypertriglyceridemia and 
obesity (40), while Berson and Yalow as developed insulin radioimmunoassay 
methods that allowed the observation that the majority of patients with T2DM were 
hyperinsulinaemic. These developments allowed Albrink, Farquhar and Reaven et al 
(41) to outline the concept of an IR syndrome and its association to CHD and 
hypertriglyceridaemia. The following decades brought forward several studies that 
showed hyperinsulinemia was regularly linked to CHD. These studies were enhanced 
more recently in a validation by researchers in the Insulin Resistance Atherosclerosis 
Study (IRAS), showing the association between atherosclerosis and a direct measure 
of IR (16, 42). Furthermore, the protective role of the high-density lipoprotein (HDL) 
were found in the 1970s (16, 43), along with the classification of low-density 
lipoproteins (LDL) in the following decade, which led to the classification of 
dyslipidaemia, a pattern that is a typically central feature of the IR syndrome. 
Welborn et al added the observation of the importance of hypertension to 
hyperinsulinemia in the 1960s (44). Lastly, the understanding that IR impairs 
fibrinolysis and increases hypercoagulation (45) gave a pathological base for an 
elevation in acute CHD incidence in IR syndrome and atherosclerosis.  
1.2. Thesis importance 
Many studies have shown that patients with T2DM are more likely to have CHD and 
TB (16, 19, 24, 43). However, few studies have compared the prevalence of IR with 
normal glucose status among people with TB or CHD to identify whether IR is a risk 
factor for these conditions.  
IR can occur in individuals with normal glucose (euglycaemic), who despite having 
low sensitivity are able to maintain normal glucose levels by increasing the amount 
of insulin secreted. IR in euglycaemic patients, may still be a risk factor for 
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infectious and non-infectious diseases and increase the severity of disease 
presentation. Patients with IR, therefore, may be at increased risk of communicable 
and non-communicable diseases, such as TB or CHD.   
Both T2DM and IR have increased considerably worldwide over recent decades. The 
prevalence of T2DM in Saudi Arabia is 23.7% among the adult population (47). 
According to the International Diabetes Federation (IDF) website, the number of 
cases of T2DM in Saudi Arabia in 2017 was 3,852,000 while the prevalence among 
adults was 18.5% (48). The map of Saudi Arabia (Figure 1), Saudi population trends 
(Figure 2) and demographic indicators (Table 1) are shown below (46, 47). TB is one 
of the top 10 causes of death globally and it considered to be the first frequent cause 
of death due to infectious diseases, causing 1.6 million deaths and 10 million cases 
worldwide (2017) (48). The Saudi National TB program reports that TB is more 
common in foreigners (26 cases/100,000 individuals) than Saudi nationals (11 
cases/100,000 individuals), and visitors to Mecca are a common source of infection. 
Although T2DM is a known risk factor of TB, the prevalence of euglycaemic IR 
among cases and its role as a risk factor for TB and severity of clinical presentation 
are poorly established in Saudi Arabia.  
CHD is the leading cause of death due to non-communicable diseases worldwide and 
T2DM doubles the risk of CHD. In 2016, 17.9 million deaths occurring were due to 
CVDs, accounting for 31% of all worldwide deaths. Of these mortalities, 85% are 
due to heart attack and stroke (49). Individuals with CHD and T2DM have a higher 
mortality than individuals without T2DM. Although there has been extensive 
research of the link between CHD and T2DM, the link between CHD in euglycaemic 
patients with IR and its role in the severity to the CHD remains ambiguous and has 
not been studied in Saudi Arabia. 
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Figure 1. Saudi Arabia. Figure 2. Saudi Population trends, 
(1950 - 2019). 
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Table 1. Saudi Population 
Indicators Data 
Current population (as of Wednesday, January 23, 2019) 34,252,119 
Population growth rate 2.31 % 
Total area 2,149,690 km2 
Population density 15.9 per km2 
Sex ratio (male to female) 1.23 
Median age (years) 29.8 
Life expectancy 94.7 % 
Young people under 15 years old 10,070,121 
Persons between 15 and 64 years old 23,122,867 
Persons above 64 years old 1,011,424 
Female life expectancy at birth (years) 76.2 
Male life expectancy at birth is (years) 72.2 
Net migration (2018) 190,556 
Percentage of population recognized as a national 68.9 
Percentage of population recognized as a non-national 31.1 
(Population figures are estimates by Country-meters (countrymeters.info) based on the latest 
United Nations data) 
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1.3. Thesis aims 
This study aimed to describe the prevalence of T2DM and IR in Saudi Arabia among 
patients with (a) TB from Jeddah city and (b) CHD from Taif city (Figure 1) and 
compare the characteristics of these patients to (c) apparently healthy controls 
without the disease of interest to investigate the association of IR with TB and CHD. 
In addition, we investigated whether patients with TB and T2DM or IR had different 
severity of the clinical presentation to patients with TB and normal glucose 
metabolism and patients with CHD and T2DM or IR had different quality of life to 
patients with CHD and normal glucose metabolism.   
 
1.4. Study objectives 
1. To describe the prevalence of T2DM and IR among patients with TB in 
Jeddah city, Saudi Arabia.  
2. To describe the prevalence of T2DM and IR among patients with CHD in 
Taif city, Saudi Arabia.  
3. To explore risk factor for TB and risk factors for T2DM and IR among 
patients with TB. 
4. To explore risk factor for CHD and risk factors for T2DM and IR among 
patients with CHD. 
5. To describe whether the severity of the clinical presentation of TB varies 
among patients with and without IR and/or T2DM.  
6. To describe whether the quality of life of patients with CHD varies among 
patients with and without IR and/or T2DM. 
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1.5. Literature review 
1.5.1. Diabetes Mellitus  
Diabetes mellitus is cluster of diseases that cause an impaired insulin use and/or 
render the body unable to produce insulin, which is the hormone that is required by 
the liver, muscle and fat to metabolize glucose. The diagnosis of diabetes is based on 
the detection of elevated concentrations of blood glucose, and this occurs when 
insulin action or insulin secretion is compromised. The classification of diabetes falls 
into two main categories, Type 1 diabetes mellitus (T1DM) and T2DM based on the 
disease’s fundamental pathological process. T1DM, which includes idiopathic and 
immune-mediated subtypes, can be defined as diabetes resulting from the destruction 
of the beta cell, leading to a total deficiency in insulin in time, needing additional 
insulin. T1DM represents around 5 - 10% of all cases of DM in the USA and it is 
commonly referred to as juvenile diabetes as the disease onset commonly occurs in 
adolescence or childhood. The consensus suggests that there is a strong genetic 
component in T1DM, however, the condition is not understood very well.  
Another form of diabetes only occurs in pregnancy and is known as gestational 
diabetes. Most woman with gestational diabetes revert to normal glucose levels after 
delivery, however, its occurrence can be an important risk factor, as gestational 
diabetes signal a higher risk of developing T2DM in the future. 
T2DM accounts for around 90% to 95% of DM cases and usually develops 
inconspicuously, primarily in adults. Historically, T2DM was considered a disease of 
industrialised countries, for example, in the USA. It is estimated that there are around 
18 million diabetes sufferers, corresponding to 9% of the adult population. T2DM, 
nowadays, is a disease that is on the rise globally and is a significant and serious health 
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concern that is posed to health professionals and clinicians, which is largely related to 
large scale lifestyle changes and obesity. According to World Health Organisation 
(WHO), T2DM affected 422 million in 2014, with an estimated 1.6 million deaths in 
2016 (28). It is anticipated that by 2035 the number of individuals with T2DM will 
rise to 592 million (28) if there is no action taken to try and resolve the issue.  
1.5.2. T2DM in Saudi Arabia 
Studies published by the IDF indicate that of the 10 countries with the largest incidence 
of T2DM across the world, five are in the Gulf. These countries are Saudi Arabia, 
Bahrain, Oman, and the United Arab Emirates (UAE). A survey in Saudi Arabia 
regarding chronic metabolic diseases reported that nationally 25% of citizens over the 
age of 40 had T2DM and that in the northern and eastern regions, 50% of citizens aged 
50 and over had T2DM (47). An age specific study of T2DM by Guariguata et. al. to 
establish the incidence of T2DM in 219 countries. Some of these countries are shown 
in Table 2. This process allowed the estimation of the age related incidence of T2DM 
among 20 to 79 year old adults for the years 2013 and 2035 (50). Saudi Arabia had the 
highest estimated prevalence and one of the highest estimates for the number of 
individuals affected by T2DM, which was comparable to countries with much larger 
populations such as Nigeria in Africa. 
Alzaid et. al. performed a further study to describe the trends of T2DM in Saudi 
Arabia (51). This study reported a ten-fold increase in the rate of T2DM and 
predicted that at the current rate T2DM would affect half of the population in the 
near future (Table 3) (51).  
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Table 2. Age-specific prevalence for T2DM in selected countries (50). 
Country 
 
 
Prevalence 
(anp*) (%) 
Prevalence 
(awp*) (%) 
T2DM cases (20 – 79) in 
1000s 
Mean annual 
increment (000s) 
Proportional 
change from 
2013 to 2035 (%) 
Percentage 
change from 
2013 - 2035 (%) 
2013 2035 2013 2035 2013 2035 
Saudi Arabia 20.2 27.1 23.9 24.5 3651 7499 175 53.4 105.4 
India 8.6 10.5 9.1 9.7 65,076 109,028 1998 37.0 67.5 
UAE 10.0 23.1 19.0 19.4 746 2575 83 49.8 245.3 
Yemen 6.1 7.5 8.5 8.7 708 1633 42 88.7 130.6 
Sudan 7.7 8.7 9.6 9.8 1402 2904 68 85.1 107.1 
Nigeria 5.0 5.5 5.8 6.3 3922 8160 193 89.8 108.1 
anp* = adjusted to national population, awp* = adjusted to world population 
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The alarming figures reported in the Saudi literature (51-53) have shown that the 
prevalence of T2DM will continue to grow within the country, and that this increase 
is partly fuelled by the general Saudi lifestyle (52-54). Recently, the Saudi Ministry of 
Health has acted and developed a ten-year (2010 until 2020) plan to control the spread 
of T2DM. The government and all private organisations have been called upon to 
support the plan by raising awareness of the health risks and the risk factors increasing 
the occurrence of T2DM within the population. 
1.5.3. Epidemiology of T2DM 
Saudi Arabia is one of the wealthiest and largest countries within the Middle East 
and North Africa (MENA) region. Its increasing wealth and major socioeconomic 
development since it became one of the leading oil producing countries has resulted 
in increased urbanization and lifestyle changes in the past 50 years. The IDF 
classifies Saudi Arabia as one of the 10 countries with the largest estimated T2DM 
prevalence in the world, with 16.2% prevalence in 2011 and an estimated 20.8% of 
the population having T2DM in 2030 (54, 55). Saudi Arabia also has one of the 
highest incidence of T2DM risk factors, such as obesity (56). 
  
Table 3. T2DM Prevalence in Saudi Arabia over last three decades (51). 
Year Prevalence Rate Author 
1982 2.5% (age > 15yrs) Bacchus et al 
1987 4.3% Fatani et al 
1992 4.6% AbuZeid & Al-Kassab 
1996 9.5% (age > 14yrs) El-Hazmi et al 
1997 17% (age > 30yrs) Al-Nuaim 
2004 24% (age > 30yrs) Al-Nozha 
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1.5.4. Glucose Regulation 
Plasma glucose is a fundamental energy source and its regulation and homeostasis is 
vital for survival. Glucose level can fluctuate widely during exercise and during 
meals. However, an intricate gluco-regulatory system maintains plasma glucose 
within a narrow range of 70 – 150 mg/dL (57). Plasma glucose levels are primarily 
regulated by insulin, which acts on tissue to subdue endogenous production of 
glucose as stimulates the uptake and utilization of glucose. If the secretion or action 
of insulin is impaired, the production of glucose will rise along with a decrease in its 
utilization, increasing the levels of plasma glucose. T2DM is characterized by several 
pathophysiological systems that include surplus hepatic production of glucose, 
insulin resistance and pancreatic beta cell failure. 
Hyperglycaemia, in T2DM can occur with normal and increased levels of insulin in 
circulation and this is due to the target cell developing resistance to the insulin 
effects. Tissue resistance becomes difficult to overcome even with elevated insulin 
levels. A host of complex environmental and genetic factors combine in the 
development of T2DM; however, the exact cause of the disease is still unclear.  
1.5.5. T2DM Pathogenesis   
The natural history of T2DM usually starts with regular glucose tolerance, which 
progresses to IR and compensatory hyperinsulinemia. This state proceeds from an 
impaired state of glucose tolerance to overt T2DM resulting from many genetic and 
environmental factors, ultimately resulting in increased blood glucose due to a 
deficiency in insulin action, secretion or both. Essentially, overt T2DM is the result 
of a deficiency in insulin production to overcome a fundamental abnormality of 
elevated resistance to the action of insulin (58). 
14 
1.5.6. Normal Glucose Homeostasis  
Glucose disposal takes place mainly in insulin-independent tissues; 50% of this is in 
the brain, 25% in the liver and gastrointestinal tissues (splanchnic area). The 
outstanding 25% takes place in insulin-dependent tissues; mainly in muscle tissues 
and to a lesser extent adipose tissues (59). Glucose is produced in the body and 85% 
is endogenously produced in the liver, 15% by the kidney via gluconeogenesis and 
glycogenolysis. When glucose is ingested and absorbed, the concentration of glucose 
in plasma increases and stimulates the release of insulin. Glucose uptake is 
stimulated by both hyperglycaemia and hyperinsulinemia in the splanchnic tissues 
and muscles whilst the endogenous production of glucose is suppressed (60).  
Fat tissues play a small role in glucose disposal, however, this role is key in 
maintaining total glucose homeostasis by controlling the release of free fatty acids 
from stored triglycerides, adipocytokine production and its influence on insulin 
sensitivity in liver and muscles (59, 61-64). Lipolysis is inhibited with increased 
concentrations of plasma insulin, and this leads to a decreased concentration of free 
fatty acids in plasma. This decline intensifies the glucose uptake in the muscles and 
contributes to the inhibition of the production of hepatic glucose (61-64). Glucagon 
is also an important factor in the regulation of glucose after meals (65). Glucagon is 
inhibited after consuming carbohydrates by hyperinsulinemia. This contributes to the 
inhibition of the storage of hepatic glucose instead of oxidation (60). 
1.5.7. Insulin Secretion and Resistance  
The early natural T2DM history presents peripheral resistance to glucose uptake by 
insulin in adipose, liver and skeletal muscle. Although, the concentrations of fasting 
glucose and tolerance of postprandial glucose are typically normal, this is usually due 
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to a compensatory increase in insulin being secreted. A rise in postprandial and 
fasting levels of plasma insulin is an adjustment of the pancreas to overcome tissue 
resistance and maintain normal glucose concentrations (10, 60). However, the 
biochemical pathology of IR is not precisely understood, and it appears to be caused 
by interactions of the environment and genetics. Some phenotypical traits of 
individuals with IR include obesity (especially of visceral cavity), excessive liver and 
skeletal muscle fat. Excessive free fatty acids hinder insulin action on the hepatic 
insulin receptors. Individuals with severe IR and compromised beta cell function 
and/or mass, will have insufficient production to overcome tissue resistance and the 
production of hepatic glucose begins to increase irregularly (60, 64, 66). The rise in 
blood glucose from normal to the abnormal levels maintain glucose-stimulated and 
fasting plasma levels of insulin persistently high (60). This intermediary state 
between well-defined T2DM and normoglycemia is referred to as impaired fasting 
glucose (IFG) and can be defined by a fasting concentration of blood glucose being 
between 100 – 125 mg/dL or a 140 - 199 mg/dL concentration of blood glucose two 
hours after taking in 75g of glucose in a solution, known as impaired glucose 
tolerance (IGT). In the development from IFG/IGT to T2DM the ability of the beta 
cell to maintain insulin secretion deteriorates progressively (58, 60) due to apoptosis 
of the beta cells, decrease in beta cell mass or dysfunction of the beta cell. Not all 
individuals with IR and IGT or IFG develop T2DM and able to maintain an 
indefinite state of hyperinsulinemias, there are genetic polymorphism relative to the 
function of the beta cell. 
1.5.8. Hypoinsulinaemia and T2DM 
T2DM can also manifest without the presence of insulin resistance. T1DM is 
differentiated from T2DM without IR because of the rapid loss of beta cells, usually 
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in early life, whereas in T2DM beta cells are compromised gradually and usually at 
an older age. 
1.5.9. Causes of Impaired Insulin Secretion in T2DM 
Evidence from twin and genome-wide studies strongly indicate the dysfunction of 
the beta cell is associated to genetic background (67-73). The secretion and synthesis 
of insulin decreases due to the glucotoxicity, when beta cell are persistently exposed 
to high glucose concentrations (58) and lipotoxicity. Although the short term 
exposure to free fatty acids (FFAs) stimulates insulin secretion, the long term 
exposure, generally in an obese phenotype of IR, triggers beta cell function 
impairment, oxidative stress and inflammation (60). Other factors include the deposit 
of amylin in the beta cell and incretin resistance, which are gut hormones responsible 
for triggering the secretion of insulin (60).  
1.5.10. Insulin Resistance and T2DM 
Hyperglycaemia and insulin support glucose disposal by three close-knit mechanisms 
including suppressing endogenous glucose production, stimulating the uptake of 
glucose via the splanchnic tissues and stimulating the uptake of glucose via 
peripheral tissues (mainly muscle). Glucose produced in the liver is vital to meet the 
brain’s requirements (58, 59). Ingesting carbohydrates allows glucose absorption 
stimulating the secretion of insulin into the portal vein and uptake by the liver to 
suppress the output of glucose. If the liver does not use insulin appropriately, glucose 
production continues, causing an excess state of fasting plasma glucose (FPG). In a 
basal state, the splanchnic tissues are also insensitive to glucose. When glucose is 
ingested, it enhances the uptake of glucose by the splanchnic tissues (60). The main 
site of insulin-stimulated glucose disposal is the skeletal muscle tissue, accounting 
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for around 80% (74). Individuals with T2DM usually have an imbalance between 
insulin secretion and IR in the muscles and liver resulting in glucose intolerance and 
fasting hyperglycaemia.  
1.5.11. Diagnosis of T2DM 
The diagnosis of T2DM generally relies on the measurement of plasma or whole 
blood glucose in the presence or absence of symptoms of hyperglycaemia. However, 
T2DM often has an insidious onset and patients with early stages are generally 
symptom-free and often up to one third of patients are unaware of the diagnosis. The 
challenge of screening individuals with high-risk of T2DM remains a public health 
concern. The gold standard for diagnosis is still a random/two-hour post glucose 
load. The oral glucose tolerance test (OGTT) is used to assess elevated levels of 
glucose two hours prior to a carbohydrate load (75-gram glucose), measuring the 
postprandial blood concentration of glucose, with the diagnostic criteria being a ≥ 
11.1mmol/L (200 mg/dL) cut-off. However, with the exception of pregnant women, 
in clinical practice this test is not generally used (75). 
Although T2DM is a syndrome with a continuous spectrum, there is a need for a cut-
off for diagnostic purposes as patients with higher plasma glucose level experience 
clinical complications such as diabetic retinopathy (76, 77). For a fasting test, the 
cut-off point of plasma glucose is ≥ 7.0 mmol/L (126 mg/dL). Unless there are clear 
symptoms such as explicit hyperglycaemia and acute metabolic decompensation, the 
test is replicated on another day to confirm the diagnosis (78), as it has a lower 
reproducibility than the OGTT in some cases (79, 80). Glycated Haemoglobin 
(HbA1c) levels can also be used for T2DM screening (81), although it can be less 
sensitive than the OGTT and standardized laboratory techniques still vary (78). 
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The American Diabetes Association (ADA) state that each test should be confirmed 
using the same method or an alternative test on a later date (82). If the later date is 
confirmed, an FPG should be ≥ 126 mg/dL, after ≥ 8-hour or overnight fasting. 
Patients with glucose > 200 mg/dL, a non-fasting glucose assessment above this 
level is thought to be indicative of T2DM when classic symptoms are observed. To 
distinguish normoglycemic individuals from patients with impaired glucose 
homeostasis or T2DM, the diagnostic cut-points in Table 4 are used. 
Table 4. Diagnostic Criteria for T2DM 
 FPG 
Random Plasma 
Glucose 
OGTT 
Diabetes 
≥ 126 mg/dL 
(7.0 mmol/L) 
≥ 200 mg/dL 
(11.1 mmol/L) 
plus symptoms 
≥ 200 mg/dL 
(11.1 mmol/L) 
Impaired 
Glucose 
Homeostasis 
(prediabetes) 
100 mg/dL (5.6 
mmol/L) to 125 
mg/dL (6.9 mmol/L) 
- 
140 mg/dL (7.8 
mmol/L) to 199 
mg/dL (11.0 
mmol/L) 
Normal 
< 100 mg/dL (5.6 
mmol/L) 
- 
< 140 mg/dL (7.8 
mmol/L) 
Source: The American Diabetes Association (83) 
1.5.12. HbA1c 
Glucose binds irreversibly to haemoglobin generating glycated haemoglobin. The 
form of glycated haemoglobin in circulation mostly haemoglobin A1 (HbA1) which 
comprise haemoglobin A1a, A1b and A1c. The main sub-fraction is HbA1c, which 
directly reflects the average levels of blood glucose over the circulating lifespan of 
haemoglobin. Red blood cells have a half-life of 120 days and HbA1c mirrors the 
average level of blood glucose for the previous 8 - 12 weeks (84). 
HbA1c test gives a reliable perspective of glycaemic control and does not require a 
carbohydrate challenge or fasting blood tests. However, HbA1c is considered to 
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underestimate FPG (85) with inter-individual variation with post-prandial, random 
and fasting glucose (85, 86). However, intra-individual HbA1c variation is negligible 
(85, 87, 88). The ADA does not recommend HbA1c for screening but recommends 
using the test to assess glycaemic control in clinical settings, where it has become the 
standard to monitor patients. The normal HbA1c range is 4 - 6%. Patients with 
T2DM should have levels ≤ 8% (84), as individuals above this threshold have a 
higher risk of nephropathy, neuropathy and retinopathy (75). 
1.5.13. Modifiable risk factors for T2DM 
1.5.13.1. Diet 
For many years nutrition and diet have been known to be significant risk factors for 
the development of T2DM. However, specific nutritional factors are not clearly 
outlined in the development of T2DM and there is considerable disparity in the 
connection between carbohydrate consumption and amount of dietary fat as risk 
factors (89). Commonly, the western dietary patterns characterized by excessive 
intake of processed/refined/red meat, fried foods, refined grains, saturated fats, 
deserts and sweets and sugary drinks are considered contributing elements to the 
development of T2DM (90, 91). Studies among Hispanic Americans undertaken 
plant-based diets have shown the diet results in a lower risk of T2DM than controls 
(92). In Saudi Arabia, diabetic patients consume high daily levels of refined sugars, 
especially in tea, throughout the day (93) and traditional foods are rich in 
carbohydrates and calories. In addition, the emergence of fast food outlets are 
becoming increasingly popular, increasing the risk of T2DM (94). The Saudi 
population also has a large consumption of dates, which are home-grown and rice 
dishes covered with meat contain high levels of fats and carbohydrates (95, 96) and 
one quarter do not consume the recommended amount of fruits and vegetables (97). 
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1.5.13.2. Alcohol 
Alcohol consumption in an independent risk factor that increases or decreases the 
risk of T2DM depending on the amount consumed with a U-shaped relationship. 
Moderate consumption of alcohol is associated with a reduced prevalence of T2DM 
(98). Although a number of studies in men and women have described a robust and 
independent inverse link between alcohol consumption and the risk of developing 
T2DM (99-102), a study in Australia reported that there was no objective connection 
between the consumption of alcohol as a T2DM risk factor (103).  
1.5.13.3. Coffee 
Recently, studies have explored whether coffee is associated with the development of 
T2DM, with most studies reporting an inverse association in several ethnic groups 
(104-106). This association has not been reported in SA.  
1.5.13.4. Smoking 
Smoking is linked to an impaired fasting glucose, glucose intolerance and poor 
T2DM control (107-114). The US Centers for Disease Control indicate that smoking 
could lead to T2DM and that smokers are more likely (30 - 40%) to develop T2DM 
than non-smokers (115). A prospective study over 14 years by Jee et al. on 1.2 
million 30 - 95 years old Korean males and females found that smoking correlated 
with an increase of T2DM.  Males smoking ≥ 20 cigarettes per day had a greater risk 
of T2DM than non-smokers (111). Smoking is also widespread in SA, with over 15 
billion cigarettes being smoked each year and is the fourth tobacco importer in the 
world, with 17% of smokers being high school and 14% university students, 23% 
adults and 25% elderly (116). Studies in Saudi Arabia have reported that T2DM and 
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smoking habits are statistically associated, with diabetic subjects being heavier 
smokers than subjects without T2DM (113). 
1.5.13.5. Overweight/ Obesity 
Obesity is associated with an amplified risk of T2DM (112, 117) and affects IR 
(112), with 80% - 90% of patients with T2DM being overweight (97, 118). Al-
Quwaidhi et al. studied obesity trends in adults in Saudi Arabia between 1992 and 
2022, reporting that obesity had increased by 14% among adults, from 22% in 1993 
to 36% in 2005.  If this trend continued, 41% of men and 78% of women will be 
obese by 2022 (119). Murad et al. reported the increased T2DM prevalence within 
the Saudi Arabia population was associated to the obesity levels and physical 
inactivity (112). 
Studies in adults ≥ 30 years old followed over > 10 years indicate that body mass 
index (BMI) is a key indicator of T2DM, with a BMI of 27.8 (in any given year) or a 
BMI > 25 over 10 years being predictors of T2DM (120). In Saudi Arabia, obesity 
was not originally linked to T2DM (93); however, further studies have reported that 
individuals with T2DM are more frequently overweight (65%) than those without 
T2DM (26%) (121) and that both diabetic males (49%) and females (73%) have 
more overweight/obesity than non-diabetic (38% and 34%, respectively) (122). 
1.5.13.6. Physical Activity 
Glucose metabolism is influenced by physical activity and glycaemia and insulin 
responses in athletes are lower after a glucose load. Conversely, inactivity is linked 
to higher insulin levels and abnormal glucose tolerance (123). In African-Americans, 
there is a strong association between moderate physical activity and a reduced T2DM 
risk, with the risk being a third lower (124).  
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The lack of physical activity is associated with T2DM (52, 107, 109, 125-127) and 
this is highly prevalence in the Saudi population (97, 107, 126, 128, 129). In a study 
of 450 Saudis participating in a cross-sectional survey at King Khalid University 
Hospital, Riyadh, 82% were not physically active and females were less active than 
males (88% and 72%, respectively) (130). A epidemiological health survey of  
117,395 participants 30 – 70 years old found 93% of males and 98% of females did 
not do significant physical activity (128). The lack of exercise is often associated to 
the dry and hot climate, especially in Riyadh, which encourages sedentary 
behaviours (93, 131). In contrast, in the southwest region of Al-Baha, there is a lower 
occurrence of T2DM in males which may be due to males working in farms and 
being more physically active (122). 
1.5.13.7. Socioeconomic status (SES) 
T2DM is often associated with affluence. However, low socioeconomic status is a 
risk factor for T2DM. Poverty is associated with consumption of cheap and calorie 
dense foods and obesity. Other factors have also been postulated including lifestyle, 
lack of access to recreational services in Middle-Income Countries, a higher 
prevalence of depression and stress (132, 133).  
1.5.13.8. Acculturation 
Acculturation, which is the process where immigrants integrate and embrace the 
behavioural and lifestyle traits of the country. It is complex, dynamic and 
multidimensional. The Honolulu Heart Program (HHP) evaluated acculturation using 
three factors; the place of birth (Hawaii vs. Japan), dietary habits and the number of 
years lived in Japan and found an inverse association between the prevalence of 
T2DM and the traditional lifestyle of Japan (134). A further study, the San Antonio 
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Heart Study, established a linear decline in T2DM and obesity in Mexican 
Americans with high acculturation (135) and another study found that Mexicans born 
in the USA who were less assimilated to the USA lifestyle had a higher risk of 
developing T2DM in comparison to English speaking, US born Mexicans (136). The 
prevalence of T2DM in Mexican Americans was lower among the more acculturated 
their behaviours, attitudes and values (137). Furthermore, in Michigan, a lack of 
acculturation by Arab Americans was a significant T2DM risk factor (138), but in 
Texas, high acculturation by Filipino Americans was a T2DM risk factor (139). In 
Virgin Islands, Afro-Caribbean immigrants highly acculturated had high IR and this 
was a risk factor for T2DM (140). 
1.5.14. Non-Modifiable Risk Factors 
1.5.14.1. Genetic factors 
Although there is a strong association of genetic defects and family clustering with 
T2DM (141), the specific defects responsible for most cases are not yet identified 
and genetic differences can vary with ethnicity. Several genomic studies have aimed 
to identify genetic constituents associated with T2DM. A literature review of Asian 
and European populations found around 60 loci linked with T2DM. The large 
number of genetic variants suggests that numerous genes are involved. However, to 
date the loci identified only represent around 10% of heritable T2DM (142).  
First-degree relatives of individuals with T2DM have a higher incidence of the 
disease (143). Stratification analysis on Pima Americans suggests that inheriting a 
single co-dominant gene was attributed to prevalence of T2DM (144). An 
investigation into T2DM and familial aggregation showed that 60% of adults with 
T2DM have a family history with at least one first-degree relative being diabetic 
(145).   
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Studies on Saudi populations indicate that fifty Single Nucleotide Polymorphisms 
(SNPs) give a greater risk of T2DM. However, of these 50 SNPs only 12 were 
replicated as risk factors in follow on studies. The inability to replicate the remaining 
SNPs could be explained by the small sample size of the studies’ sample size ranging 
between 185 and 2401 (146-151). The largest of these studies (149) (2401 
individuals) examined 38 genetic variants and found eight associations. The range of 
effects of variants that gave rise to a larger T2DM risk had a greater variation range 
and this was susceptible to the sample size and method used. In a further study of 
300 Saudi women with T2DM, 70% had a family history of T2DM (152).  
1.5.14.2. Age and Gender 
T2DM risk increases with age. T2DM incidence is low before the age of 30 years 
and above this age increases dramatically (153). Lee & Park reported that 38% of the 
population worldwide over 65 had T2DM (154). This prevalence is consistent with 
findings in Saudi Arabia where T2DM incidence increases significantly with age 
(107, 155). Although T2DM prevalence was seen to be more commonly in women in 
the first half of the 20th century, the current global prevalence is almost equal among 
men and women (156). Although T2DM prevalence in the US is still higher among 
females, in other countries such as India the prevalence is greater in males (157). The 
gender differences across different societies is often a reflection of the frequency of 
physical activity and obesity and this varies across backgrounds and culture (158). In 
a national household health survey of the Saudi population from all Saudi Arabia 
regions (eastern, western, southern, northern and central) reported the crude 
prevalence of T2DM among 30 – 70-year-old residents between 1995 to 2000, 4004 
out of 16,917 subjects, was 23.7% (95% CI 23.1-24.3). The prevalence was higher in 
males than females (26.2% and 21.5%, respectively, p < 0.00001) (159). In Jeddah 
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city, a study of 1420 residents reported that T2DM and prediabetic prevalence 
increased with age, with 46% of males > 50 years and 44% of females having T2DM 
(160). Smaller studies, however, have shown contradictory outcomes with the 
prevalence in males being reported higher than females (94, 161, 162) and vice versa 
(163). 
1.5.14.3. Inflammation and risk of T2DM 
More than twenty years ago, Pickup et al. reported a potential interaction between 
T2DM and inflammation as patients with IR and metabolic syndrome had high levels 
of the inflammatory marker C-reactive protein (CRP) (164). Since then, prospective 
studies corroborated the link between the development of T2DM and CRP. This 
relationship has been shown across several ethnic groups (American, European, 
Finnish, Japanese, Mexican, and Scottish) (165-169). A high CRP is associated by a 
4-fold increase in T2DM risk within the highest CRP quartile (170, 171). Studies on 
African American and US non-Hispanic whites reported that low-grade chronic 
inflammation is linked to increased T2DM risk (172). A relatively small number of 
studies, however, have reported no association between CRP values and T2DM in 
Pima Indians (173) and Mexican nationals (168).  
1.5.14.4. Ethnicity  
The incidence and prevalence of T2DM varies across ethnic groups; as for example 
Native and Mexican-Americans are 2 - 3 times more likely to develop T2DM and 
Aborigine Australians that dwell in urban areas have a greater prevalence of T2DM 
than Australian of other backgrounds (157). In the elderly Hispanics had twice the 
T2DM prevalence than non-Hispanics whites (174).  
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1.5.15. Tuberculosis  
TB is a chronic communicable disease caused by Mycobacterium tuberculosis which 
primarily affects the lungs but can invade any other tissue of the body. One third of 
the global population has been infected with M. tuberculosis (175). TB is one of the 
top 10 causes of death worldwide and main cause of death due to infection in the 
world, with the World Health Organisation (WHO) reporting 1.6 million deaths and 
10 million new cases in 2017 alone (176).  
1.5.15.1. The association of TB and T2DM 
The association of TB and T2DM has been recognised since ancient times. Skeletal 
remains dated back to the 8th millennium BC were affected with TB and diseases 
analogous to what is now known as T2DM (177, 178). Morton’s Phthisiologia 
described that this link was already known in Roman times (179) and that both 
Susruta and Avicenna had reported DM often complicated ‘phthisis’ (180). 
In the early 20th century the co-morbidity of T2DM and TB was often discussed in 
the medical literature (181), but became less frequent with the introduction of anti-
TB treatment and the development of insulin for T2DM. The 1980s, however, 
witnessed a resurgence of joint publications with the increased prevalence of T2DM 
(182). T2DM, a chronic disease as TB, has increased dramatically in recent decades 
in areas that are still affected by TB.  In 2014 it was estimated that 422 million adults 
suffered from T2DM, with an accelerated increase in LMIC accounting for over 70% 
of cases (183). Saudi Arabia is also one of the 10 countries with the highest 
prevalence of T2DM (184) (Figure 3) with a sharp increase since 1989 (185, 186). 
Estimations suggest that by 2040 there will be 642 million cases, the majority being 
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from LMIC where TB is also prevalent (187). The WHO has subsequently identified 
T2DM as a significant, overlooked TB risk factor (188).  
Figure 3. Top ten countries with the highest T2DM age-adjusted prevalence 
according to the IIDF(189) 
 
1.5.15.2. Global TB-T2DM burden  
It is estimated globally that 1 million of the 9.6 million individuals with TB have 
T2DM (190), with the number of patients with T2DM and TB comorbidity is similar 
to the number of cases with TB-Human immunodeficiency virus (HIV) on a global 
scale (191). Harries et al. The response to TB-T2DM, however, has been sluggish 
and uncoordinated compared to the responses to TB-HIV in recent decades (192). 
The association between T2DM and TB has increased especially in places with an 
increased prevalence of both diseases along with a low socio-economic background. 
There are six countries identified by WHO as having a ‘high burden’ for TB among 
the ten countries that recognised to have the greatest T2DM incidence and these 
countries account for 80% of the global TB incidence (Figure 4). For example, some 
countries have a very high T2DM and TB comorbidity (e.g. 54% in South India, 40% 
in the Pacific Islands and 36% in northeast Mexico) (193-196). The risk is also 
present among middle/high income countries such as the United Kingdom (UK), 
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United States (US) and Saudi Arabia (196-199), particularly among population 
subgroups such as those from an Asian background that are already at a higher risk 
of both diseases (200, 201).  
Figure 4. Six of 22 high-TB burden countries are among the ten countries with 
the highest T2DM incidence (202). 
 
The risk of TB increases threefold among patients with T2DM (relative risk 3.11; 
95% CI 2.27 - 4.26) (30), with the risk ratios varying from 0.99 to 7.83. China with a 
growing population of T2DM cases has one of the highest TB burden globally, 
accounting for 17% of the global TB burden, while T2DM affects nearly 100 million 
individuals (203). In 2011, there were 61.3 million cases of T2DM in India along 
with 1.98 million cases of TB (204); while in Indonesia there were 450,000 new TB 
cases yearly and T2DM prevalence ranks 6th in the world (205). 
The 2010 prevalence of TB in the Middle East was 6.2 cases per 100,000 in the 
UAE, while Yemen had 71 cases per 100,000, Kuwait 51 cases per 100,000 and Iran 
and Saudi Arabia had 23 cases per 100,000 population (203). The increased 
prevalence of T2DM in these countries, along with an increase number of 
immigrants from countries with high TB prevalence has made the issue of T2DM 
and TB comorbidity more significant. A review in 2015 of 59 T2DM and TB studies 
of ten Middle-eastern countries reported a co-prevalence that ranges from 4.2% in 
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Iran to 41.1% in Iraq (189). T2DM and TB comorbidity also varies significantly in 
Africa, ranging from 3.35% to 16.4% (203).  
In Saudi Arabia, along with the increased prevalence of T2DM, the morbidity of TB 
remains a significant issue, as control and prevention remains a challenge due to the 
large influx of visitors for events such as Hajj (mass gathering) on a short-term basis 
along with migrant workers (206, 207). Hajj is the largest global event of mass 
gathering where millions of Muslims travel to perform a religious pilgrimage (207). 
The nature of the gathering poses immense opportunities for infectious diseases to 
spread (207), crowding enhances the transmission of TB (206) and pneumonia is the 
most frequent cause of hospitalisation during the Hajj season (208). TB skin test 
conversions for pilgrims travelling to the Hajj are more frequent than among 
individuals travelling to TB endemic areas (209).  
In 2014 - 2015 there were > 6.5 million immigrant workers in Saudi Arabia (210). 
The majority come from high prevalence countries such as Bangladesh, Chad, 
Indonesia, Pakistan, Sudan, Ethiopia, Sri Lanka, Somali and Nigeria (211, 212). 
Figures from 1991 illustrated that there was a ratio of 2:1 for TB in non-Saudis 
versus Saudi citizens (213). Immigrants are more prone to have latent TB infection, 
ultimately having a greater risk of TB reactivation (214). 
T2DM and TB co-morbidity is considerable in the region (Table 5). The prevalence 
of TB within the region was highest in Yemen and although the prevalence of T2DM 
was low, 21% of patients had co-prevalence of both conditions. Co-prevalence 
studies in Turkey, Iran and Saudi Arabia reported co-prevalence ranging between < 
10% and > 30% (189). 
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Table 5. T2DM and TB epidemiology and country specific citations 
Country 
TB 
prevalence* 
(range) 
T2DM 
prevalence 
in the 
20 – 79 
years 
population 
T2DM % 
among 
TB 
patients 
Year 
 
 
Mean age ± 
SD of 
participants 
Yemen 60 (24 – 112) 8.45% 21% 2007 – 2010 < 45 (89%) 
Qatar 37 (11 – 79) 22.87% 5 – 25.5% 1996 – 2009 ≥ 45 (11%) 
Iran 32 (16 – 53) 9.9% 4.2 – 30% 1991 – 2008 34 ± 4 
Iraq 29 (8.6 – 61) 9.5% 41.1% 2012 – 2013 44 ± 5 
Egypt 27 (14 – 44) 16.8% 
16.4 – 
29.3% 
2001 – 2011 52 ± 10 
Kuwait 25 (7.3 – 52) 23.1% 
29.8 – 
35% 
1996 – 2005 47 ± 6 
Turkey 23 (11 – 39) 14.85% 7.9 – 34% 1997 – 2010 37 ± 6 
Lebanon 16 (4.8 – 34) 15.0% No studies   
Bahrain 15 (4.4 – 31) 21.8% No studies   
Saudi 
Arabia 
14 (4.3 – 30) 23.87% 14 – 26% 1989 – 2009 47 ± 13 
Syria 14 (4.2 – 30) 8.91% No studies   
Oman 13 (4.7 – 25) 14.24% 25% 2001 – 2006 20 - > 60 
Israel 7.1 (2.9 – 13) 9.1% 5 – 12.9% 2000 – 2005 50 ± 10 
Cyprus 6.6 (2.2 – 13) 9.3% No studies   
Jordan 5 (1.5 – 10) 11.4% No studies   
UAE 1.3 (0.38 – 2.7) 18.98% No studies   
* per 100 000 population 
The association of T2DM and TB has also been reported from industrialized 
countries. In Barcelona between 4% and 7.2% of patients have both conditions (215), 
while in the UK, a case-control study reported a TB-adjusted OR (odds ratio) of 
patients with a T2DM history of 3.8 (p < 0.05) (216). Numerous studies from the US, 
Australia and Denmark, however, have found that T2DM only marginally increases 
the risk of TB (203), except in Japan where 13.1% of patients had both conditions. 
The latter being attributed to the proportion of elderly population of Japan (23%) 
being higher than in the UK (16%) and the US (12%) (217). 
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1.5.15.3. Profile of patients with TB and T2DM 
TB patients newly diagnosed with T2DM have a different profile to those previously 
diagnosed, as they are more likely to have lower HbA1c, to be younger and male 
(218). Patients with TB and T2DM also have a different profile to patients with TB 
without T2DM, being more likely to be female, obese and older and do not have 
behavioural risk factors associated with TB such as incarceration, consumption of 
drugs or alcohol, more likely to be unemployed and have low education (218, 219). 
1.5.15.4. Directionality of the TB and T2DM association 
Most studies are observational, and it is difficult to infer the directionality of 
association from cross sectional studies. Cohort studies suggests that T2DM 
increases the risk of TB (220). Patients with TB, however, may also have an 
increased risk of developing T2DM, although this uncommonly considered in 
literature (221). A number of studies have described that early phases of TB, have 
impaired glucose tolerance and hyperglycaemia (222). Although this is likely due to 
the inflammatory process reducing insulin sensitivity, it may also signal a higher risk 
of developing T2DM as 20% to 50% of individuals with IGT develop overt T2DM 3 
to 5 years later (222, 223). Deducing the relevance of hyperglycaemia in individuals 
with TB is difficult as it might reverse after TB treatment (222, 223). 
Hyperglycaemia may be a side effect of Isoniazid and Rifampicin treatment (224) or 
stress hyperglycaemia (225) and not a sign of metabolic dysfunction.  
1.5.15.5. T2DM among patients with TB patients in Asian countries  
Global estimates indicate that T2DM is present in 15% of cases of TB  and China 
and India make up 40% of these cases (190). A review on T2DM and TB in 11 
countries through reviewing 33 studies shows that 27 studies reported the prevalence 
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of T2DM in individuals with TB. The prevalence of T2DM in individuals with TB 
varied between 6.3% and 54.1% (Table 6) and the highest association was in India, 
where one study reported 54.1% of those with TB also had T2DM. (203). 
Table 6. T2DM and TB epidemiology by country (203). 
Country 
Estimated TB 
prevalence per 
100,000 
population 
(range) 
Estimated 
T2DM 
prevalence as a 
percentage of 
the population 
aged 20 – 79 
years 
T2DM prevalence among 
TB patients 
Bangladesh 404 (211 – 659) 8.3 37 
China 89 (78 – 102) 9.8 
5.05, 6.3, 12.4, 16.2, 19.9, 
27.9 
India 195 (131 – 271) 9.3 
14.7, 14, 25, 25.3, 29, 33, 
35.5, 54.1 
Indonesia 647 (513 – 797) 6.5 13.2, 14.8 
Democratic 
People’s 
Republic of 
Korea 
552 (150 – 
1210) 
4.4 20 
Malaysia 135 (63 – 232) 17.9 17.7, 28.5, 30 
Nepal 215 (102 – 369) 3.7 9.1 
Pakistan 341 (285 – 402) 8.1 25.9 
Sri Lanka 99 (51 – 164) 8.0 9 
Thailand 236 (161 – 326) 7.1 16.3, 23 
Vietnam 198 (83 – 362) 6.0 8.8 
 
1.5.15.6. TB among patients with T2DM in Asian countries  
The prevalence of TB in individuals with T2DM is fourfold greater than among 
individuals without T2DM (31, 226). A review of studies from China, Bangladesh, 
Korea, Nepal and Pakistan of the prevalence of TB in individuals with T2DM (203) 
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reported the incidence of TB among 17,344 patients with T2DM in Dhaka, 
Bangladesh was twice as high as the incidence in the general population (227). In 
China, TB case notification in patients with T2DM were several times greater than 
the general population (228) and in Yunnan province this risk was three times higher 
than in the general population (229). In Korea, a three-year follow up study shows 
that TB case notifications amounted to 180 cases per 100,000 individuals (230) and 
in Nepal 8% of patients with T2DM had pulmonary TB (231); while in Pakistan TB 
prevalence in T2DM patients was 10 times greater than in patients without T2DM 
(11.9% and 1.7% respectively, p < 0.05) (232). 
1.5.15.7. IR as a risk factor for TB.  
Some populations have a high prevalence of IR and this may increase their 
susceptibility to TB. TB in turn affects insulin production and sensitivity (26). 
Insulin regulates macrophage phagocytosis of Mycobacterium tuberculosis, although 
the potential role of IR as a risk factor for TB has not been described (233). 
Macrophages of patients with IR have a reduced ability to attack the bacilli, which 
may increase the risk of disease progression from latent to active TB (19, 234). 
Furthermore, the underlying mechanisms of IR varies across population and in Asia 
IR, hypertriglyceridaemia and hyperinsulinaemia are observed in individuals without 
high levels of intraperitoneal fat and obesity (235). 
1.5.15.8. Poor glycaemic control 
Poor glycaemic control is a risk factor for TB (234). Studies assessing HbA1c levels 
have reported that increased concentrations are associated with disease progression 
from infection to overt TB (234). In Hong Kong, elderly patients with T2DM (n = 
4,690) and HbA1c > 7% were three times likely to have TB than individuals with 
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HbA1c readings < 7% (HR 3.11; 95% CI 1.63 – 5.92, p < 0.01) (236). In Taiwan, a 
large study of 123,546 individuals reported that participants with poor glycaemic 
control had considerably higher risk of TB than individuals without T2DM (237). 
In Saudi Arabia, studies have reported that nearly 60% of individuals with T2DM 
have poor glucose control (HbA1c > 8%) and less than 20% achieve optimum 
control (HbA1c ≤ 7) (238). Furthermore, amongst patients with T2DM and TB, 73% 
had poor glycaemic control (239).  
1.5.16. Coronary Heart Disease 
Coronary artery disease (CAD), CHD and ischaemic heart disease (IHD) are often 
used interchangeably, although CAD refers to coronary artery atherosclerosis and 
CHD often involves other causes of muscles receiving insufficient blood flow, such 
as pulmonary hypertension or valvular heart disease and IHD is used to indicate the 
appearance of clinical symptoms. In this study the term CHD will be used to 
represent coronary heart atherosclerosis and IHD (240). 
Atherosclerosis affects the walls of the coronary artery vessels and the semi-
permeable barrier that is created by the lining of endothelial cells to allow transfers 
between the artery wall and the blood stream. The process of atherosclerosis can be 
triggered by subtle chemical or physical injuries (the “Response to Injury Theory”) 
(241). Injuries may include stress or physical injury due to hypertension, direct 
trauma, oxidative stress, turbulent blood flow, hyperlipidaemia, inflammation, 
homocysteinaemia and chronic high glucose concentrations. Injured endothelial cells 
trigger a maintained inflammatory response secreting cytokines and attracting T-
lymphocytes and monocytes and cell surface adhesion molecules cause T-
lymphocytes and monocytes to attach to the endothelium. Changing their shape and 
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loosening the tight formations between cells, increasing its permeability to 
leucocytes, lipids and fluids. Lipoprotein particles, LDL, penetrate the arterial wall 
and becomes oxidized with exposure to macrophages, nitric oxide and enzymes (e.g. 
lipoxygenase). Once monocytes reach the intima layer, they differentiate into 
macrophages with intake of oxidised LDL and become laden with lipid, creating 
‘foam cells’. Foam cells eventually go through apoptosis, with lipid accumulating as 
fatty streaks within the intima. The fatty streaks may regress, remain stable, or 
evolve to become atherosclerotic plaques (242). Atherosclerotic plaques grow slowly 
and expand with smooth muscle cell proliferation and migration. The fibrin cap 
matures on the lesion, with the plaque hardening and building up leading to a 
narrowing passage for blood circulation leading to ischemia.  
Conversely, some plaques may develop quickly with a thinner fibrin cap more 
susceptible to rupture. The plaques rupture can lead to blood clots and acute 
thrombosis, initiating the clotting cascade and platelet activation triggering an acute 
coronary syndrome with complete or partial blockage (243, 244).  
1.5.16.1. Ischaemic heart disease (IHD)  
IHD was the main global cause of death in 2010 (245) and the main cause of 
disability and death within the CVDs. IHD is not only prevalent among senior 
citizens of wealthier countries but also among adults of working age and is 
increasingly a health problem of LMICs (246, 247).  
1.5.16.2. Myocardial ischaemia and infarction 
MI is often the initial expression of CHD or appear recurrently in individuals with 
established disease. MI incidence can be used as a proxy to identify CHD prevalence 
(248). WHO estimated that CVDs caused 17.5 million deaths in 2005 worldwide, 
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accounting for 30% of fatalities. Of these, 5.7 million were due to strokes and 7.6 
million to CHD (249). In 2015, this number had increased to 17.7 million, or 31% of 
all fatalities. Of these deaths, stroke and CHD accounted for 6.7 and 7.4 million, 
respectively (250).  
CVD risk factors include T2DM, hypertension, excess body mass, cigarette smoking, 
hypercholesterolaemia and sedentary lifestyle (251). These factors are influenced by 
economic, cultural, social factors and behaviour (249).  
The burden of CVDs, particularly stroke and IHD, varies across the world. While 
industrialised countries have reported declining rates, the risk on LMICs has 
increased and CVD may be the main cause of death by 2020 (249). These variances 
is attributable to factors such as smoking control, healthcare and diet (249, 252).  
1.5.16.3. CVD within the Middle East and North Africa Region 
Socioeconomic growth within the MENA region in the last decades has resulted in 
major lifestyle and diet changes and sedentary living with an increase in risk factors 
associated with CVD (253). The regional number of deaths due to hypertension and 
IHD were 115 and 294 per 100,000 individuals, respectively and the number of 
disability-adjusted life years (DALYs) were 1389 and 3702 per 100,000 population, 
respectively (254). WHO estimated in 2008 that CVD was responsible for 49% of 
fatalities due to non-communicable diseases in Oman and 46% in Kuwait. These 
figures were also high for Bahrain (32%), Saudi Arabia (42%), Qatar (23%) and the 
UAE (38%) (255).  
1.5.16.4. Incidence and prevalence Saudi Arabia. 
In Saudi Arabia IHD and stroke are the second and fourth causes of death, 
respectively (254, 256) and CVD are estimated to account for 42% of total mortality. 
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However, prevalence data is limited. Some studies have reported the prevalence of 
hypertension and CHD are circa 25.5% and 5.5% respectively, and figures vary by 
setting, age and gender (257). 
The large CHD prevalence is attributed to the prevalence of risk factors including a 
typical Saudi sedentary lifestyle, obesity, smoking, hypertension and dyslipidaemia. 
This reflects the higher socioeconomic status of the population in previous decades. 
Hospital-based studies often report that T2DM, hypertension and smoking are highly 
prevalent risk factors among patients with MI (258). 
Studies in the Eastern Province of the country, reported that CHD was associated 
with 26% of all deaths (27% males and 23.5% females) (258, 259) and 21% of the 
population had hypertension, which was more common in divorced women, 
individuals that were older and had low education (260). A further national study on 
obesity highlighted that 28.7% of the population were obese in 2013 (117). A large 
survey on T2DM in 2009 reported the prevalence was 30% in Saudi Arabia, which 
was more common in females above 50 years old (258).  
In Jeddah, one of the cities for this study, 50% of school and university staff were 
overweight; 18.8% smokers and 19.9% hypertensive, with 10.1% having 
hyperlipidaemia. The prevalence of these factors increased with age, particularly 
above 40 years (258, 261). 
1.5.16.5. Risk Factors for CHD 
Over 200 CHD risk factors have been recognised with well-established associations 
with impaired glucose tolerance, high blood-cholesterol, hypertension and smoking 
(262). Conventional risk factors usually aggregate in people with CHD (263). The 
American Heart Association (AHA) indicates the most significant non-modifiable 
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risk factors are heredity, male gender, race and age. While modifiable risk factors 
include T2DM, obesity, physical inactivity, high blood cholesterol and smoking 
(264). 
Ethnic minorities have a higher risk of CHD (e.g. Mexican Americans, African 
Americans, Native Americans) (262). Smoking is also one of the most strong risk 
factors for progression or development of CHD (265) and deaths attributed to 
cigarette smoking are related to the duration and dose (266). Total blood cholesterol 
plays an important role in CHD. The USA Framingham study demonstrated that total 
cholesterol correlated significantly with an increased risk of CHD independently of 
other risk factors (262) although there were significant variations across ethnic 
groups. 
One lipoprotein class LDL Cholesterol also contributes to CHD, with LDL 
Cholesterol oxidation being a major feature, with the risk increasing by 20% when 
LDL Cholesterol is increased by 10% (267). Contrastingly, there is a strong inverse 
relationship between low CHD risk and high HDL Cholesterol levels with the risk 
decrease by 2 - 3% when the HDL Cholesterol serum levels increase by 1% (262, 
268).  
Many prospective and epidemiological studies have reported the independent, graded 
and positive association between hypertension and CHD risk with blood pressure 
over 130/85 mmHg increasing CHD mortality significantly in young men (269). 
Both systolic (SBP) and diastolic blood pressure (DBP) predict a CHD event or risk, 
with a continuous risk increase with higher SBP levels and a lower mortality with 
lower DBP (269). SBP is an independent CHD mortality risk factor in the elderly 
(270). T2DM coupled with hypertension (above 140/90 mmHg) increases even 
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further the risk of CHD (271), while the United Kingdom Prospective Diabetes Study 
described the risk of MI decreased by 11% for every 10 mmHg decline in SBP (272). 
Physical inactivity or the sedentary lifestyles are independent risk factors for CHD. 
Physical activity prevents overweight/obesity, reduces weight, lowers LDL 
Cholesterol and raises HDL Cholesterol levels, lowers blood pressure , and increases 
insulin sensitivity. In addition, to these indirect associations, sedentary lifestyles are 
independent risk factors for CHD (262).  
Physical activity, however, is heterogeneous in duration, energy expenditure, 
intensity and the type of exercise. There is a strong inverse relationship between 
CHD and time spent walking (273), with the risk being halved in men that walked 
more than 1.5 miles each day (274). Sesso et al., reported the risk is reduced 
significantly with vigorous activities in comparison with light/moderate activity 
(275), while Wannamethee et al. reported the lowest age-adjusted relative risk for 
CHD is found in moderately active males, compared to moderately vigorous, 
vigorous, light and occasionally active males (276).  
Obesity is one of the main etiological CHD risk factors through the effects it has on 
decreased glucose tolerance, dyslipidaemia and hypertension (262), with a gradient 
increase in BMI and CHD incidence (277). Central obesity is a better predictor than 
BMI (262). This association has been reported by many large studies such as the 
Honolulu Heart Program in Japanese-Americans (N = 8000) (278) and in Pima 
Indians (279). Obesity is also closely associated with diet. The Mediterranean and 
western diet rich in salt, cholesterol and saturated fats affects hypertension and lipid 
profiles (280), while reviews indicated that diet high in fibre and low in saturated fats 
has positive effects on blood lipid profiles (281). 
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1.5.16.6. CHD Risk Factors in T2DM 
There is a well-established relationship between CHD and T2DM (282). Individuals 
with T2DM or insulin resistance in combination with other risk factors are more 
liable to experience strokes or heart disease (283). T2DM is considered equivalent to 
CHD as they share risk factors, and it has been hypothesised that CHD and T2DM 
have common environmental and genetic backgrounds. The clinical management of 
individuals with T2DM includes management of the same factors for CHD, such as 
adverse nutrition, physical inactivity, obesity/overweight, hypertension, cigarette 
smoking, LDL Cholesterol and atherogenic dyslipidaemia, plus risk markers, such as 
CRP and Homocysteine (Hcy) which may underscore underlying inflammatory 
processes (284). IR, elevated blood pressure, prothrombotic state, atherogenic 
dyslipidaemia and abdominal obesity tend to co-exist at a higher rate in patients with 
both conditions and they have a synergistic effect on CHD. Moreover, controlling 
these risk factors can delay or even avoid CHD (284). 
In T2DM, atherosclerotic CHD and other CVDs are the main cause of low quality of 
life, morbidity and mortality. In patients with T2DM the incidence risk of CHD and 
fatal CHD can be two to four times higher and long-term prognosis is poorer (285). 
Patients with T2DM without MI have a similarly high risk of MI than those that are 
non-diabetic but have had a previous MI (286). The increased risk of CHD in 
patients with T2DM is likely due to a combination of hyperglycaemia with other 
metabolic risk factors (285, 287). 
Patients with T2DM, have more severe and diffuse coronary artery atherosclerosis 
than patients without T2DM and tend to have distinct CHD risk factors. When IR 
and CHD risk factors are found together, the WHO defines this constellation as the 
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‘metabolic syndrome’ (285, 287). The cardiovascular risk profile of T2DM with IR 
is proatherogenic, which incorporates specific prothrombotic and proinflammatory 
abnormalities of vascular functions and endothelial cells, microalbuminuria, 
atherogenic dyslipidaemia, hypertension, abdominal obesity and impaired glucose 
regulation (287). The occurrence of metabolic syndrome in individuals with normal 
glucose tolerance can give rise to a high risk of developing T2DM (288). While 
every element of metabolic syndrome increases the risk of CHD, these elements 
combined lead to a synergistic effect and a threefold rise in the risk of stroke and 
CHD and mortality (289).  
Metabolic syndrome is highly prevalent in Western societies. The USA 2002 census 
reported that 47 million individuals were affected with a prevalence of 24% and 
several studies have reported its frequency increases with age to 44% in the 60 - 69 
year olds (290). Around 85% of patients with T2DM were categorised to have 
metabolic syndrome, compared to 12% of individuals with normal fasting glucose 
(291). 
1.5.16.7. Abnormal lipid profiles  
In patients with and without T2DM, dyslipidaemia is a risk factor for CHD (287, 
292). Dyslipidaemia linked to T2DM is more complicated than an increase of LDL 
Cholesterol. Atherogenicity is linked to T2DM dyslipidaemia could be related to 
apolipoprotein B levels, low HDL Cholesterol plasma concentrations and 
irregularities in lipoprotein subclass distribution and particle sizes (293). Lipoprotein 
subclasses are numerous and of these subclasses the unbalanced number of dense, 
small LDL and HDL particles are believed to form a strong atherogenic profile, as 
they are very susceptible to oxidation (294). Numerous mechanisms are thought to 
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account for atherogenic lipid irregularities of T2DM. Adiposopathy or dysfunctional 
adipose tissue is believed to appear due to a combination of genetic predisposition 
and fat accumulation. In comparison to normal adipose tissue, dysfunctional tissue 
has lower sensitivity to insulin and hormone-sensitive lipase action. Intracellular 
triglycerides are broken down more frequently and increases the amount of 
circulating FFAs (Figure 5a). This process causes fat infiltration of muscles, liver 
and pancreatic β-cells, exacerbating the muscles and liver IR. With prolonged FFA 
exposure the pancreatic β-cell function may become compromised contributing 
towards an increased T2DM risk (285). An increase in hepatic FFAs leads to hepatic 
synthesis of triglycerides, which in turn increase very low-density lipoprotein 
concentrations (Figure 5b), resulting in hypertriglyceridemia as commonly found in 
patients with IR. Subsequently, very low-density lipoprotein (VLDL) is remodelled 
to form small, dense LDL particles (Figure 5d); cholesteryl ester transfer protein 
takes triglycerides found in VLDL and exchanges them with the cholesterol found in 
LDL and HDL producing atherogenic VLDL particles. The kidneys more readily 
clear modified HDL particles and this results in a decrease in the level of HDL 
Cholesterol (Figure 5c). Lipases metabolise the LDL particles that are triglyceride-
rich and this results in small, dense LDL that exhibits elevated atherogenicity (285). 
Figure 5. Hypertriglyceridemia and an atherogenic lipid profile.  
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1.5.16.8. Hypertension  
The combination of T2DM and hypertension is common with 30% of patients with 
T2DM being hypertensive in Europe. This figure is double the prevalence in patients 
without T2DM (295). Individuals with T2DM are predisposed to hypertension due to 
sodium retention, which increases vascular tone and can lead to nephropathy. 
Hypertension in T2DM can be caused somewhat by hyperinsulinemia and IR. 
Moreover, vascular stiffness is affected by age and blood vessels of patients with 
T2DM tend to age at an enhanced speed (296). 
1.5.16.9. Inflammation and T2DM  
Endothelial dysfunction and inflammation are closely associated with T2DM and 
low-grade inflammation reflects the innate immune system activation and the 
development of atherosclerosis and dyslipidaemia (297). Patients with IR and T2DM 
have a continuous acute phase response stimulated by cytokines and inflammatory 
markers, such as Interleukin (IL)-1, IL-6, CRP, plasminogen activator inhibitor (PAI-
1), tumour necrosis factor-alpha (TNF-α), leptin, fibrinogen and angiotensinogen 
(298). Vasodilation is endothelium-dependent, and the vascular environment and 
endothelial cells are impaired by the chronic inflammation, increasing the risk of 
cardiovascular events as endothelial cells induce the expression of the adhesion 
molecules on the cell surface. CRP may cause further tissue macrophages to 
stimulate the production of IL-1 and TNF-α, amplifying the inflammatory response 
(285). Therefore, CRP is associated with the development of T2DM and CHD 
mortality (297, 299, 300). CRP also stimulates PAI-1 and this fibrinolysis inhibitor 
promotes the prothrombotic state induced in obesity (298). T2DM is associated with 
cyclooxygenase-2 (COX-2), CD40 and CD40 ligand (285).  
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1.5.16.10. Hyperglycaemia and oxidative stress  
Hyperglycaemia can stimulate protein oxidation, glycation, lipo-oxidation and 
glycoxidation (301, 302). Elevated glucose levels affect collagen and other 
connective tissues. Patients with T2DM experience a gradual collagen glycation 
which is age-dependent and can be impaired two to threefold faster in patients with 
T2DM (303). Moreover, hyperglycaemia causes the development of advanced 
glycation end products, such as pentosidine and carboxymethyllysine agents 
produced by reducing sugars modifying free proteins via non-enzymatic covalent 
modification. Cell surface receptor of AGE (RAGE) activates AGEs and induce free 
radical oxidation with damaging effect on macrovascular and microvascular 
endothelial cells (304). 
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2. Chapter 2  
Methods 
2.1. Study plan 
This study was based in Taif and Jeddah city in Saudi Arabia. The study enrolled 
patients in two centres, patients attending the King Faisal Hospital in the city of Taif 
and patients attending the Tuberculosis and Chest Diseases Centre in Jeddah city.  
All field work was conducted by me, Fareed Almaleki, with support of my PhD 
supervisors who maintained close communication via email and Skype. Any changes 
that occurred to the protocol were made in consultation with my supervisors 
Professors Luis Cuevas and Geoff Gill. 
2.2. Description of study location 
2.2.1. Taif City.   
Taif is in the Mecca Province in the Western Region of the Saudi Arabia. The city 
has an elevation of ~1,800 m above sea level, with a total area of eight hundred 
hectares and an estimated 2014 population of 1,109,846 inhabitants.  
2.2.2. Jeddah City 
Jeddah is the largest city in the Mecca Province and the largest seaport on the Red 
Sea and is also located in the western region of the Saudi Arabia, with total 
population of 3.4 million. Jeddah is the principal gateway to Mecca and Medina and, 
therefore, receives large number of visitors each year.  
2.2.3. King Faisal Hospital: 
King Faisal Hospital is one of the main referral hospitals in the Western region with 
a bed capacity of 500 for general patients and 300 for Obstetrics and Gynaecology. 
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The hospital has many specialties in various disciplines and departments and is 
accredited by the Saudi Central Board for Accreditation of Healthcare Institutions 
(CBAHI). King Faisal Hospital was selected because most of the patients with CHD 
in the region are referred to this hospital. The hospital belongs to the Saudi Arabia 
Ministry of Health (MOH), which will facilitates conducting my studies under an 
agreement between Liverpool School of Tropical Medicine (LSTM) and the MOH of 
Saudi Arabia. All blood samples obtained for the study participants were processed 
in the hospital laboratory. 
2.2.4. Tuberculosis and Chest Diseases Centre:  
The Tuberculosis and Chest Diseases Centre is in Jeddah and consists of five clinics 
for diagnosis, treatment and follow-up of patients. The clinic has five doctors 
providing clinical services and is headed by a Medical Director. The centre also has 
X-Rays and pharmacy facilities, a nursing department, an infection control and 
quality units and a health education department. The centre provides epidemiological 
surveillance for Jeddah city, examines and diagnoses suspected cases of TB and 
initiates treatment, checking and examining contacts of TB patients, doing annual 
statistical reports for TB and home visits for patients who do not complete treatment. 
In addition, the centre provides therapeutic services for patients with newly 
diagnosed TB and follow patients undergoing TB treatment until they are fully cured, 
and outreach services and education for the patients and their families. The centre 
offers a nutrition aid program for patients with TB. The centre selected for the study 
because all TB patients in the city are referred to this centre with an estimated 350 
new TB patients per year. The centre also belongs to the Saudi Arabia-MOH, which 
facilitated engagement with staff through the agreement between the LSTM and the 
Saudi Arabia-MOH.  
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All blood samples obtained for the study participants at the Tuberculosis and Chest 
Diseases Centre were sent to King Fahad Hospital laboratory. 
2.3. Study design: 
These were two cross-sectional surveys to describe the characteristics of the patients 
with TB and CHD, followed by case control studies to identify risk factors. The 
study took place from November 2016 to June 2017 and included 175 confirmed 
pulmonary TB patients’ ≥ 18 years old registered at TB and Chest Diseases Centre, 
and 325 patients with stable CHD ≥ 18 years old registered at the cardiology 
department at the King Faisal Hospital in Taif city. 
2.4. Methods for each objective 
2.4.1. Objective 1: To describe the prevalence of T2DM and IR among patients 
with TB.  
2.4.1.1.Study design:  
This was a cross-sectional descriptive survey of patients’ ≥ 18 years old registered at 
Tuberculosis and Chest Diseases Centre. Patients eligible to participate were those 
with bacteriologically-confirmed pulmonary TB who had received TB treatment for 
at least two months since diagnosis. Only cases considered to be new TB cases at the 
time of their diagnosis (this is, who have not received treatment before) were 
eligible. A bacteriologically confirmed case was defined as any adult whose sputum 
had acid-fast bacilli in smear microscopy or a positive TB culture. GeneXpert tests 
were not available in the centre at the time of the study. In addition, only patients 
who had responded well to the intensive phase of treatment (first 2 months) were 
selected, to avoid patients with drug-resistance TB that may have had a continued 
inflammation process. Patients were selected while taking the continuation phase of 
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treatment (i.e. after receiving at least two months of treatment) because the 
inflammation associated with TB in the first two months would result in 
inflammation-related IR. Participants were identified from the Tuberculosis and 
Chest Diseases Centre treatment registers under the following inclusion and 
exclusion criteria: 
2.4.1.2.Inclusion criteria  
1- Patients with bacteriologically confirmed pulmonary TB. 
2- Patients aged ≥ 18 and residing in Jeddah city. 
3- Registered at TB and chest diseases centre in Jeddah city and still attending 
the clinic for treatment.  
4- Patients had received at least 2 months of anti-TB treatment and were 
responding clinically to treatment. 
5- Patients accepted to participate when approached at the Directly Observed 
Treatment, Short Course (DOTS) clinic. 
2.4.1.3.Exclusion criteria   
1- Patients with missing contact information and those deported from the country. 
2- Clinical presentation as predominantly Extra-pulmonary TB. 
3- Coexistence of a malignancy. 
4- Known to be pregnant. 
5- Known HIV infection 
Once the participants were identified, they were informed of the study and received 
counselling and guidance and asked if they agreed to participate and signed the 
consent form. A team of trained interviewers performed the interviews at a mutually 
convenient location in the healthcare facilities. Field assistants used a structured 
questionnaire in Arabic and/or English. Data collected consisted of general 
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demographic details such as gender, age, socio-economic status, ethnic group and 
medical history and other potential risk factors for T2DM and insulin resistance. 
Patients were examined to measure height and weight, waist and hip circumference 
and waist-to-hip ratio (WHR). The blood pressure was recorded twice from the right 
arm in a seated position using a Professional Digital Blood Pressure Monitor after 15 
to 30 minutes of rest in 5-minutes intervals. 
2.4.1.4.Sample collection and laboratory tests  
At a mutually convenient date, patients were asked to provide blood samples after 
fasting for 12 hours. A phlebotomist collected 10 ml of venous blood in three 
different blood tubes as follows: 2 ml in an EDTA tube for HbA1c level, 4 ml in 
gold-top (serum separator) tube for chemistry laboratory and 4 ml gold-top (serum 
separator) tube for hormones laboratory. The samples were collected at the 
phlebotomy area of the Tuberculosis and Chest Diseases Centre in Jeddah city and 
then sent to the King Fahad Hospital laboratory in Jeddah for processing. The blood 
samples were used to do the following tests: fasting plasma glucose (FPG), fasting 
plasma insulin, HbA1c and lipid profile including Total cholesterol, LDL cholesterol, 
HDL cholesterol and triglycerides. If the patient had not fasted, the instructions were 
to ask them to return to the clinic the next day after fasting for 12 hours from 8 PM 
until 8 AM.  
The gold standard method for the quantification of IR is the euglycaemic clamp 
technique, however, for the purposes of our study we used the homeostasis model 
assessment-2-Insulin resistance (HOMA2-IR) calculation to quantify IR, as this 
method is more practical as it is less sophisticated. Several tests are combined to 
form the homeostasis model assessment (HOMA) model and it looks at the balance 
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physiologically between the concentration of glucose in the blood and the secretion 
of insulin, reflected by insulin production and the uptake of glucose by tissues, where 
the HOMA2-IR cut off point is < 2. 
Matthews et al. (1995) initially published the HOMA calculation (fasting glucose x 
fasting insulin / 22.5) and in 1998 it was later calibrated as HOMA2-IR. The 
advantages that this new model offered were that the beta-cell percentage and 
sensitivity percentage could be calculated using fasting readings of insulin, 
glycaemia as well as C-peptide. Free software was launched by Oxford University in 
2014, known as the HOMA2 calculator (http://www.dtu.ox.ac.uk/homacalculator/) 
and this allows for a fast and precise HOMA2-IR calculation (305). The automated 
immunoassay test analyser (ADVIA centaur xp) was used to determine the insulin 
level. All patients with normal results were informed of their results via email or 
phone calls. Patients with abnormal results were asked to attend the clinic to discuss 
the results with the clinic doctors.  
2.4.2. Objective 2: To describe the prevalence of T2DM and IR among patients 
with CHD.  
2.4.2.1.Study design:  
This was a cross-sectional descriptive survey of patient’s ≥ 18 years old registered at 
the cardiology department the King Faisal Hospital in Taif city. Patients were 
eligible for selection into the study if they had documented CHD using ECG, 
exercise test followed by angiography and were medically stable. A stable CHD was 
defined as an adult with an established pattern of angina pectoris who was not having 
acute pain, a history of confirmed myocardial infarction (MI), or the presence of 
plaques documented by catheterization. Only patients with stable CHD were 
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enrolled. Participants were eligible under the following inclusion and exclusion 
criteria: 
2.4.2.2.Inclusion Criteria  
1- Patient with stable CHD attending the outpatient clinic. 
2- Patients aged ≥ 18 and residing in Taif city. 
3- Registered at Taif King Faisal Hospital, cardiology department, and still 
attending the clinic for treatment.  
4- Patients accepted participation. 
2.4.2.3.Exclusion Criteria 
1- Patients with missing contact information and those deported from the country. 
2- Known renal disease. 
3- Known hepatic disease. 
4- Smoking more than 20 cigarettes per day. 
5- Known to be pregnant. 
All clinical diagnosis and clinical history were obtained from the clinical records of 
the patients. With regards to the definition of patients with established CHD, we 
identified all patients with a diagnosis of CHD in the hospital records and selected 
those who had a confirmed CHD diagnosis in their medical records. The diagnosis 
was made by staff of the cardiology department of King Faisal Hospital, which used 
the Joint Committee of the European Society of Cardiology/American College of 
Cardiology definitions to diagnose MI and CHD (306). The diagnosis of renal and 
hepatic disease were also taken as recorded in the clinical record of the patients. 
These diagnoses had been recorded by the consultants managing the case, but were 
not confirmed by further tests in this study. 
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Once the participants were identified, they were informed of the study and received 
counselling and guidance, agreed to participate and signed the consent form. A team 
of interviewers then performed the interviews with the participants at a mutually 
convenient location in the healthcare facilities. Field assistants used a structured 
questionnaire in lay Arabic and/or English. Data collected consisted of general 
demographic details such as gender, age, socio-economic status, ethnic group and 
medical history and other potential risk factors for T2DM and insulin resistance. 
Patients were examined to measure height and weight, waist and hip circumference 
and waist-to-hip ratio (WHR). The blood pressure was recorded twice from the right 
arm in a seated position using a Professional Digital Blood Pressure Monitor after 15 
to 30 minutes of rest in 5-minutes intervals.  
2.4.2.4.Sample collection and laboratory tests  
Patients were asked to fast for 12 hours and to provide three venous blood samples as 
described for TB patients and to conduct the same tests. The samples were then sent 
to the King Faisal Hospital laboratory for processing. HOMA2-IR calculator was 
used to calculate IR in all participants. Patients were then classified into normal, 
euglycaemia with IR or T2DM. All the patients received their results using the same 
procedures as described for TB patients. 
2.4.3. Objective 3: To explore risk factor for TB and risk factors for T2DM 
and IR among patients with TB. 
2.4.3.1.Study design:  
This was a case-controlled study in which cases were the same patients with TB 
included for objective 1. A control group was selected, which comprised of patients 
without TB. Controls were individuals attending the same centre, who were being 
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treated for other conditions or to undergo examinations for occupational requests to 
discard TB and who were deemed not to have TB. Controls were selected using 
systematic random sampling by selecting every fifth patient starting from first patient 
without TB attending to the TB and chest diseases centre and being invited to 
participate until the desired sample size was achieved. Controls were deemed not to 
have TB if they were apparently healthy individuals who had been referred for 
examination by the chest physician but had been confirmed  not to have TB because 
their symptoms were acute (less than one week duration or had an alternative 
diagnosis such as asthma; or adults without symptoms who were attending the centre 
to be screened for TB due to having a new employment that require an occupational 
health consultation to exclude TB. Only individuals who had been declared to be free 
of active TB were included. If a participant refused to participate, we invited the 
following participant in the list of attendees. Controls were made to undergo the 
same tests as cases and both groups were examined to establish if they had IR. The 
questionnaire included a comprehensive list of factors associated with risk of T2DM 
and/or IR such as lifestyle, physical activity, diet, BMI, medical history and others. 
We obtained anthropometric measurements (by a nurse of the same gender) 
including height (cm), weight (kg) and waist and hip circumference (cm). BMI was 
calculated as weight (kg)/height² (m²). Participants were eligible under the following 
inclusion and exclusion criteria: 
2.4.3.2.Inclusion criteria: 
1- Patients participating in the survey for objective 1. 
2- Controls were adults attending the TB Centre without TB. 
3- Participant aged ≥ 18 and residing in Jeddah city. 
4- Patients accepted participation. 
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2.4.3.3.Exclusion criteria: 
1- Same as objective 1. 
According to the HOMA2-IR measurement and glucose testing, participants were 
classified as having IR without T2DM. The prevalence of T2DM among TB patients 
in Saudi Arabia is reported in the literature to be between 14% and 26%. This data 
was summarized from 11 studies ranging from 1989 to 2009 with a mean age of 47 
±13 years (189). We expected the prevalence of IR among TB patients to be 35%. Of 
these, 15% would have T2DM. We also expected the prevalence of IR among the 
control group without TB to be 20% i.e. 5% with IR but without hyperglycaemia and 
15% with T2DM.  
2.4.3.4.Blood tests:  
Participants were asked to fast for 12 hours from 8 PM until 8 AM to provide blood 
samples. Patients were then asked if they had fasted and those that did not fast were 
asked to come back the next day. Patients that did not attend were contacted by 
phone or email. The phlebotomist at the phlebotomy area collected blood between 8 - 
10 AM under safety precautions using a vacutainer blood-collection system or a 
large syringe to collect approximately 10 ml of blood. The sample was split into 
three tubes and a carrier transported the samples within two hours of collection using 
a cold chain. The samples were then processed by two laboratory technicians in King 
Fahad Hospital Laboratory in Jeddah. One of the staff belonged to the hormone 
department for insulin estimation and one from the chemistry department for 
glucose, HbA1c and lipid profile including Total Cholesterol, LDL Cholesterol, HDL 
Cholesterol and triglycerides. If the sample was unlabelled or improperly labelled, 
collected in the wrong tube or when the sample volume was not sufficient for the 
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requirements of the test protocol, the sample was rejected, and we contacted the 
patient to come for another blood collection on a convenient day.  
Although lipids and glucose in the UK are measured in mmol/dl and HbA1c 
mmol/mol, the unit used for this dissertation is mg/dl for lipids and glucose and 
percentage for HbA1c since the data were collected in Saudi and these are the units 
used locally. However, converting them to the units used in the UK will be a major 
task and is unnecessary for this dissertation mainly because we compare groups 
rather than absolute values and the data is mostly relevant to Saudi Arabia. 
2.4.3.4.1. FPG: Four ml of venous blood collected in a tube with no additive gold-
top (serum separator) was used for glucose determination based on the 
UV test, enzymatic method with hexokinase using an automated 
chemistry analyser (Roche Cobas C601). 
2.4.3.4.2. Insulin: The blood samples collected in a tube with no additive gold-top 
(serum separator) were used for measuring insulin based on the sandwich 
principle using an automated immunoassay test analyser (Roche Cobas 
E601) 
2.4.3.4.3. HbA1c:  Two ml of blood in a lavender-top EDTA-containing tube was 
used to measure HbA1c based on the immunoassay sensitivity using 
advanced Chemiluminescence Technology (siemens Dimension Exl). 
2.4.3.4.4. Lipid profile: The four ml of blood collected in a tube with no additive 
gold-top (serum separator) was used to establish the lipid profile 
including Total Cholesterol, LDL Cholesterol, HDL Cholesterol and 
triglycerides determination based on the enzymatic colorimetric method 
using an automated chemistry analyser (Roche Cobas C601). 
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2.4.4. Objective 4: To explore risk factor for CHD and risk factors for T2DM 
and IR among patients with CHD. 
2.4.4.1.Study design:  
This was a second case-controlled study in which cases were the CHD patients 
described for objective two. The controls were the same adults attending the 
outpatient’s department of the Tuberculosis and Chest Diseases Centre who were 
deemed not to have CHD. The questionnaire included a comprehensive list of 
possible risk factors for T2DM and/or IR such as lifestyle, physical activity, diet, 
BMI, medical history and others. We obtained the same anthropometric 
measurements as described in objective three. Participants were eligible under the 
following inclusion and exclusion criteria: 
2.4.4.2.Inclusion criteria: 
1- Cases were participants in the survey for objective 2 attending the King 
Faisal Hospital. 
2- Controls were adults attending the outpatient’s department of 
Tuberculosis and Chest Diseases Centre without CHD. 
3- Participant aged ≥ 18 and residing in Taif city. 
4- Patients accepted participation. 
2.4.4.3.Exclusion criteria: 
1- Same as objective 2. 
Adults with T2DM are two to four times more likely to have CHD than those without 
T2DM. The American Diabetes Association (ADA) recognizes T2DM to be one of 
the six main CHD risk factors. The major risk factors for CHD are uncontrolled 
hypertension, triglyceride, and cholesterol and/or poor glycaemic control, lack of 
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physical activity, obesity, and smoking. Subjects with euglycaemia IR or T2DM in 
combination with one or more of these risk factors are more likely to get CHD. To 
determine whether euglycaemic IR is a risk factor for CHD, we enrolled all the cases 
from the cross-sectional survey second objective and controls without CHD. The 
prevalence of metabolic syndrome (MS), as a surrogate of IR, in an adult Saudi 
population is 39.3% (307, 308).  
A previous community-based national epidemiological health survey on Saudi 
population confirmed the clear association of metabolic syndrome with CHD. The 
prevalence of CHD among metabolic syndrome patients was higher (6.7%) 
compared to participants without CHD (4.6%) (P < 0.001) (307, 308). 
A study among Saudi diabetic patients also evaluated risk factors for CHD, 
concluding that the risk of CHD among diabetic patients was between 15 – 30%. We 
expected the prevalence of IR among adult’s CHD patients to be 35% i.e. 20% with 
IR without hyperglycaemia and 15 % with T2DM. We also predicted that the 
prevalence of IR among the adult control group without CHD would be 20% i.e. 5% 
with IR and 15% with T2DM.  
2.4.4.4.Laboratory tests: All Laboratory tests conducted were the same as those 
stated in objective 3. Specimens were collected in King Faisal Hospital 
phlebotomy area and were sent to the King Faisal hospital Laboratory.  
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2.4.5. Objective (5): To describe whether the severity of the clinical 
presentation of TB varies among patients with and without IR and/or 
T2DM.  
2.4.5.1.Study design:  
This was a retrospective case-controlled study. Cases were the patients diagnosed 
with TB who had T2DM, TB patients who had euglycaemic IR and controls (patients 
with TB without IR or T2DM). Participants were eligible under the following 
inclusion and exclusion criteria: 
2.4.5.2.Inclusion criteria: 
1- Patients participating in the survey for objectives 1 and 3.  
2- Cases were patients diagnosed with TB who have T2DM and 
euglycaemic TB patients who have IR. 
3- Controls were patients with TB without IR or T2DM. 
2.4.5.3.Exclusion criteria: 
1- Same as objectives 1 and 3. 
Data on clinical presentation at the time of diagnosis was collected retrospectively 
from the medical records (treatment register) of patients enrolled into objective 1 at 
the Tuberculosis and Chest Diseases centre in Jeddah. TB disease severity was 
assessed using a scoring system modified from previously published studies (36, 
309). A score of disease severity was used as described by Gil-Santana (2016), which 
included the presence or absence of each TB-related symptom (chest pain, sputum, 
cough, sputum with blood [haemoptysis], fever, night sweats, poor appetite, weight 
loss and shortness of breath [dyspnoea]). Cases and controls were assessed according 
to the number of symptoms. Data was extracted from the patient medical records 
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using a structured form including age, gender and symptoms at presentation. The 
scores for cases ranged from 0 to 9 where zero was the absence of any symptom and 
nine the presence of all symptoms. The characteristics used to do the scoring were 
those listed above. Participants with a score ≤ 3 were classified as group-1; a score 4 
- 6 as group-2 and a score 7 - 9 as group-3. At the time of interviewing the patients 
we completed any data that were missing. The severity score for the control group 
was assessed using the same scoring system. 
2.4.6. Objective (6): To describe whether the quality of life of patients with 
CHD varies among patients with and without IR and/or T2DM.  
2.4.6.1.Study design:  
This was a retrospective case-controlled study. Cases were the same patients with 
stable CHD who had T2DM and stable CHD patients who had euglycaemic IR. 
Controls were patients with stable CHD without IR or T2DM. Participants were 
eligible under the following inclusion and exclusion criteria: 
2.4.6.2.Inclusion criteria: 
1- Patients participating in the survey for objectives 2 and 4 
2- Cases were patients with stable CHD who had T2DM and those with stable 
CHD and euglycaemic IR. 
3- Controls were patients with CHD without IR or T2DM. 
2.4.6.3.Exclusion criteria: 
1- Same as objectives 2 and 4. 
All participants undertook a questionnaire to assess their quality of life. The scoring 
system used to assess the quality of life was the World Health Organisation quality 
of life assessment-BREF (WHOQOL-BREF), an abbreviated version of the World 
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Health Organisation quality of life assessment-100 (WHOQOL-100) developed by 
the WHOQOL group (310).  
The World Health Organisation Quality of Life (WHOQOL) 100 assessment 
measures several domain areas to assess quality of life. This assessment provides 
detailed information regarding each individual aspect of the quality of life. However, 
in some cases it may not be practical to use, as the WHOQOL-100 can be too long-
winded. Therefore, a field trial form known as WHOQOL-BREF was formulated as 
a shorter quality of life assessment that uses domain-level profiles from the pilot 
WHOQOL assessment data as well as all data available from the WHOQOL-100 
field trial system. The WHOQOL assessment tool allows for comprehensive 
epidemiological research on quality of life (310).  
2.4.6.4.WHOQOL-BREF scoring 
There are four domain scores that can be derived from the profile produced from the 
WHOQOL-BREF quality of life assessment. A further examination on two more 
items is also done separately and these are in the form of two questions. The first of 
these latter questions identifies the overall perception that an individual has on the 
quality of life and the second question examines the view of the individual’s health. 
The four scores were used to indicate how an individual perceived their quality of 
life for each specific domain. The scores for each domain ascended positively so that 
a high score represented a high quality of life. Using the mean score from each 
domain identified the total domain score, and these scores were then multiplied by 
four so that it is possible to compare them with WHOQOL-100 scores. Cleaning and 
checking data, calculating each individual score, computing the domain scores and 
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the procedure for translating the raw scores to converted scores can be found on the 
WHO website; https://www.who.int/substance_abuse/research_tools/whoqolbref/en/ 
2.5. Sample size calculations: 
2.5.1. The sample size for the cross-section survey for TB (objective 1): 
The sample size was calculated using the epi info programme with the menu for 
sample size calculations for population surveys. The reference population size was 
the total number of people attending to the Tuberculosis and Chest Diseases Centre 
per year, the expected proportion of T2DM and IR which was 35% and confidence 
limits of 5%. We assumed that there were 350 adults available. To do a survey with a 
5% confidence limit would require a sample size of 175 adults. After additions for 
potential drop-outs, the sample size was estimated to be 190 participants. 
2.5.2. The sample size of the cross-section survey for CHD group (objective 2): 
The sample size was calculated using the same standard formula for estimating a single 
population proportion in Epi-Info. The reference population size was the total number 
of people attending King Faisal Hospital cardiology department in one year. For the 
cross-sectional survey, we assumed that there were more than 4500 adults available for 
the study and the expected proportion of T2DM and IR to be 35%. To do a survey 
with a 5% confidence limit we required a sample size of 347 adults. After addition the 
potential drop-outs, the sample size was estimated to be 370 participants. 
2.5.3. The sample size for the case control study for TB (objective 3): 
We used epi info sample size calculator for unmatched case-control studies. We used 
a power of 80%, a ratio of 1 case per 1 control and the proportion of TB cases with 
T2DM being 35% compared to 20% for controls having T2DM. We estimated that 
this required 140 cases and an equal number of controls to achieve 80% power to 
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detect an odds ratio of 2.0 at the 95% significance level if 10% or more of the 
general population were exposed to the risk factor. 
Sample size was estimated for T2DM as the main objective. A second sample size 
calculation was conducted for IR, as a secondary objective. We expected that the 
prevalence of IR was 20% in the TB cases and 5% in the control group. To assess 
this difference would require a sample size of 77 participants. This sample size was 
smaller than required for the first objective and was deemed to be too small for the 
multivariate analysis of risk factors. Therefore, we accepted the sample size for 
T2DM.   
2.5.4. The sample size for the case control study for CHD (objective 4):  
The sample size was based on the confidence interval, the power and the ratio of 
cases and controls and percentage of cases and controls expected to be exposed to the 
risk factor. We used a power of 80%, a ratio of 1 case for 1 control and the 
proportion of CHD cases having T2DM being 35% compared to 20% for controls. 
An estimated 140 cases and an equal number of controls was required to achieve 
80% power to detect an odds ratio of 2.0 at the 95% significance level provided 10% 
or more of the general population were exposed to the risk factor. 
Sample size was estimated for T2DM as the main objective. A second sample size 
calculation was conducted for IR, as a secondary objective. We expected that the 
prevalence of IR was 20% in the CHD cases and 5% in the control group. To asses 
this difference would require a sample size of 77 participants. This sample size was 
smaller than required for the main objective and was deemed to be too small for the 
multivariate analysis. Therefore, we accepted the sample size for T2DM. 
2.6. Study outcomes: 
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The following were the main outcomes for each objective:  
Objective 1: The general characteristics of patients with TB and the prevalence of 
T2DM and IR among patients with TB. 
Objective 2: The general characteristics of patients with CHD and the prevalence of 
T2DM and IR among patients with CHD. 
Objective 3: Risk factors for TB and for T2DM and IR among patients with TB. 
Objective 4: Risk factors for CHD and for T2DM and IR among patients with CHD. 
Objective 5: severity score of the clinical presentation of TB among patients with and 
without IR and/or T2DM.  
Objective 6: quality of life scores of patients with CHD with and without IR and/or 
T2DM. 
2.7. Study management: 
2.7.1. Study team 
The study activities were initiated by Prof Luis Cuevas, Prof Geoff Gill and Fareed 
Almaleki, the Tuberculosis and Chest Diseases Centre and the King Faisal Hospital in 
Saudi Arabia. The study was then carried out within the context of routine clinical 
and laboratory practices at the study sites and the clinical procedures were then 
conducted by those providing patient services. 
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2.7.2. Responsibility of study team members 
2.7.2.1.Responsibility of LSTM team 
• Development of the initial protocol. 
• Initial site assessment visit. 
• Coordination of ethical approval applications. 
• Facilitate study initiation. 
• Study monitoring. 
• Development of standardised study forms and record keeping procedures. 
• Development of standardised databases. 
2.7.2.2.Responsibility of King Faisal Hospital 
• Feedback of the initial protocol in collaboration with LSTM; 
• Support data analysis and reporting; 
• Provision of the study support staff in Saudi Arabia. 
• Facilitate the enrolment of patients at its hospital facilities. 
• Record results in laboratory record book. 
• Support and conduct of the following tests: Fasting Plasma Glucose (FPG), 
Fasting plasma insulin, HbA1c and lipid profile including Total Cholesterol, 
LDL Cholesterol, HDL Cholesterol and triglycerides. 
• Support and conduct the study survey. 
2.7.2.3.Responsibility of Tuberculosis and Chest Diseases Centre:  
• Feedback of the initial protocol in collaboration with LSTM; 
• Support data analysis and reporting; 
• Provision of the study support staff in Saudi Arabia.  
• Facilitate the enrolment of patients at its centre facilities. 
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• Record results in laboratory record book. 
• Support and conduct the following tests: Fasting Plasma Glucose (FPG), 
Fasting plasma insulin, HbA1c and lipid profile including Total Cholesterol, 
LDL Cholesterol, HDL Cholesterol and triglycerides. 
• Support and conduct the study survey.  
2.8. Trouble shooting: 
Clinical and laboratory staff of the Tuberculosis and Chest Diseases Centre and the 
King Faisal Hospital approached the study coordinators and in turn the latter then 
approached LSTM. We then arranged for external technical assistance when needed. 
2.9. Study site preparation: 
The Tuberculosis Chest Diseases Centre, the King Faisal Hospital and the LSTM 
investigators reviewed the master protocol with the study team. Any changes to the 
master protocol were put to Prof Cuevas and Prof Geoff Gill at LSTM to be 
approved. 
2.10. Ethical considerations: 
The study was initiated after ethical approval, which was obtained from the LSTM 
Research Ethics Committee and the Department of Preventive Medicine and Ministry of 
Health, Riyadh, Saudi Arabia. Permission from the Saudi Arabia Ministry of Health 
Preventive Medicine Directorate and from health authorities of the study sites was 
received prior to the start of the study. Oral and written information was provided to study 
participants before informed consent was obtained. Those patients with TB and patients 
with CHD that were found to have abnormal results were referred to TB specialist clinics 
and CHD specialist clinics for further investigation and appropriate management. 
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Voluntary consent was obtained from all individual and they were able to exercise their 
free power of choice without the intervention of force, fraud, deceit, or other forms of 
constraint. This right to exercise choice was present throughout the entire research 
process. Study participation was decided by the patients. If the patient did not want to 
be in this study, he/she did not have to participate. This did not affect their routine 
diagnosis and treatment. For patients that did not know they were diabetic patients or 
had IR before the study, we arranged a speedy appointment with the endocrinologist to 
be evaluated and managed. The data collection procedures included elements where 
participants were asked to self-report activities and participants may not have provided 
honest answers. To minimize this risk, we tried to make the participants feel that their 
input was valued and that it would have a scientific importance. 
2.11. Benefits to participants: 
By participating in this study, we were able to detect whether they had T2DM and if 
they were at risk of developing T2DM (raised IR). If we detected that they had 
T2DM, we arranged them to meet a specialist and provided them with a leaflet on 
T2DM risk awareness.  
2.12. Potential harms to participants: 
There were no serious adverse effects in participating in this study. However, the 
interview may have raised discomforting memories. Patients were also required to 
dedicate some time for the interview to take place. There was an appropriate room 
with comfortable chairs provided and we ensured that the interviewer adhered to 
academic principles by confirming that the participants were aware of the importance 
and the purpose of this study. The languages used in the interviews were Arabic and/or 
English, and the questions were structured in a manner that was clear and easy for the 
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participants to understand. The participants were free to cycle between the topic 
areas or questions going back or skipping forward to any area. 
The participants also gave blood samples. Blood collecting procedures may have 
caused some minor adverse effects such as local bleeding, haematoma or pain. 
2.13. Training for study staff: 
Training was only required for completion of the questionnaire. We trained the clinic 
nurses when we initiated the fieldwork. 
2.14. Biosafety guidelines for clinic and laboratory staff: 
Health care workers (HCWs) would have been exposed to airborne pathogens as they 
were dealing with TB patients, blood-borne pathogens from needle sticks, sharps 
injuries are primarily associated with HCWs transmission of hepatitis B virus 
(HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). The 
staff were encouraged to follow the TB infection-control measures by the Centres for 
Disease Control and Prevention (CDC) and the local infection control guidelines 
precautions for preventing transmission of blood-born and airborne infections. 
Laboratory workers were responsible for their own safety and that of their co-
workers. 
2.15. Statistical analysis: 
2.15.1. First and Second objectives: 
Bacteriologically confirmed pulmonary TB patients and patients with stable CHD 
were classified as having normal glucose values or T2DM according to their medical 
history, glycaemic status and HbA1c level using the WHO guidelines to determine 
the T2DM diagnostic criteria. Furthermore, IR status was classified according the 
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HOMA2 calculation using the latest version of HOMA calculator which is called 
Homa2-IR. The cut-off point for IR was (< 2.0).  
➢ Diabetic patients were defined as having an abnormal FPG if it was (≥ 126 
mg/dl) [7.0 mmol/L] or an abnormal HbA1c level (≥ 6.5%). 
➢ Euglycaemic participants with FPG (< 125 mg/dl) [6.9 mmol/L] were defined 
as having increased IR if the HOMA2-IR was (≥ 2). 
➢ Participant with FPG (< 110 mg/dl) (6.1 mmol/L), HbA1c level (< 6.5%) and 
HOMA2-IR (< 2) were defined as not having T2DM or IR. 
We used the WHO diagnostic criteria for the diagnosis of T2DM and prediabetic 
state. These criteria have been in place and are used worldwide for nearly a decade. 
Though, there are other guidelines by the American Diabetes Association, we used 
the WHO guidelines because these guidelines are used in Saudi Arabia and the 
doctors use them to interpret the test results and to classify patients. Furthermore, my 
PhD was based in the UK and the diabetes UK supports the use of the WHO 
diagnosis criteria. Many studies conducted in Saudi Arabia use the WHO guidelines, 
which would make this thesis findings easier to compare.. 
2.15.2. Third and fourth objectives: 
The outcome measures to describe the association of T2DM and IR were the following 
assumed risk factors: age, sex, BMI, blood pressure, Total Cholesterol, LDL 
Cholesterol, HDL Cholesterol and triglycerides, family history of T2DM, smoking, 
dietary habits and physical activity were also included. Data analysis for this study 
compared the characteristics of patients with and without IR. SPSS software was used 
to input and analyse the data. Univariate analysis and multiple backward stepwise 
logistic regression analyses were conducted to analyse the significant factors 
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associated with the dependent variable. The independent variables were selected on 
the basis of the literature of T2DM risk factors and were analysed using the logistic 
regressions. The results were presented as crude and adjusted odds ratios (AOR) with 
95% CI. Mean ± standard deviation was used to describe normal and continuously 
distributed data. Continuous and ordinal data with outliers or skew distribution was 
analysed using medians, first and third quartiles.  
2.15.3. Fifth objective: 
The outcome measure was the mean severity score of the clinical presentation of TB 
among patients with and without IR and/or T2DM.  
2.15.4. Sixth objective: 
We described the quality of life of patients with CHD among patients with and 
without IR and/or T2DM using the methods described by WHO for the WHOQOL-
BREF questionnaire.
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Figures 6. Flow chart of TB study: 
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Figures 7. Flow chart of CHD study: 
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3. Chapter 3 – TB Results 
3.1. Prevalence of T2DM and IR among patients with TB and IR as a risk 
factor for TB. 
We performed a case control study from November 2016 to June 2017, as described 
in the methods chapter. The study included the 175 patients ≥18 years old with 
confirmed pulmonary TB who had registered at the TB and Chest Diseases Centre in 
Jeddah city, Saudi Arabia, for treatment in the previous year. All patients who had 
received TB treatment for at least two months at the time of enrolment were eligible 
to participate. Participants with TB are called ‘cases’ in this sub-study. One hundred 
and forty controls attending the same centre with respiratory problems other than TB 
or who attended the centre to undergo TB screening to obtain a work permit were 
recruited using systematic sampling. Every 5th patient was selected, starting from the 
first patient attending the centre every day, until the desired sample size was 
achieved. Both cases and controls signed a written informed consent and underwent a 
structured interview and physical examination. 
The demographic characteristics of the participants are shown in table 7. Cases were 
younger than controls with a median age of 33 versus 40 years, respectively (p ˂ 
0.001). The age of cases and controls ranged from 18 to 78 and 18 to 76 years, 
respectively. One hundred eleven (63.4%) cases were male and 64 (36.6%) female, 
compared to 83 (59.3%) and 57 (40.7%) controls, respectively (p = 0.453). Cases 
were more likely to be single (58, 33.1% versus 33, 23.6%, p = 0.012) and to have 
primary education (47, 26.9% versus 21, 15.0%) than controls, but less likely to have 
intermediate (13, 7.4%) or secondary education (33, 18.9%) than controls (32, 22.9% 
and 36, 25,7%, respectively) (p = 0.001). Cases were more likely to work in the 
private sector (34, 19.4%) and to be manual workers (46, 26.3%) than controls (14, 
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10.0% and 27, 19.3%, respectively), while controls were more likely to work in the 
government (19, 13.6%) or to belong to non-employed categories (74, 52.9%) than 
cases (9, 5.1% and 80, 45.7%, respectively) (p = 0.002). 
With regards to the ethnicity, cases were less likely to be Saudi (37, 21.1%) than 
controls (73, 52.1%) (p ˂ 0.001). The ethnicity of the non-Saudi participants is show 
in table (8). Although frequencies are low for each country, there were considerable 
proportions from Somalia (27, 15.4%), Yemen (25, 14.3%), Ethiopia (17, 9.7%), 
Pakistan (16, 9.1 %), Sudan (9, 5.1%), Chad (8, 4.6%), Bangladesh (7, 4.0%), Eritrea 
(6, 3.4%) and the Philippines (6, 3.4%). 
The medical histories of cases and controls are summarised in table 9. Participants 
were asked whether they knew if they had T2DM, hypertension, hyperlipidaemia, 
gestational T2DM or polycystic ovaries and if they were taking medications for these 
conditions. There was no difference between cases and controls in terms of a 
personal history of T2DM or insulin-using T2DM. However, cases were less likely 
to have a family history of diabetes (52, 29.7%) than controls (57, 40.7%) (p = 
0.041). Most relatives with T2DM among cases and controls were first degree 
relatives (48, 27.4% versus 49, 35.0%, respectively, p = 0.148). 
Cases also had a lower prevalence of hypertension than controls (9, 5.1% versus 31, 
22.1%, p ˂ 0.001). Correspondingly, the proportion of cases taking hypertensive 
medications was lower among cases than controls (8, 4.6% versus 23, 16.4%, 
respectively, p ˂ 0.001). Cases were less likely to have hyperlipidaemia (8, 4.6% and 
28, 20.0%, respectively, p ˂ 0.001) and to be taking lipid lowering therapy (5, 2.9% 
versus 17, 12.1%, respectively, p = 0.002). There were no differences between cases 
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and controls regarding the medical history of heart problems, gestational diabetes 
and polycystic ovaries. 
Table 7. Demographic characteristics of cases and controls. 
Demographic characteristics 
N = 315 
Cases 
n = 175 (%) 
Controls 
n = 140 (%) 
p 
Sex Male 111 (63.4) 83 (59.3) 
0.453 
Female 64 (36.6) 57 (40.7) 
Age Range 18 – 78 18 - 76 
˂ 0.001 
Median (IQR) 33 (25 - 45) 40 (28 - 53) 
Age group 18 - 29 71 (40.6) 39 (27.9) 
0.002 
30 – 39 45 (25.7) 23 (16.4) 
40 – 49 22 (12.6) 29 (20.7) 
≥ 50 37 (21.1) 49 (35.0) 
Marital status Single 58 (33.1) 33 (23.6) 
0.012 
With partner/married 105 (60.0) 102 (72.9) 
Divorced/separated 11 (6.3) 2 (1.4) 
Widowed 1 (0.6) 3 (2.1) 
Education No education 19 (10.9) 13 (9.3) 
0.001 
Literacy 36 (20.6) 21 (15.0) 
Primary education 47 (26.9) 21 (15.0) 
Intermediate education 13 (7.4) 32 (22.9) 
Secondary education 33 (18.9) 36 (25.7) 
Higher education 26 (14.9) 17 (12.1) 
Prefer not to answer 1 (0.6) 0 (0.0) 
Education 
group 
Educated 119 (68.0) 106 (75.7) 
0.152 
Uneducated 55 (31.4) 34 (24.3) 
Occupation Governmental 9 (5.1) 19 (13.6) 
0.002 
Private 34 (19.4) 14 (10.0) 
Labourer 46 (26.3) 27 (19.3) 
Unemployed 80 (45.7) 74 (52.9) 
Retired 1 (0.6) 5 (3.6) 
Other 5 (2.9) 1 (0.7) 
Ethnicity Saudi 37 (21.1) 73 (52.1) 
˂ 0.001 
Non-Saudi 138 (78.9) 67 (47.9) 
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Table 8. Ethnicity of cases and controls. 
Country 
N = 315 
Cases 
n = 175 (%) 
Controls 
n = 140 (%) 
Saudi Arabia 37 (21.1) 73 (52.1) 
Somalia 27 (15.4) 6 (4.3) 
Yemen 25 (14.3) 20 (14.3) 
Ethiopia 17 (9.7) 1 (0.7) 
Pakistan 16 (9.1) 6 (4.3) 
Sudan 9 (5.1) 7 (5.0) 
Chad 8 (4.6) 4 (2.9) 
Bangladesh 7 (4.0) 3 (2.1) 
Eritrea 6 (3.4) 4 (2.9) 
Philippines 6 (3.4) 0 (0.0) 
Barmawi 3 (1.7) 1 (0.7) 
India 3 (1.7) 4 (2.9) 
Indonesia 3 (1.7) 3 (2.1) 
Afghanistan 2 (1.1) 2 (1.4) 
Nigeria 2 (1.1) 0 (0.0) 
Nepal 2 (1.1) 0 (0.0) 
Egypt 1 (0.6) 4 (2.9) 
Mali 1 (0.6) 0 (0.0) 
Syria 0 (0.0) 1 (0.7) 
South Asia 0 (0.0) 1 (0.7) 
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Table 9. Medical history of cases and controls. 
Medical history 
N = 315 
Cases 
n = 175 (%) 
Controls 
n = 140 (%) 
p 
T2DM Yes 45 (25.7) 27 (19.3) 
0.066 No 129 (73.7) 108 (77.1) 
Don't know 1 (0.6) 5 (3.6) 
T2DM using insulin (N=45) Yes 10 (22.2) 2 (7.4) 
0.190 
No 35 (77.8) 25 (92.6) 
Family history of diabetes Yes 52* (29.7) 57 (40.7) 
0.041 
No 123 (70.3) 83 (59.3) 
1st degree 
Yes 48 (27.4) 49 (35.0) 
0.148 
No 127 (72.6) 91 (65.0) 
2nd degree 
Yes 6 (3.4) 7 (5.0) 
0.486 
No 169 (96.6) 133 (95.0) 
3rd degree 
Yes 1 (0.6) 1 (0.7) 
1 
No 174 (99.4) 139 (99.3) 
Hypertension Yes 9 (5.1) 31 (22.1) 
˂ 0.001 No 164 (93.7) 106 (75.7) 
Don’t know 2 (1.1) 3 (2.1) 
Takes hypertensive 
medication 
Yes 8 (4.6) 23 (16.4) 
˂ 0.001 
No 167 (95.4) 117 (83.6) 
Hyperlipidaemia  Yes 8 (4.6) 28 (20.0) 
˂ 0.001 No 164 (93.7) 103 (73.6) 
Don’t know 2 (1.1) 9 (6.4) 
Takes lipid lowering therapy Yes 5 (2.9) 17 (12.1) 
0.002 No 169 (96.6) 120 (85.7) 
Don’t know 1 (0.6) 3 (2.1) 
Heart problems Yes 3 (1.7) 2 (1.4) 
0.543 No 171 (97.7) 138 (98.6) 
Don’t know 1 (0.6) 0 (0.0) 
History of gestational 
diabetes 
Yes 5 (2.9) 4 (2.9) 
0.681 No 59 (33.7) 53 (37.9) 
Not applicable 111 (63.4) 83 (59.3) 
History of polycystic ovaries Yes 0 (0.0) 3 (2.1) 
0.052 
No 63 (36.0) 50 (35.7) 
Don’t know 1 (0.6) 4 (2.9) 
Not applicable 111 (63.4) 83 (59.3) 
*Three cases had more than one relative with T2DM, resulting in 55 relatives. 
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The lifestyle and diet of cases and controls are shown in table 10. Participants were 
asked about occupation, monthly income, level of stress, overweight and completed a 
recall of their diet. The monthly income was less than SAR 3000 (GBP 600) in 139 
(79.4%) cases compared to 93 (66.4%) controls and only (5, 2.9%) cases and (13, 
9.2%) controls had an income above SAR 5000 (p = 0.010). Cases were more likely 
to report increased levels of stress (19, 10.9%) than controls (3, 2.1%) (p = 0.009). 
Cases were more likely to report a poor diet than controls (48, 27.4% versus 11, 
7.9%, respectively) and less likely to rate their diet as good (10, 5.7%) than controls 
(76, 54.3%) (p ˂ 0.001). Many more cases ate fast foods more than five times per 
week (25, 14.3%) than controls (14, 10.0%) (p = 0.018). There were no differences 
between cases and controls regarding occupation, family overweight, being 
overweight in childhood, the number of times they ate breakfast, lunch and dinner in 
a week and their description of their food portions sizes. 
The physical activities of cases and controls are shown in table 11. The level of 
physical activity was very low in both groups, with the median number of days doing 
moderate to vigorous activity being zero for both. Only seven of 175 cases and two 
of 140 controls reported to do vigorous activity (medians of 5 and 4.5 days per week 
among these subgroups, respectively) and 30 cases and 17 controls indicated they did 
moderate activity up to five days a week. There were no statistically significant 
differences between cases and controls regarding physical activity.  
Table 10. Lifestyle and diet of cases and controls. 
Lifestyle and diet 
N = 315 
Cases 
n = 175 (%) 
Controls 
n = 140 (%) 
p 
Occupation Sedentary 124 (70.9) 97 (69.3) 
0.812 Moderate 43 (24.6) 38 (27.1) 
Physically demanding 8 (4.6) 5 (3.6) 
78 
Monthly income (SAR) ≤ 3000 139 (79.4) 93 (66.4) 
0.010 
3000-5000 31 (17.7) 34 (24.3) 
5001-10000 5 (2.9) 10 (7.1) 
≥10000 0 (0.0) 3 (2.1) 
Level of stress Low 130 (74.3) 111 (79.3) 
0.009 Medium 26 (14.9) 26 (18.6) 
High 19 (10.9) 3 (2.1) 
Family overweight Yes 25 (14.3) 29 (20.7) 
0.167 
No 149 (85.1) 110 (78.6) 
Don’t know 1 (0.6) 0 (0.0) 
Prefer not to say 0 (0.0) 1 (0.7) 
If yes, who? Father 4 (2.3) 8 (5.7) 0.114 
Mother 16 (9.1) 9 (6.4) 0.376 
Sibling 7 (4.0) 6 (4.3) 0.899 
Other 7 (4.0) 9 (6.4) 0.329 
Overweight as a child Yes 18 (10.3) 14 (10.0) 
0.341 No 152 (86.9) 125 (89.3) 
Don’t know 5 (2.9) 1 (0.7) 
Number of breakfast 
meals last week 
None 6 (3.4) 6 (4.2) 
0.209 1 – 6/per week 27 (15.4) 32 (22.9) 
Always 142 (81.2) 102 (72.9) 
Number of lunch meals 
last week 
None 1 (0.6) 0 (0.0) 
0.446 1 – 6/per week 16 (9.1) 10 (7.1) 
Always 158 (90.3) 130 (92.9) 
Number of dinner 
meals last week 
Never 0 (0.0) 2 (1.4) 
0.106 1 – 6/per week 17 (9.7) 19 (13.6) 
Always 158 (90.3) 119 (85.0) 
Participant self-rating 
the diet quality 
Good 10 (5.7) 76 (54.3) 
˂ 0.001 Fair 117 (66.9) 53 (37.9) 
Poor 48 (27.4) 11 (7.9) 
Fast food consumption 0 - 1/Month 40 (22.9) 52 (37.1) 
0.018 
2 - 3/Month 43 (24.6) 21 (15.0) 
1 - 2/Week 47 (26.9) 31 (22.1) 
3 - 4/Week 20 (11.4) 22 (15.7) 
≥ 5 /Week 25 (14.3) 14 (10.0) 
Food portion size Small 23 (13.1) 15 (10.7) 
0.791 Intermediate 111 (63.4) 90 (64.3) 
Large 41 (23.4) 35 (25.0) 
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Table 11. Physical activity of cases and controls. 
Physical activity 
(days per week) 
N = 315 
Cases 
n = 175 
Controls 
n = 140 
p 
N 
Median 
(IQR) 
N 
Median 
(IQR) 
Vigorous  7 0 (0 – 0) 2 0 (0 – 0) 0.174 
Moderate  30 0 (0 – 0) 17 0 (0 – 0) 0.214 
Walking 175 7 (7 – 7) 140 7 (7 – 7) 0.421 
Minutes walked/day 175 30 (20 – 60) 140 30 (20 – 60) 0.063 
 
A symptom comparison among cases with positive and negative (or not done) TB 
culture is shown in table 12. There was no difference between the two groups except 
that cases with negative/not done culture were more likely to have night sweats (83, 
92.2% versus 68, 80.0%, respectively, p = 0.019). 
Table 12. Symptoms comparison among cases between positive TB culture and 
negative or not done. 
TB Culture 
N=175 
Negative/Not done 
n = 90 (%) 
Positive 
n= 85 (%) 
p 
Chest Pain 64 (71.1) 59 (69.4) 0.806 
Sputum 83 (92.2) 81 (95.3) 0.403 
Cough 87 (96.7) 84 (98.8) 0.654 
Sputum with blood 16 (17.8) 21 (24.7) 0.262 
Shortness of breath 44 (48.9) 35 (41.2) 0.306 
Fever 88 (97.8) 82 (96.5) 0.948 
Night sweats 83 (92.2) 68 (80.0) 0.019 
Poor Appetite 80 (88.9) 73 (85.9) 0.549 
Weight loss 84 (93.3) 79 (92.9) 0.918 
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A comparison of TB cases with positive and negative/not done Acid Fast Bacilli 
(AFB) smear microscopy is shown in table 13. There was no difference between the 
two groups except that cases with positive smear microscopy were more likely to 
have cough than patients with negative/not done smears (132, 99.3% versus 39, 
92.9%, respectively, p = 0.043). 
Table 13. Comparison among cases between AFB Smear-positive and -
negative/not done. 
AFB Smear 
N=175 
Negative/Not done 
n = 42 (%) 
Positive 
n= 133 (%) 
p 
Chest Pain 26 (61.9) 97 (72.9) 0.173 
Sputum 38 (90.5) 126 (94.7) 0.531 
Cough 39 (92.9) 132 (99.3) 0.043 
Sputum with blood 8 (19.1) 29 (21.8) 0.703 
Shortness of breath 17 (40.5) 62 (46.6) 0.486 
Fever 40 (95.2) 130 (97.7) 0.750 
Night sweats 37 (88.1) 114 (85.7) 0.696 
Poor Appetite 38 (90.5) 115 (86.5) 0.494 
Weight loss 38 (90.5) 125 (93.9) 0.664 
 
The anthropometry data of all participants are shown in table 14. Among males, 
cases had lower weight than controls with medians of 64 and 72 Kgs and a median 
difference of 8 Kgs, respectively (p ˂ 0.001). The median BMI among males was 22 
for cases and 26 for controls with a median BMI difference of 4 (p ˂ 0.001). Male 
cases, therefore, were less likely to be obese than controls (13, 11.7% versus 22, 
26.5%, respectively, p ˂ 0.001); to have a lower median waist circumference with a 
median difference of 10 cms and lower hip circumference with a median difference 
of 8 cms (p ˂ 0.001). The median WHR of male cases (0.87) was lower than male 
controls (0.90) with a median difference of (0.03) (p = 0.019). 
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Among females, cases were taller than controls with medians of 159 and 156 cms, 
respectively, and a median difference of 3 cms (p = 0.035). Female cases, however, 
had a lower weight with medians of 56 Kgs and 69 Kgs, respectively, and a median 
difference of 13 Kgs (p ˂ 0.001). Their median BMI was 22 for cases compared to 
28 for controls and with a median difference of 6 (p ˂ 0.001). Female cases, 
therefore, were less likely to be obese than controls (7, 10.9% versus 21, 36.8%, 
respectively), to have a lower median waist circumference with a median difference 
of 3 cms and lower hip circumference than controls with a median difference of 14 
cms (p ˂ 0.001). 
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Table 14. Anthropometry of cases and controls 
Anthropometry 
N = 315 
Male 
P 
Female  
p Cases 
n = 111 
Controls 
n = 83 
Cases 
n = 64 
Controls 
n = 57 
Height (cm) Median (IQR) 172 (167 - 178) 170 (163 -175) 0.065 159 (155 -163) 156 (153 -161) 0.035 
Weight (kg) Median (IQR) 64 (56 -76) 72 (65 -83) ˂ 0.001 56 (47 -68) 69 (60 -86) ˂ 0.001 
BMI* (kg/m2) Median (IQR) 22 (19 -25) 26 (22 -30) ˂ 0.001 22 (19 -26) 28 (24 -35) ˂ 0.001 
BMI* groups 
≤ 18.4 22 (19.8%) 7 (8.4%) 
˂ 0.001 
16 (25.0%) 3 (5.3%) 
˂ 0.001 
18.5 - 24.9 57 (51.4%) 27 (32.5%) 28 (43.8%) 14 (24.6%) 
25 - 29.9 19 (17.1%) 27 (32.5%) 13 (20.3%) 19 (33.3%) 
≥ 30 13 (11.7%) 22 (26.5%) 7 (10.9%) 21 (36.8%) 
Waist (cm) Median (IQR) 83 (76 -94) 93 (82 -104) ˂ 0.001 78 (68 -90) 91 (81 -101) ˂ 0.001 
Hip (cm) Median (IQR) 95 (91 -102) 103 (97 -110) ˂ 0.001 92 (83 -104) 106 (97 -115) ˂ 0.001 
WHR* Median (IQR) 0.87 (0.83 -0.93) 0.90 (0.84 - 0.96) 0.019 0.83 (0.78 - 0.90) 0.86 (0.80 - 0.91) 0.283 
WHR* groups 
Low 70 (63.1%) 42 (50.6%) 
0.207 
27 (42.2%) 18 (31.6%) 
0.468 Moderate 37 (33.3%) 36 (43.4%) 21 (32.8%) 21 (36.8%) 
High 4 (3.6%) 5 (6.0%) 16 (25.0%) 18 (31.6%) 
*BMI = Body Mass index, *WHR = Waist/Hip Ratio 
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The metabolic and clinical characteristics of participants are shown in table 15. 
Variables are presented as medians interquartile ranges (IQR) as they had skewed 
distributions. Cases had lower median triglycerides than controls (94 versus 106 
mg/dL, respectively, p = 0.009) with a lower proportion having high triglycerides 
concentrations (8, 4.6% versus 20, 14.3%, respectively, p = 0.009). Cases also had 
higher median HDL cholesterol (49 mg/dL and 42 mg/dL, respectively, p ˂ 0.001) 
and a lower proportion had at risk HDL cholesterol levels (60, 34.3% versus 76, 
54.3%, respectively, p ˂ 0.001). Hypertension was less frequent among cases than 
controls, with a lower median systolic blood pressure (SBP) (118 mmHg) than 
controls (121 mmHg), although this difference is unlikely to be of clinical 
significance.  
The diabetes status of cases and controls is shown in table 16. The total number of 
diabetic patients was calculated by merging patients with known T2DM (from 
medical history) and FPG test results. Despite being younger, cases were more likely 
to be diabetic patients (51, 29.0%, 95% CI 22.5 - 36.5%) than controls (39, 27.9%, 
95% CI 20.6 - 36.1%), but this difference was not statistically significant at the 
univariate analysis (p = 0.801) (figure 8). Among diabetic patients, a higher 
proportion of cases used insulin (10, 19.6%, 95% CI 9.8 - 33.1%) than controls (2, 
5.1%, 95% CI 0.6 - 17.3%), although the difference was not statistically significant 
(p = 0.061) (figure 9). 
Normoglycemic participants were classified according to whether they had IR using 
a HOMA2-IR cut-off of ≥ 2. Out of 175 cases, 124 had a normoglycemic status 
(71%, 95% CI 63.5 - 77.5%) compared to 101 (72.1%, 95% CI 63.9 - 79.4%) of 140 
controls. Among 124 normoglycemic cases, 27 (22%, 95% CI 14.9 - 30.1%) had IR 
compared to 26 of 101 normoglycemic controls (25.7%, 95% CI 17.6 - 35.4%). 
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There was no statistically significant difference at the univariate analysis between 
normoglycemic cases and controls regarding to diabetic status and IR (p = 0.485) 
(figure 10). 
The total number of patients with metabolic syndrome was calculated according to 
the National Cholesterol Education Program Adult Treatment Panel III Guidelines 
(NCEP ATP III) definition. The proportion of patients with metabolic syndrome was 
lower among cases (45 (25.7%), 95% CI 19.4 – 32.9%) than controls (68 (48.6%), 
95% CI 40.0 – 57.2%) (p ˂ 0.001). 
 
Table 15. Metabolic and clinical characteristics of cases and controls. 
Metabolic/clinical characteristics 
N = 315 
Cases 
n = 175 (%) 
Controls 
n = 140 (%) 
p 
FPG* (mg/dL) Range 68 - 440 55 – 394 
0.155 
Median (IQR) 94 (85 - 118) 94 (83 - 105) 
< 110 121 (69.1) 111 (79.3) 
0.120 110 – 125 15 (8.6) 7 (5.0) 
≥ 126 39 (22.3) 22 (15.7) 
HbA1c* (%) Range 3.9 - 13.6 4.1 - 11.9 
0.291 
Median (IQR) 5.7 (5.2 - 7) 5.9 (5.5 - 6.4) 
< 5.7 83 (47.4) 57 (40.7) 
0.122 ≥ 5.7 – 6.4 45 (25.7) 51 (36.4) 
≥ 6.5 47 (26.9) 32 (22.9) 
Fasting Plasma 
Insulin (µU/ml) 
Range 2.1 - 57.0 2.9 - 57.1 
0.130 
Median (IQR) 10.2 (6.5 - 15.4) 11.6 (7.1 - 17.7) 
2 – < 25 157 (89.7) 119 (85.0) 
0.207 
≥ 25 18 (10.3) 21 (15.0) 
HOMA2-IR* Range 0.4 - 9.2 0.4 - 6.5 
0.447 
Median (IQR) 1.40 (0.9 - 2.3) 1.55 (0.9 - 2.5) 
Normal < 2 126 (72.0) 96 (68.6) 
0.507 
IR ≥ 2 49 (28.0) 44 (31.4) 
Total cholesterol 
(mg/dL) 
Range 70 - 333 107 – 333 
0.189 
Median (IQR) 190 (164 - 220) 187 (152 - 216) 
< 150 27 (15.4) 31 (22.1) 
0.127 
≥ 150 148 (84.6) 109 (77.9) 
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Triglycerides 
(mg/dL) 
Range 24 - 999 32 – 846 
0.009 
Median (IQR) 94 (67 - 127) 106 (75 - 156) 
< 150 146 (83.4) 102 (72.9) 
0.009 < 200 21 (12.0) 18 (12.9) 
≥ 200 8 (4.6) 20 (14.3) 
HDL* 
Cholesterol 
(mg/dL) 
Range 6.0 - 99.9 19.5 - 90.8 
˂ 0.001 
Median (IQR) 49 (37 - 60) 42 (34 - 51) 
Optimal 115 (65.7) 64 (45.7) 
˂ 0.001 
Risky 60 (34.3) 76 (54.3) 
LDL* 
Cholesterol 
(mg/dL) 
Range 6.3 - 245.8 27.6 - 234.4 
0.489 
Median (IQR) 119 (96 - 141) 113 (88 - 141) 
< 100 48 (27.4) 49 (35.0) 
0.148 
≥ 100 127 (72.6) 91 (65.0) 
Systolic BP* Median (IQR) 118 (107 - 129) 121 (108 - 136) 0.045 
Diastolic BP* Median (IQR) 62 (57 - 72) 64 (57 - 76) 0.129 
*FPG = Fasting plasma glucose, *HbA1c = Glycated haemoglobin, *HOMA2-IR = Homeostasis 
model assessment-(2)-Insulin resistance, *HDL = High-density lipoprotein, *LDL = Low-density 
lipoprotein, *BP = Blood pressure. HDL cholesterol: Optimal = Male ≥ 40 Female ≥ 50; Risky = Male 
<40, Female < 50 
 
Table 16. T2DM and IR cases among cases and controls. 
Study population  
N = 315 
Cases 
n = 175 
(%) 
95% CI 
Controls 
n = 140 
(%) 
95% CI p 
T2DM participants 51 (29.0) 22.5 - 36.5 39 (27.9) 20.6 - 36.1 0.801 
 
T2DM using insulin 10 (19.6) 9.8 - 33.1 2 (5.1) 0.6 - 17.3 
0.061 
T2DM not using insulin 41 (80.4) 66.9 - 90.2 37 (94.9) 82.7 - 99.4 
Normoglycemic participants 124 (71.0) 63.5 - 77.5 101 (72.1) 63.9 - 79.4 0.801 
 
Normoglycemic with IR 27 (22.0) 14.9 - 30.1 26 (25.7) 17.6 - 35.4 
0.485 Normoglycemic without 
IR 
97 (78.0) 69.9 - 85.1 75 (74.3) 64.6 - 82.4 
 Participants with MS 45 (25.7) 19.4 - 32.9 68 (48.6) 40.0 - 57.2 
˂ 0.001 
 Participants without MS 130 (74.3) 67.1 - 80.6 72 (51.4) 42.8 - 60.0 
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Figure 8. Diabetes status of cases and 
controls 
Figure 9. Insulin use among cases and 
controls 
  
 
Figure 10. IR status of normoglycemic cases and controls 
 
 
3.2. Logistic Regression 
As many variables had significant correlations with each other, we undertook 
multivariable backward stepwise logistic regression for clusters of variables, to 
identify the main variables for each cluster. Variables with p-values < 0.2 were 
selected into a multivariable backward stepwise logistic regression. These included 
age, nationality, marital status, education, occupation, T2DM, family history of 
diabetes, hypertension, takes hypertensive medication, hyperlipidaemia, takes lipid 
lowering therapy, polycystic ovaries, monthly income, level of stress, family 
overweight, number of dinner meals last week, participant self-rating the diet quality, 
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fast food consumption, WHR, BMI, FPG, HbA1c, fasting plasma insulin, total 
cholesterol, triglycerides, LDL Cholesterol, HDL Cholesterol, systolic BP and 
diastolic BP. Multivariable backward stepwise logistic regressions were conducted 
separately for demographic characteristics, medical history, lifestyle and diet, 
anthropometry and metabolic and clinical characteristics of cases and controls. As 
shown in appendix (13). For each cluster, the variables remaining statistically 
significant were carried forward into multivariate analysis using backward statistics 
regressions with replacement. We adjusted for age, gender, marital status, obesity 
and ethnicity to obtain the Adjusted ORs (AOR).  
The results of the final multivariable backward stepwise logistic regression including 
T2DM are shown in table 17. Cases were more likely to be non-Saudis (AOR 3.565, 
95% CI 1.83 - 6.97, p ˂ 0.001), to have T2DM (AOR 2.950, 95% CI 1.31 - 6.62, p = 
0.009) and to indicate they had a fair (AOR 12.944, 95% CI 5.60 - 29.93, p ˂ 0.001) 
or poor diet (AOR 33.625, 95% CI 10.75 - 105.20, p ˂ 0.001) than controls. Cases 
were more likely to eat fast foods 1 – 2 times/week (AOR 2.468, 95% CI 0.03 - 5.93, 
p = 0.043) or 2 – 3 times/month (AOR 2.655, 95% CI 1.00 - 7.04, p = 0.050), less 
likely to be obese (AOR 0.190, 95% CI 0.05 - 0.70, p = 0.012), to have higher total 
cholesterol (AOR 3.035, 95% CI 1.34 - 6.87, p = 0.008) and a lower level of risky 
HDL Cholesterol (AOR 0.400, 95% CI 0.21 - 0.76, p = 0.005) than controls. 
 
The results of the final multivariable backward stepwise logistic regression including 
metabolic syndrome are shown in table 18. This further analysis excluded T2DM as 
a single factor, as this diagnosis is included in the definition of metabolic syndrome. 
Cases were more likely to be non-Saudis (AOR 3.448, 95% CI 1.81 - 6.58, p ˂ 
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0.001) and to indicate they had a fair (AOR 12.893, 95% CI 5.71 - 29.11, p ˂ 0.001) 
or poor diet (AOR 30.197, 95% CI 10.10 - 90.29, p ˂ 0.001) than controls. Cases 
were less likely to be obese (AOR 0.224, 95% CI 0.06 - 0.81, p = 0.022), to have 
higher total cholesterol (AOR 3.382, 95% CI 1.55 - 7.40, p = 0.002) than controls. 
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Table 17. Logistic regression model for factors predicting TB including T2DM. 
Variables 
N = 315 
Univariate  Multivariate  
Cases 
n = 175 (%) 
Controls 
n = 140 (%) 
p AOR* (95% CI) p 
Sex Male 111 (63.4) 83 (59.3) 
0.453 
1 
Female 64 (36.6) 57 (40.7) 0.656 (0.32 - 1.33) 0.243 
Age group 18 – 29 71 (40.6) 39 (27.9) 
0.002 
1 
30 – 39 45 (25.7) 23 (16.4) 2.235 (0.86 - 5.83) 0.100 
40 – 49 22 (12.6) 29 (20.7) 1.297 (0.43 - 3.96) 0.648 
≥ 50  37 (21.1) 49 (35.0) 0.408 (0.14 - 1.18) 0.099 
Education Groups Uneducated 55 (31.4) 34 (24.3) 
0.152 
1 
Educated 119 (68.0) 106 (75.7) 0.627 (0.30 - 1.33) 0.223 
Ethnicity Saudi 37 (21.1) 73 (52.1) 
˂ 0.001 
1 
Non-Saudi 138 (78.9) 67 (47.9) 3.565 (1.83 - 6.97) ˂ 0.001 
Marital status Single 58 (33.1) 33 (23.6) 
˂ 0.001 
1 
Married 117 (66.9) 107 (76.4) 0.974 (0.41 - 2.32) 0.953 
T2DM No 124 (71.0) 101 (72.1) 
0.801 
1 
Yes 51 (29.0) 39 (27.9) 2.950 (1.31 - 6.62) 0.009 
Participant self-
rating the diet 
quality 
Good 10 (5.7) 76 (54.3) 
˂ 0.001 
1 
Fair 117 (66.9) 53 (37.9) 12.944 (5.60 - 29.93) ˂ 0.001 
Poor 48 (27.4) 11 (7.9) 33.625 (10.75 - 105.20) ˂ 0.001 
Fast food 
consumption 
0 - 1/Month 40 (22.9) 52 (37.1) 
0.018 
1 
2 - 3/Month 43 (24.6) 21 (15.0) 2.655 (1.00 - 7.04) 0.050 
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1 - 2/Week 47 (26.9) 31 (22.1) 2.468 (0.03 - 5.93) 0.043 
3 - 4/Week 20 (11.4) 22 (15.7) 0.490 (0.18 - 1.34) 0.166 
≥ 5 /Week 25 (14.3) 14 (10.0) 1.027 (0.36 - 2.91) 0.960 
BMI* groups ≤ 18.4 38 (21.7) 10 (7.1) 
˂ 0.001 
1 
18.5 - 24.9 85 (48.6) 41 (29.3) 0.627 (0.23 - 1.73) 0.367 
25 - 29.9 32 (18.3) 46 (32.6) 0.307 (0.09 - 1.00) 0.050 
≥ 30 20 (11.4) 43 (30.7) 0.190 (0.05 - 0.70) 0.012 
Total cholesterol 
(mg/dL) 
< 150 27 (15.4) 31 (22.1) 
 
1 
≥ 150 148 (84.6) 109 (77.9) 3.035 (1.34 - 6.87) 0.008 
HDL* Cholesterol 
(mg/dL) 
Optimal 115 (65.7) 64 (45.7) 
˂ 0.001 
1 
Risky 60 (34.3) 76 (54.3) 0.400 (0.21 - 0.76) 0.005 
Constant    0.090 0.005 
*AOR = Adjusted Odds Ratio, *BMI = Body Mass index, *FPG = Fasting plasma glucose, *HbA1c = Glycated haemoglobin, *HDL = High-density lipoprotein. 
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Table 18. Logistic regression model for factors predicting TB including metabolic syndrome. 
Variables 
N = 315 
Univariate  Multivariate  
Cases 
n = 175 (%) 
Controls 
n = 140 (%) 
p AOR* (95% CI) p 
Sex Male 111 (63.4) 83 (59.3) 
0.453 
1 
Female 64 (36.6) 57 (40.7) 0.627 (0.32 - 1.25) 0.183 
Age group 18 – 29 71 (40.6) 39 (27.9) 
0.002 
1 
30 – 39 45 (25.7) 23 (16.4) 2.332 (0.91 - 5.95) 0.076 
40 – 49 22 (12.6) 29 (20.7) 1.480 (0.50 - 4.40) 0.480 
≥ 50  37 (21.1) 49 (35.0) 0.693 (0.25 - 1.92) 0.481 
Education Groups Uneducated 55 (31.4) 34 (24.3) 
0.152 
1 
Educated 119 (68.0) 106 (75.7) 0.666 (0.32 - 1.38) 0.271 
Ethnicity Saudi 37 (21.1) 73 (52.1) 
˂ 0.001 
1 
Non-Saudi 138 (78.9) 67 (47.9) 3.448 (1.81 - 6.58) ˂ 0.001 
Marital status Single 58 (33.1) 33 (23.6) 
˂ 0.001 
1 
Married 117 (66.9) 107 (76.4) 1.054 (0.46 - 2.44) 0.902 
Metabolic 
syndrome 
No 130 (74.3) 72 (51.4) 
˂ 0.001 
1 
Yes 45 (25.7) 68 (48.6) 0.881 (0.42 - 1.86) 0.741 
Participant self-
rating the diet 
quality 
Good 10 (5.7) 76 (54.3) 
˂ 0.001 
1 
Fair 117 (66.9) 53 (37.9) 12.893 (5.71 - 29.11) ˂ 0.001 
Poor 48 (27.4) 11 (7.9) 30.197 (10.10 - 90.29) ˂ 0.001 
Fast food 
consumption 
0 - 1/Month 40 (22.9) 52 (37.1) 
0.018 
1 
2 - 3/Month 43 (24.6) 21 (15.0) 2.072 (0.89 - 4.81) 0.090 
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1 - 2/Week 47 (26.9) 31 (22.1) 2.355 (0.92 - 6.06) 0.076 
3 - 4/Week 20 (11.4) 22 (15.7) 0.537 (0.20 - 1.45) 0.218 
≥ 5 /Week 25 (14.3) 14 (10.0) 0.920 (0.33 - 2.53) 0.871 
BMI* groups ≤ 18.4 38 (21.7) 10 (7.1) 
˂ 0.001 
1 
18.5 - 24.9 85 (48.6) 41 (29.3) 0.632 (0.24 - 1.70) 0.362 
25 - 29.9 32 (18.3) 46 (32.6) 0.320 (0.10 - 1.02) 0.054 
≥ 30 20 (11.4) 43 (30.7) 0.224 (0.06 - 0.81) 0.022 
Total cholesterol 
(mg/dL) 
< 150 27 (15.4) 31 (22.1) 
 
1 
≥ 150 148 (84.6) 109 (77.9) 3.382 (1.55 - 7.40) 0.002 
Constant    0.064  0.001 
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3.3. Comparison of TB cases with and without IR and T2DM  
We conducted a sub-analysis for (a) normoglycemic TB cases without IR; (b) 
euglycemic TB cases with IR and (c) TB cases with T2DM to determine factors 
among TB cases independently associated with T2DM and IR. Independent variables 
for these analyses were chosen based on the literature of risk factors for T2DM. We 
will call normoglycemic TB cases without IR as ‘TB-controls’ (n= 97) and 
euglycemic TB cases with IR as ‘TB-IR’ (n=29) and the 49 diabetic TB cases as 
‘TB-diabetic’.  
The demographic characteristics of TB-diabetic and TB-IR cases and TB-controls 
are shown in table 19. Among TB-diabetic cases, 40 (81.6%) were male and nine 
(18.4%) female compared to 57 (58.8%) and 40 (41.2%) TB-controls, respectively (p 
= 0.006) (figure 11). TB-diabetic cases were older than TB-controls (figure 12), with 
median age of 49 and 27 years, respectively (p ˂ 0.001), were more likely to be 
married (39, 79.6% versus 52, 53.6%, respectively, p ˂ 0.001) and to work in the 
private sector (16, 32.7% versus 13, 13.4%) or as manual workers (15, 30.6% versus 
26, 26.8%) (p = 0.017). There were no significant differences between TB-IR cases 
and TB-controls. Given the small sample size we were unable to conduct a logistic 
regression analysis. 
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Table 19. Demographic characteristics of TB-IR cases, TB-diabetic cases and TB-controls. 
Demographic characteristic 
N = 175 
TB-Controls 
n = 97 (%) 
 TB-IR 
n = 29 (%) 
P 
 TB-T2DM 
n = 49 (%) 
P 
Gender 
Male 57 (58.8) 14 (48.3) 
0.318 
40 (81.6) 
0.006 
Female 40 (41.2) 15 (51.7) 9 (18.4) 
Age 
Min-Max 18 – 70 18 – 58 
0.866 
21 – 78 
< 0.001 
Median (IQR) 27 (23 - 37) 30 (21 - 40) 49 (39 - 55) 
Age groups 
18-29 55 (56.7) 14 (48.3) 
0.388 
2 (4.1) 
< 0.001 
30-39 26 (26.8) 8 (27.6) 11 (22.4) 
40-49 6 (6.2) 4 (13.8) 12 (24.5) 
50+ 10 (10.3) 3 (10.3) 24 (49.0) 
Marital status Single 41 (42.3) 13 (44.8) 
0.807 
4 (8.2) 
< 0.001 
With partner/married 52 (53.6) 14 (48.3) 39 (79.6) 
Divorced/separated 4 (4.1) 2 (6.9) 5 (10.2) 
Widowed 0 (0.0) 0 (0.0) 1 (2.0) 
Education No education 7 (7.2) 1 (3.4) 
0.166 
11 (22.4) 
0.495 
Literacy education 20 (20.6) 11 (37.9) 5 (10.2) 
Primary education 23 (23.7) 7 (24.1) 17 (34.7) 
Intermediate education 11 (11.3) 1 (3.4) 1 (2.0) 
Secondary education 21 (21.6) 3 (10.3) 9 (18.4) 
Higher education 15 (15.5) 6 (20.7) 5 (10.2) 
Prefer not to answer 0 (0.0) 0 (0.0) 1 (2.0) 
Occupation Governmental 6 (6.2) 1 (3.4) 0.421 2 (4.1) 0.017 
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Private 13 (13.4) 5 (17.2) 16 (32.7) 
Labourer 26 (26.8) 5 (17.2) 15 (30.6) 
Not employed 47 (48.5) 18 (62.1) 15 (30.6) 
Retired 1 (1.0) 0 (0.0) 0 (0.0) 
Other 4 (4.1) 0 (0.0) 1 (2.0) 
Ethnicity 
Groups 
Saudi  25 (25.8) 4 (13.8) 
0.179 
8 (16.3) 
0.198 
Non-Saudi 72 (74.2) 25 (86.2) 41 (83.7) 
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Figure 11. Gender of TB-diabetic 
and TB-controls 
Figure 12. Age groups of TB-diabetic 
and TB-controls 
   
 
The medical histories of TB-diabetic and TB-IR cases and TB-controls are shown in 
table 20. TB-diabetic cases were more likely to have hyperlipidaemia than TB-
controls (6, 12.2% versus 1, 1.0%, p = 0.009) and to take lipid lowering therapy (4, 
8.2% versus 0, 0.0%, respectively) (p = 0.008). TB-IR cases in turn had a higher 
prevalence of heart problems than TB-controls (2, 6.9% versus 0, 0.0%, p = 0.039) 
(figure 13). Given the small sample sizes we were unable to conduct a logistic 
regression analysis. 
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Table 20. Medical history of TB-IR cases, TB-diabetic cases and TB-controls. 
Medical history 
N = 175 
TB-Controls 
n = 97 (%) 
 TB-IR 
n = 29 (%) 
P 
 TB-T2DM 
n = 49 (%) 
P 
Family history of diabetes Yes 25 (25.8) 9 (31.0) 
0.575 
18 (36.7) 
0.170 
No 72 (74.2) 20 (69.0) 31 (63.3) 
1st degree 
Yes 23 (23.7) 9 (31.0) 
0.427 
16 (32.7) 
0.249 
No 74 (76.3) 20 (69.0) 33 (67.3) 
2nd degree 
Yes 4 (4.1) 0 (0.0) 
0.573 
2 (4.1) 
1 
No 93 (95.9) 29 (100.0) 47 (95.9) 
3rd degree 
Yes 0 (0.0) 0 (0.0) 
ND* 
1 (2.0) 
0.336 
No 97 (100.0) 29 (100.0) 48 (98.0) 
Hypertension Yes 3 (3.1) 2 (6.9) 
0.413 
4 (8.2) 
0.193 No 92 (94.8) 27 (93.1) 45 (91.8) 
Don’t know 2 (2.1) 0 (0.0) 0 (0.0) 
Takes hypertensive medication Yes 3 (3.1) 1 (3.4) 
1 
4 (8.2) 
0.224 
No 94 (96.9) 28 (96.6) 45 (91.8) 
Hyperlipidaemia Yes 1 (1.0) 1 (3.4) 
0.489 
6 (12.2) 
0.009 No 95 (97.9) 27 (93.1) 43 (87.8) 
Don’t know 1 (1.0) 1 (3.4) 0 (0.0) 
Takes lipid lowering therapy Yes 0 (0.0) 1 (3.4) 
0.176 
4 (8.2) 
0.008 No 96 (99.0) 28 (96.6) 45 (91.8) 
Don’t know 1 (1.0) 0 (0.0) 0 (0.0) 
Heart problems Yes 0 (0.0) 2 (6.9) 0.039 1 (2.0) 0.223 
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No 96 (99.0) 27 (93.1) 48 (98.0) 
Don’t know 1 (1.0) 0 (0.0) 0 (0.0) 
History of gestational diabetes Yes 1 (1.0) 2 (6.9) 
0.183 
2 (4.1) 
0.086 
No 38 (39.2) 13 (44.8) 7 (14.3) 
History of polycystic ovaries Yes 0 (0.0) 0 (0.0) 
ND* 
0 (0.0) 
ND* No 39 (40.2) 15 (51.7) 9 (18.4) 
Don’t know 1 (1.0) 0 (0.0) 0 (0.0) 
*ND = Not defined
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The lifestyle and diet of TB-diabetic and TB-IR cases and TB-controls are shown in 
table 21. The proportion of TB-diabetic cases with a poor diet was lower (10, 20.4%) 
than among TB-controls (32, 33.0%) with TB-diabetic cases being more likely to 
rate their diet as good (5, 10.2%) than TB-controls (2, 2.1%) (p = 0.046). TB-diabetic 
cases were more likely to have a sedentary job (34, 69.4) than TB-controls (66, 
68.0%) (p = 0.029). With regards to IR cases, the proportion of TB-IR cases with a 
history of overweight during childhood was higher than among TB-controls (4, 
13.8% versus 7, 7.2%, respectively, p = 0.039) (figure 14). Given the small sample 
size we were unable to conduct a logistic regression analysis. 
 
Figure 13. Proportion of TB-IR and TB-controls with heart problems  
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Table 21. Lifestyle and diet of TB-IR cases, TB-diabetic cases and TB-controls. 
Life style and diet 
N = 175 
TB-Controls 
n = 97 (%) 
 TB-IR 
n = 29 (%) 
P 
 TB-T2DM 
n = 49 (%) 
P 
Type of job Sedentary 66 (68.0) 24 (82.8) 
0.110 
34 (69.4) 
0.029 
Moderate Physical 
Activity 
27 (27.8) 3 (10.3) 13 (26.5) 
Physically Very 
Demanding 
4 (4.1) 2 (6.9) 2 (4.1) 
Monthly income (SAR) ≤ 3000 75 (77.3) 26 (89.7) 
0.220 
38 (77.6) 
0.149 
3000 - 5000 19 (19.6) 2 (6.9) 10 (20.4) 
5001 - 10000 3 (3.1) 1 (3.4) 1 (2.0) 
≥ 10000 0 (0.0) 0 (0.0) 0 (0.0) 
Level of stress Low 70 (72.2) 22 (75.9) 
0.920 
38 (77.6) 
0.757 Medium 16 (16.5) 4 (13.8) 6 (12.2) 
High 11 (11.3) 3 (10.3) 5 (10.2) 
Overweight among family Yes 14 (14.4) 6 (20.7) 
0.400 
5 (10.2) 
0.263 
No 83 (85.6) 6 (20.7) 43 (87.8) 
Don’t know 0 (0.0) 23 (79.3) 1 (2.0) 
Prefer not to say 0 (0.0) 0 (0.0) 0 (0.0) 
If yes, who? 
Father 
Yes 3 (3.1) 0 (0.0) 
1.000 
1 (2.0) 
1.000 
No 94 (96.9) 29 (100.0) 48 (98.0) 
Mother 
Yes 9 (9.3) 4 (13.8) 
0.494 
3 (6.1) 
0.751 
No 88 (90.7) 25 (86.2) 46 (93.9) 
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Sibling 
Yes 5 (5.2) 1 (3.4) 
1.000 
1 (2.0) 
0.664 
No 92 (94.8) 28 (96.6) 48 (98.0) 
Grandfather 
Yes 0 (0.0) 0 (0.0) 
ND* 
0 (0.0) 
ND* 
No 97 (100.0) 29 (100.0) 49 (100.0) 
Other 
Yes 2 (2.1) 2 (6.9) 
0.227 
3 (6.1) 
0.335 
No 95 (97.9) 27 (93.1) 46 (93.9) 
Overweight as a child Yes 7 (7.2) 4 (13.8) 
0.039 
7 (14.3) 
0.355 No 89 (91.8) 22 (75.9) 41 (83.7) 
Don’t know 1 (1.0) 3 (10.3) 1 (2.0) 
Number of breakfast meals last week Never 6 (6.2) 0 (0.0) 
0.153 
0 (0.0) 
0.258 1 - 6 16 (16.5) 6 (20.7) 5 (10.2) 
Always 75 (77.3) 23 (79.3) 44 (89.8) 
Number of lunch meals last week Never 1 (1.0) 0 (0.0) 
0.524 
0 (0.0) 
0.150 1 - 6 12 (12.6) 3 (10.3) 1 (2.0) 
Always 84 (86.6) 26 (89.7) 48 (98.0) 
Number of dinner meals last week Never 0 (0.0) 0 (0.0) 
0.480 
0 (0.0) 
0.389 1 - 6 13 (13.4) 2 (6.9) 1 (4.1) 
Always 84 (86.6) 27 (93.1) 47 (95.9) 
Participant rating of his/her diet Good 2 (2.1) 3 (10.3) 
0.111 
5 (10.2) 
0.046 Fair 63 (64.9) 20 (69.0) 34 (69.4) 
Poor 32 (33.0) 6 (20.7) 10 (20.4) 
Fast food consumption 0 ‐ 1 Times/Month 22 (22.7) 7 (24.1) 
0.431 
11 (22.4) 
0.954 
2 ‐ 3 Times/Month 25 (25.8) 9 (31.0) 13 (26.5) 
1 ‐ 2 Times/Week 23 (23.7) 9 (31.0) 11 (22.4) 
3 ‐ 4 Times/Week 10 (10.3) 3 (10.3) 7 (14.3) 
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≥ 5 Times/Week 17 (17.5) 1 (3.4) 7 (14.3) 
Food portions description Small 14 (14.4) 4 (13.8) 
0.914 
5 (10.2) 
0.640 Intermediate 60 (61.9) 17 (58.6) 34 (69.4) 
Large 23 (23.7) 8 (27.6) 10 (20.4) 
*ND = Not defined 
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Figure 14. Proportion of TB-IR cases and TB-controls with childhood 
overweight  
 
The anthropometry of male TB-diabetic and TB-IR cases and TB-controls are shown 
in table 22. Male TB-diabetic cases were shorter than male TB-controls with medians 
of 169 and 172 cms, respectively, and a median difference of 3 cms (p = 0.012). The 
median BMI was 24 for male TB-diabetic cases compared to 20 for male TB-
controls, with a median difference of 4 (p = 0.006). Male TB-diabetic cases, 
therefore, were more likely to be obese than male TB-controls (7, 18% versus 4, 7%, 
respectively, p = 0.019), to have a higher median waist circumference, with a median 
difference of 9 cms (p = 0.002). Moreover, male TB-diabetic cases had higher 
median WHR than male TB-controls with median difference of 0.08 and were more 
likely to have high WHR (2, 5.0% versus 2, 3.5%, respectively) (p ˂ 0.001). Male 
TB-IR cases in turn had higher median weight than male TB-controls (74 and 59 
Kgs, respectively) with a median difference of 15 Kgs (p = 0.028) and were less 
likely to have high WHR than among male TB-controls (0, 0.0% versus 2, 3.5%, 
respectively, p = 0.010). Given the small sample size we were unable to conduct a 
logistic regression analysis. 
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Table 22. Male anthropometry of TB-IR cases, TB-diabetic cases and TB-controls. 
Anthropometry (Male) 
N = 111 
TB-Controls 
n = 57 (%) 
TB-IR 
n = 14 (%) 
p 
TB-T2DM 
n = 40 (%) 
p 
Height (cm) Median (IQR) 172 (169 -179) 175 (168 -184) 0.336 169 (163 -174) 0.012 
Weight (kg) Median (IQR) 59 (55 -71) 74 (59 -86) 0.028 68 (57 -79) 0.067 
BMI (kg/m2) Median (IQR) 20 (18 -23) 24 (19 -26) 0.191 24 (20 -27) 0.006 
BMI groups 
≤ 18.4 15 (26) 3 (21) 
0.817 
4 (10) 
0.019 
18.5 - 24.9 32 (56) 7 (50) 18 (45) 
25 - 29.9 6 (11) 2 (14) 11 (28) 
≥ 30 4 (7) 2 (14) 7 (18) 
Waist (cm) Median (IQR) 80 (75 -88) 91 (77 -98) 0.059 89 (81 -97) 0.002 
Hip (cm) Median (IQR) 94 (91 -101) 101 (94 -107) 0.106 97 (90 -102) 0.741 
WHR Median (IQR) 0.84 (0.79 -0.88) 0.90 (0.81 -0.94) 0.077 0.92 (0.86 -0.94) < 0.001 
WHR groups 
Low 48 (84.2) 7 (50.0) 
0.010 
15 (37.5) 
< 0.001 Moderate 7 (12.3) 7 (50.0) 23 (57.5) 
High 2 (3.5) 0 (0.0) 2 (5.0) 
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The anthropometric data of female TB-diabetic and TB-IR cases and TB-controls are 
shown in table 23. The median BMI for female TB-IR cases was 24 compared to 20 
for female TB-controls, with a median difference of 4 (p = 0.036). On the other hand, 
female TB-diabetic cases had a higher weight than female TB-controls with medians 
of 72 and 53 Kgs and a median difference of 19 Kgs (p < 0.001). The median BMI 
for female TB-diabetic cases was 30 compared to 20 for female TB-controls, with 
median difference of 10. Female TB-diabetic cases, therefore, were much more 
likely to be obese than TB-controls (5, 56% versus 1, 3%, respectively), to have a 
higher median waist circumference with a median difference of 20 cms and higher 
hip circumference than female TB-controls with a median difference of 18 cms (p ˂ 
0.001). Given the small sample size we were unable to conduct a logistic regression 
analysis. 
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Table 23. Female anthropometry of TB-IR cases, TB-diabetic cases and TB-controls. 
Anthropometry (Female) 
N = 64 
TB-controls 
n = 40 (%) 
TB-IR 
n = 15 (%) 
p 
TB-T2DM 
n = 9 (%) 
p 
Height (cm) Median (IQR) 160 (156 -164) 159 (155 -161) 0.514 158 (153 -164) 0.550 
Weight (kg) Median (IQR) 53 (46 -61) 61 (46 -72) 0.053 72 (62 -88) < 0.001 
BMI* (kg/m2) Median (IQR) 20 (18 -23) 24 (19 -27) 0.036 30 (24 -33) < 0.001 
BMI groups 
≤ 18.4 15 (38) 1 (7) 
0.074 
0 (0) 
< 0.001 
18.5 - 24.9 18 (45) 8 (53) 2 (22) 
25 - 29.9 6 (15) 5 (33) 2 (22) 
≥ 30 1 (3) 1 (7) 5 (56) 
Waist (cm) Median (IQR) 74 (67 -84) 78 (65 -91) 0.583 94 (79 -102) < 0.001 
Hip (cm) Median (IQR) 92 (83 -99) 95 (80 -110) 0.264 110 (97 -118) < 0.001 
WHR Median (IQR) 0.83 (0.76 -0.91) 0.80 (0.77 -0.87) 0.502 0.85 (0.82 -0.91) 0.352 
WHR groups 
Low 17 (42.5) 8 (53.3) 
0.502 
2 (22.2) 
0.366 Moderate 13 (32.5) 4 (26.7) 4 (44.4) 
High 10 (25.0) 3 (20.0) 3 (33.3) 
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The metabolic characteristics TB-diabetic and TB-IR cases TB-controls are shown in 
table 24. TB-diabetic cases had higher median total cholesterol than TB-controls 
(216 versus 183 mg/dL, respectively) with a median difference of 33 mg/dL (p ˂ 
0.001). TB-diabetic cases also had higher median triglycerides than TB-controls (117 
versus 77 mg/dL, respectively) with a median difference of 40 mg/dL (p ˂ 0.001); 
and a higher proportion were classified as having high triglycerides (5, 10.2% versus 
1, 1.0%, respectively, p = 0.014) (figure 15). Moreover, TB-diabetic cases had a 
higher median LDL Cholesterol (137 versus 112 mg/dL, respectively, p = 0.001) and 
were more likely to be classified as having high LDL Cholesterol than TB-controls 
(41, 83.7% versus 63, 64.9%, respectively, p = 0.018) (figure 16). Regarding cases 
with IR, a higher proportion of TB-IR cases had high total cholesterol than TB-
controls (96.6% versus 79.4%, respectively, p = 0.043) (figure 17). Given the small 
sample size we were unable to conduct a logistic regression analysis. 
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Table 24. Metabolic characteristics of TB-IR cases, TB-diabetic cases and TB-controls. 
Metabolic characteristic 
N = 175 
TB-Controls 
n = 97 (%) 
 TB-IR 
n = 29 (%) 
P 
 TB-T2DM 
n = 49 (%) 
P 
Total cholesterol (mg/dL) 
Min - Max 70 - 333 141 - 302 
0.073 
92 - 296 
< 0.001 
Median (IQR) 183 (157.5 - 206) 188 (179 - 213.5) 216 (181 - 242) 
Optimal 20 (20.6) 1 (3.4) 
0.043 
6 (12.2) 
0.212 
High 77 (79.4) 28 (96.6) 43 (87.8) 
Triglycerides (mg/dL) 
Min - Max 24 - 214 39 - 252 0.208 60 - 999 < 0.001 
Median (IQR) 77 (61.5 - 111) 94 (68.5 - 123.5)  117 (92 - 156.5)  
Optimal 85 (87.6) 26 (89.7) 
0.111 
35 (71.4) 
0.014 Border line  11 (11.3) 1 (3.4) 9 (18.4) 
High 1 (1.0) 2 (6.9) 5 (10.2) 
HDL Cholesterol (mg/dL) 
Min - Max 10.6 - 99.9 32.0 - 89.0 0.070 6.0 - 95.0 0.185 
Median (IQR) 49 (38 - 60) 55 (45 - 64.5)  43 (34.5 - 58)  
Optimal 
Male ≥ 40 
Female ≥ 50 
62 (63.9) 23 (79.3) 
0.121 
30 (61.2) 
0.750 
Risky 
Male < 40 
Female < 50 
35 (36.1) 6 (20.7) 19 (38.8) 
LDL Cholesterol (mg/dL) 
Min-Max 6.3 - 245.8 70.0 - 207.0 
0.432 
47.0 - 211.0 
0.001 
Median (IQR) 112 (91 - 132.5) 112 (100.5 - 133.5) 137 (112.5 - 162.2) 
Optimal 34 (35.1) 6 (20.7) 
0.145 
8 (16.3) 
0.018 
High 63 (64.9) 23 (79.3) 41 (83.7) 
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Figure 15. Triglycerides of TB-diabetic 
cases and TB-controls 
Figure 16. LDL Cholesterol of TB-
diabetic cases and TB-controls 
  
Figure 17. Total cholesterol of TB-IR cases and TB-controls 
 
 
The symptoms of TB, X-Ray findings and TB severity score of TB-diabetic and TB-
IR cases and TB-controls are shown in table 25. There were no statistical differences 
between the three groups, except for TB-diabetic cases being more likely to have 
blood in sputum than TB-controls (15, 30.6% versus 16, 16.5%, respectively, p = 
0.049). There were no statistical differences between the three groups regarding the 
TB score. 
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Table 25. TB symptoms, X-Ray and scoring of TB-IR cases, TB-diabetic cases and TB-controls. 
TB symptoms, x-Ray and scoring 
N=175 
TB-Controls 
n = 97 (%) 
 TB-IR 
n = 29 (%) 
P 
 TB-T2DM 
n = 49 (%) 
P 
Chest Pain 69 (71.1) 22 (75.9) 0.618 32 (65.3) 0.471 
Sputum 92 (94.8) 27 (93.1) 0.661 45 (91.8) 0.484 
Cough 94 (96.9) 29 (100.0) 1 48 (98.0) 1 
Sputum with blood 16 (16.5) 6 (20.7) 0.602 15 (30.6) 0.049 
Shortness of breath 39 (40.2) 14 (48.3) 0.440 26 (53.1) 0.140 
Fever 93 (95.9) 29 (100.0) 0.573 48 (98.0) 0.664 
Night sweats 85 (87.6) 22 (75.9) 0.142 44 (89.8) 0.700 
Poor Appetite 86 (88.7) 24 (82.8) 0.524 43 (87.8) 0.872 
Weight loss 92 (94.8) 26 (89.7) 0.384 45 (91.8) 0.484 
TB Culture 
Positive 43 (13.4) 12 (27.6) 
0.178 
30 (6.1) 
0.122 Negative 13 (44.3) 8 (41.4) 3 (61.2) 
Not done 41 (42.3) 9 (31.0) 16 (32.7) 
AFB Smear 
Positive 75 (77.3) 19 (65.5) 
0.311 
39 (79.6) 
0.650 Negative 21 (21.6) 10 (34.5) 10 (20.4) 
Not done 1 (1.0) 0 (0.0) 0 (0.0) 
Chest x-Ray 
Cavitation 
Positive 55 (56.7) 13 (44.8) 
0.196 
30 (61.2) 
0.838 Negative 39 (40.2) 16 (55.2) 18 (36.7) 
Not done 3 (3.1) 0 (0.0) 1 (2.0) 
TB score Min-Max 2 - 9 3 - 9 0.412 3 - 9 0.435 
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Median (IQR) 7 (6 - 8) 7 (6.5 - 8) 7 (6 - 8) 
Group (1) 1 - 3 5 (5.2) 2 (6.9) 
0.506 
1 (2.0) 
0.613 Group (2) 4 - 6 27 (27.8) 5 (17.2) 13 (26.5) 
Group (3) 7 - 9 65 (67.0) 22 (75.9) 35 (71.4) 
       
Group (1+2) 1 - 6 32 (33.0) 7 (24.1) 
0.365 
14 (28.5) 
0.587 
Group (3) 7 - 9 65 (67.0) 22 (75.9) 35 (71.4) 
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4. Chapter 4 –CHD Results 
4.1. Prevalence of T2DM and IR among patients with CHD and IR as a risk 
factor for CHD 
We performed a second case control study from November 2016 to June 2017 to 
describe the prevalence of T2DM and IR among patients with CHD and if IR is a 
risk factor for CHD, as described in the methods chapter. We included 325 patients 
≥18 years old with a former diagnosis of CHD registered at the King Faisal Hospital 
in Taif city who were classified to have stable CHD by the time of the study. 
Participants with stable CHD will be called ‘cases’ for this sub-study. Cases were 
compared to 138 controls, with no history of CHD (same controls recruited at the TB 
and Chest Diseases Centre in Jeddah city), as described in chapter 3. These 
participants will be called ‘controls’ for this chapter. All participants signed a written 
informed consent before the interview and examination. 
The demographic characteristics of all participants are shown in table 26. The age of 
cases and controls ranged from 37 to 98 years and from 18 to 76 years, respectively. 
Cases were older than controls with medians of 62 and 40 years, respectively, and a 
median difference of 22 years (p ˂ 0.001). Two hundred thirty (70.8%) cases were 
male and 95 (29.2%) female, whereas 83 (60.1%) and 55 (39.9%) controls were male 
and female, respectively, (p = 0.025). 
Cases were less likely to be single (29, 8.9%) than controls (33, 23.9%) (p ˂ 0.001) 
and more likely to have primary education (122, 37.5% and 21, 15.2%, respectively), 
but less likely to have intermediate (22, 6.8%) and secondary education (57, 17.5%) 
than controls (31, 22.5% and 36, 26.1%, respectively) (p ˂ 0.001). Cases were more 
likely to work in the governmental sector (65, 20.0%) and to be retired (105, 32.3%) 
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than controls (19, 13.8% and 5, 3.6%, respectively) (p ˂ 0.001). Controls were more 
likely to be manual workers (27, 19.6%) or to belong to the non-employed categories 
(72, 52.2%) than cases (9, 2.8% and 102, 31.4%, respectively) (p ˂ 0.001). With 
regards to ethnicity, cases were more likely to be Saudi (283, 87.1%) than controls 
(71, 51.4%) (p ˂ 0.001). 
The medical history of cases and controls is shown in table 27. Participants were 
asked, about their diabetes status, history of hypertension, hyperlipidaemia, 
gestational diabetes or polycystic ovaries and whether they were taking medications 
for these conditions. There were clear differences between cases and controls in 
terms of history of diabetes, with 195 (60%) cases and 26 (18.8%) controls having a 
history of diabetes (p ˂ 0.001). The proportion of diabetic cases using insulin were 
(74, 37.9% versus 1, 3.8%) of controls (p = 0.001) and the proportion of cases with a 
family history of diabetes were higher (206, 63.4%) than among controls (56, 40.6%) 
(p ˂ 0.001); with a higher frequency among first degree (181, 55.7% versus 48, 
34.8%, p ˂ 0.001), second degree (81, 24.9% versus 7, 5.1%, p ˂ 0.001) and third 
degree relatives (14, 4.3% versus 1, 0.7%, p = 0.024) than controls . 
CHD cases also had a higher prevalence of hypertension than controls (252, 77.5% 
versus 29, 21%, respectively) and were more likely to be taking anti-hypertensive 
medications (278, 85.5% versus 21, 15.2%, respectively) (p ˂ 0.001). Cases were 
more likely to have hyperlipidaemia (263, 80.9% versus 26, 18.8%) and to be taking 
lipid lowering therapy (270, 83.1% versus 15, 10.9%, respectively) (p < 0.001), to 
have experienced gestational diabetes (12, 3.7% versus 4, 2.9%, respectively, p = 
0.040) and a history of polycystic ovaries (9, 2.8%) than controls (3, 2.2%) (p = 
0.022). 
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Table 26. Demographic characteristics of cases and controls. 
Demographic characteristics 
N = 463 
Cases 
n = 325 (%) 
Controls 
n = 138 (%) 
p 
Sex Male 230 (70.8) 83 (60.1) 
0.025 
Female 95 (29.2) 55 (39.9) 
Age Min-Max 37 - 98 18 - 76 
˂ 0.001 
Median (IQR) 62 (55 - 70) 40 (28 - 53) 
Age groups 18 – 39 2 (0.6) 61 (44.6) 
˂ 0.001 
40 – 49 31 (9.5) 29 (21.0) 
50 – 59 91 (28.0) 27 (19.6) 
60 – 69 103 (31.7) 13 (9.4) 
≥ 70 98 (30.2) 8 (5.8) 
Marital 
status 
Single 29 (8.9) 33 (23.9) 
˂ 0.001 
With partner/married 243 (74.8) 100 (72.5) 
Divorced/separated 9 (2.8) 2 (1.4) 
Widowed 44 (13.5) 3 (2.2) 
Education No education 33 (10.2) 13 (9.4) 
˂ 0.001 
Literacy 73 (22.5) 20 (14.5) 
Primary education 122 (37.5) 21 (15.2) 
Intermediate 
education 
22 (6.8) 31 (22.5) 
Secondary education 57 (17.5) 36 (26.1) 
Higher education 18 (5.5) 17 (12.3) 
Occupation Governmental 65 (20.0) 19 (13.8) 
˂ 0.001 
Private 39 (12.0) 14 (10.1) 
Labourer 9 (2.8) 27 (19.6) 
Retired 105 (32.3) 5 (3.6) 
Non-employed 102 (31.4) 72 (52.2) 
Other 5 (1.5) 1 (0.7) 
Employed Yes 113 (34.8) 60 (43.5) 
0.076 
No 212 (65.2) 78 (56.5) 
Ethnicity  Saudi 283 (87.1) 71 (51.4) 
˂ 0.001 
Non-Saudi 42 (12.9) 67 (48.6) 
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Table 27. Medical history of cases and controls. 
Medical history 
N = 463 
Cases 
n = 325 (%) 
Controls 
n = 138 (%) 
p 
T2DM Yes 195 (60.0) 26 (18.8) 
˂ 0.001 No 127 (39.1) 107 (77.5) 
Don't know 3 (0.9) 5 (3.6) 
T2DM using insulin Yes 74 (37.9) 1 (3.8) 
0.001 
No 121 (62.1) 25 (96.2) 
Family history of 
diabetes 
Yes 206 (63.4) 56 (40.6) 
˂ 0.001 
No 119 (36.6) 82 (59.4) 
1st degree 
Yes 181 (55.7) 48 (34.8) 
˂ 0.001 
No 144 (44.3) 90 (65.2) 
2nd degree 
Yes 81 (24.9) 7 (5.1) 
˂ 0.001 
No 244 (75.1) 131 (94.9) 
3rd degree 
Yes 14 (4.3) 1 (0.7) 
0.024 
No 311 (95.7) 137 (99.3) 
Hypertension Yes 252 (77.5) 29 (21.0) 
˂ 0.001 No 71 (21.8) 106 (76.8) 
Don’t know 2 (0.6) 3 (2.2) 
Takes hypertensive 
medication 
Yes 278 (85.5) 21 (15.2) 
˂ 0.001 
No 47 (14.5) 117 (84.8) 
Hyperlipidaemia  Yes 263 (80.9) 26 (18.8) 
˂ 0.001 No 48 (14.8) 103 (74.6) 
Don’t know 14 (4.3) 9 (6.5) 
Takes lipid lowering 
therapy 
Yes 270 (83.1) 15 (10.9) 
˂ 0.001 No 52 (16.0) 120 (87.0) 
Don’t know 3 (0.9) 3 (2.2) 
History of gestational 
diabetes 
Yes 12 (3.7) 4 (2.9) 
0.040 
No 80 (24.6) 51 (37.0) 
Don’t know 2 (0.6) 0 (0.0) 
Not applicable 231 (71.1) 83 (60.1) 
History of polycystic 
ovaries 
Yes 9 (2.8) 3 (2.2) 
0.022 
No 85 (26.2) 48 (34.8) 
Don’t know 1 (0.3) 4 (2.9) 
Not applicable 230 (70.8) 83 (60.1) 
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The lifestyle and diet of cases and controls is shown in table 28. The proportion of 
participants having sedentary occupations was higher among cases (307, 94.5%) than 
controls (95, 68.8%) and their monthly income was < 3000 SAR in 141 (43.4%) 
cases compared to 92 (66.7%) controls (p ˂ 0.001). Cases were more likely to report 
an elevated level of stress (21, 6.5%) than controls (3, 2.2%) (p ˂ 0.001). 
The proportion of participants who had a family history of overweight was higher 
among cases (113, 34.8%) than controls (28, 20.3%) (p = 0.005), with a higher 
frequency of overweight among siblings among cases (72, 22.2%) than controls (6, 
4.3%) (p ˂ 0.001) and to have been overweight during childhood (61, 18.8% versus 
13, 9.4%, respectively, p = 0.022). 
Cases were less likely to smoke (37, 11.4% versus 29, 21.0%, p = 0.007), with only 
28 (8.6%) cases smoking 10 – 20 cigarettes per day compared to 29 (21.0%) of 
controls (p ˂ 0.001), but more likely to be past smokers than controls (118, 36.3% 
versus 8, 5.8%, respectively, p ˂ 0.001). 
Cases were more likely to routinely have breakfast than controls (275, 84.6%, versus 
101, 73.2%, respectively, p = 0.001) and to have a poor diet (83, 25.5% versus 11, 
8.0%, respectively, p ˂ 0.001). Cases were less likely to ate fast foods 3 ‐ 4 
times/week (19, 5.8%) and more than five times per week (16, 4.9%) than controls 
(22, 15.9% and 14, 10.1%, respectively) (p ˂ 0.001). Cases indicated they consumed 
more frequently large food portions (103, 31.7%) than controls (35, 25.4%) (p = 
0.011). There were no differences between cases and controls regarding the number 
of times they consumed lunch and dinner per week. 
The level of physical activity of cases and controls is shown in table 29. Cases had 
lower physical activity than controls, with median number of days doing vigorous 
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activity of three and 4.5 days, respectively. Furthermore, with median number of 
days doing moderate activity were seven and 4.5 days for cases and controls, 
respectively. With a mean rank number of walking days per week of 239 for cases 
and 208 for controls (p = 0.001) 
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Table 28. Lifestyle and diet of cases and controls. 
Lifestyle and diet 
N = 463 
Cases 
n = 325 (%) 
Controls 
n = 138 (%) 
p 
Type of job Sedentary 307 (94.5) 95 (68.8) 
˂ 0.001 
Moderate Physical 
Activity 
16 (4.9) 38 (27.5) 
Physically Very 
Demanding 
2 (0.6) 5 (3.6) 
Monthly income 
(SAR) 
≤ 3000 141 (43.4) 92 (66.7) 
˂ 0.001 
3000 – 5000 105 (32.3) 34 (24.6) 
5001 – 10000 54 (16.6) 9 (6.5) 
≥ 10000 25 (7.7) 3 (2.2) 
Level of stress Low 199 (61.2) 110 (79.7) 
˂ 0.001 Medium 105 (32.3) 25 (18.1) 
High 21 (6.5) 3 (2.2) 
Overweight among 
family 
Yes 113 (34.8) 28 (20.3) 
0.005 
No 211 (64.9) 109 (79.0) 
Don’t know 1 (0.3) 0 (0.0) 
Prefer not to say 0 (0.0) 1 (0.7) 
If yes, who? Father Yes 14 (4.3) 8 (5.8) 
0.491 
No 311 (95.7) 130 (94.2) 
Mother Yes 24 (7.4) 8 (5.8) 
0.538 
No 301 (92.6) 130 (94.2) 
Sibling Yes 72 (22.2) 6 (4.3) 
˂ 0.001 
No 253 (77.8) 132 (95.7) 
Grandfather Yes 2 (0.6) 0 (0.0) 
0.492 
No 323 (99.4) 138 (100.0) 
Other Yes 29 (8.9) 8 (5.8) 
0.257 
No 296 (91.1) 130 (94.2) 
Overweight as a 
child 
Yes 61 (18.8) 13 (9.4) 
0.022 No 259 (79.7) 124 (89.9) 
Don’t know 5 (1.5) 1 (0.7) 
Smoking Yes 37 (11.4) 29 (21.0) 
0.007 
No 288 (88.6) 109 (79.0) 
Cigarettes per day 10 per day Yes 9 (2.8) 1 (0.7) 
0.149 
No 316 (97.2) 137 (99.3) 
10–20 per day Yes 28 (8.6) 29 (21.0) ˂ 0.001 
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No 297 (91.4) 109 (79.0) 
Past smoker 
Yes 118 (36.3) 8 (5.8) 
˂ 0.001 
No 207 (63.7) 130 (94.2) 
Number of breakfast 
meals last week 
Never 18 (5.5) 5 (3.6) 
0.001 1 – 6 32 (9.8) 32 (23.2) 
Always 275 (84.6) 101 (73.2) 
Number of lunch 
meals last week 
Never 10 (3.1) 0 (0.0) 
0.111 1 – 6 25 (7.7) 10 (7.2) 
Always 290 (89.2) 128 (92.8) 
Number of dinner 
meals last week 
Never 4 (1.2) 2 (1.4) 
0.062 1 – 6 22 (6.8) 19 (13.8) 
Always 299 (92.0) 117 (84.8) 
Participant rating of 
his/her diet 
Good 22 (6.8) 73 (52.9) 
˂ 0.001 Fair 220 (67.7) 54 (39.1) 
Poor 83 (25.5) 11 (8.0) 
Fast food 
consumption 
0 ‐ 1 Times/Month 172 (52.9) 51 (37.0) 
˂ 0.001 
2 ‐ 3 Times/Month 73 (22.5) 21 (15.2) 
1 ‐ 2 Times/Week 45 (13.8) 30 (21.7) 
3 ‐ 4 Times/Week 19 (5.8) 22 (15.9) 
≥ 5 Times/Week 16 (4.9) 14 (10.1) 
Food portions 
description 
Small 62 (19.1) 15 (10.9) 
0.011 Intermediate 160 (49.2) 88 (63.8) 
Large 103 (31.7) 35 (25.4) 
 
Table 29: Physical activity of cases and controls. 
Physical activity 
(days per week) 
N = 463 
Cases 
n = 325 (%) 
Median (IQR) 
Mean 
rank 
Controls 
n = 138 (%) 
Median (IQR) 
Mean 
rank 
p 
Vigorous activity 3 (1.5 - 6) - 4.5 (2– ND*) - 0.800 
Moderate activity 7 (1 - 7) - 4.5 (2 - 6) - 0.423 
Walking 7 (7 - 7) 239 7 (7 - 7) 208 0.001 
Minutes 
walked/day 
30 (20 - 55) - 30 (20 - 60) - 0.138 
*ND = Not defined 
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The anthropometry data of all participants are shown in table 30. Male cases were 
shorter than male controls with medians of 167 and 170 cms, respectively, and a 
median difference of 3 cms (p = 0.004). Male cases had a higher weight than male 
controls with median of 77 Kgs versus 72 Kgs for male controls and a median 
difference of 5 Kgs (p = 0.009). Correspondingly, the median BMI was 28 for male 
cases compared to 26 for male controls and a median difference of 2 (p ˂ 0.001). 
Male cases, therefore, were more likely to be classified as obese than controls (83, 
36.1% versus 22, 26.5%, respectively, p ˂ 0.001) and to have a higher median waist 
circumference, with a median difference of 14 cms. The median WHR of male cases 
(1.00) was higher than male controls (0.90) with a median difference of 0.10 (p ˂ 
0.001). Again, male cases were more likely to have a high WHR than male controls 
(128, 55.7% versus 6, 7.2%, respectively, p ˂ 0.001) 
Female cases were shorter than female controls with medians of 152 and 156 cms, 
respectively, and a median difference of 4 cms (p = 0.001). The median BMI was 31 
for female cases and 28 for female controls, with a median difference of 3 (p = 
0.014).  Female cases, therefore, were more likely to be obese (55, 57.9% versus 20, 
36.4%, respectively, p = 0.008), to have a higher median waist circumference than 
female controls, with a median difference of 16 cms (p ˂ 0.001) and have a higher 
median hip circumference than female controls, with a median difference of 5 cms (p 
= 0.032). The median WHR of female cases 0.95 compared to 0.86 for female 
controls, with a median difference of 0.09 (p ˂ 0.001). Furthermore, female cases 
were more likely to have high WHR than female controls (75, 78.9% versus 17, 
30.9%, respectively, p ˂ 0.001). 
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Table 30. Anthropometry of cases and controls. 
Anthropometry 
N = 463 
Male 
p 
Female  
p Cases 
n = 230 
Controls 
n = 83 
Cases 
n = 95 
Controls 
n = 55 
Height (cm) Median (IQR) 167 (161 -171) 170 (163 -175) 0.004 152 (148 -156) 156 (152 -161) 0.001 
Weight (kg) Median (IQR) 77 (70 -90) 72 (65 -83) 0.009 75 (65 -83) 68 (59 -85) 0.156 
BMI* (kg/m2) Median (IQR) 28 (25 -31) 26 (22 -30) ˂ 0.001 31 (27 -36) 28 (24 -35) 0.014 
BMI* groups 
≤ 18.4 0 (0.0%) 7 (8.4%) 
˂ 0.001 
0 (0.0%) 3 (5.5%) 
0.008 
18.5 - 24.9 56 (24.3%) 27 (32.5%) 14 (14.7%) 14 (25.5%) 
25 - 29.9 91 (39.6%) 27 (32.5%) 26 (27.4%) 18 (32.7%) 
≥ 30 83 (36.1%) 22 (26.5%) 55 (57.9%) 20 (36.4%) 
Waist (cm) Median (IQR) 107 (99 -114) 93 (82 -104) ˂ 0.001 107 (96 -114) 91 (82 -101) ˂ 0.001 
Hip (cm) Median (IQR) 106 (100 -113) 103 (97 -110) 0.066 111 (102 -123) 106 (97 -115) 0.032 
WHR* Median (IQR) 1.00 (0.96 - 1.04) 0.90 (0.84 - 0.96) ˂ 0.001 0.95 (0.92 - 0.99) 0.86 (0.80 - 0.91) ˂ 0.001 
WHR* groups 
Low 10 (4.3%) 42 (50.6%) 
˂ 0.001 
3 (3.2%) 18 (32.7%) 
˂ 0.001 Moderate 92 (40.0%) 35 (42.2%) 17 (17.9%) 20 (36.4%) 
High 128 (55.7%) 6 (7.2%) 75 (78.9%) 17 (30.9%) 
*BMI = Body Mass index, *WHR = Waist/Hip Ratio
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The metabolic and clinical characteristics of all participants are shown in table 31. 
Cases had higher median FPG than controls (127 versus 94 mg/dL, respectively), 
with a higher proportion of cases being classified as having high FPG than controls 
(159, 51.3% versus 27, 15.2%, respectively) (p ˂ 0.001). Cases also had higher 
HbA1c, with median of 6.9% compared to a median of 5.9% for controls (p ˂ 0.001) 
and a higher proportion of cases had HbA1c levels ≥ 6.5% than controls (162, 55.7% 
versus 31, 22.5%, respectively, p ˂ 0.001). Cases had higher median plasma insulin 
levels than controls (14.6 versus 11.25 µU/ml, respectively, p = 0.002) and higher 
median HOMA2-IR than controls (2 versus 1.5, respectively, p ˂ 0.001) with a 
higher proportion of cases being classified as having HOMA2-IR ≥ 2 (131, 48.3% 
versus 42, 30.4%, respectively, p = 0.001). 
The diabetic status of cases and controls is shown in table 32. The total number of 
diabetic patients was calculated as described in the previous chapter. There was a 
higher proportion of diabetic patients among cases (213, 65.5%, 95% CI 60.1 - 
70.7%) than controls (38, 27.5%, 95% CI 20.3 - 35.8%) (p ˂ 0.001) (figure 18). 
Cases with T2DM were also more likely to be using insulin (74, 34.7%, 95% CI 28.4 
- 41.5%) than diabetic controls (1, 2.6%, 95% CI 0.1 - 13.8%) (p ˂ 0.001) (figure 
19). 
Normoglycemic participants were classified according to whether they had IR using 
a HOMA2-IR cut-off of ≥ 2. Out of 325 cases, 112 had a normoglycemic status 
(34.5%, 95% CI 30.2 - 41.2%) compared to 100 (72.5%, 95% CI 64.2 - 79.7%) of 
138 controls. Among 112 normoglycemic cases, 36 (31.3%, 95% CI 23.0 - 40.6%) 
had IR compared to 23 of 100 normoglycemic controls (23.0%, 95% CI 15.2 - 
32.5%). There was no statistically significant difference at the univariate analysis 
between normoglycemic cases and controls regarding to IR (p = 0.138) (figure 20). 
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The total number of participants with metabolic syndrome was calculated as 
described in the previous chapter. There was a higher proportion of cases with 
metabolic syndrome (285, 93.4%, 95% CI 90.1 – 95.9%) than among controls (66, 
42.8%, 95% CI 39.3 – 56.5%, p ˂ 0.001).  
Table 31. Metabolic and clinical characteristic of cases and controls. 
Metabolic/Clinical characteristic 
N = 463 
Cases 
n = 325 (%) 
Controls  
n = 138 (%) 
p 
FPG* (mg/dL) Min-Max 55 - 380 55 - 394 
˂ 0.001 
Median (IQR) 127 (99 - 192) 94 (83 - 105) 
< 110 121 (39.0) 110 (79.7) 
˂ 0.001 110 – 125 30 (9.7) 7 (5.1) 
≥ 126 159 (51.3) 21 (15.2) 
HbA1c* (%) Min-Max 2.7 - 13.5 4.1 - 11.9 
˂ 0.001 
Median (IQR) 6.9 (5.9 - 8.9) 5.9 (5.5 - 6.4) 
< 5.7 56 (19.2) 57 (41.3) 
˂ 0.001 ≥ 5.7 – 6.4 73 (25.1) 50 (36.2) 
≥ 6.5 162 (55.7) 31 (22.5) 
Fasting Plasma 
Insulin (µU/ml) 
Min-Max 2.9 - 57.6 2.9 - 57.1 
0.002 
Median (IQR) 14.6 (9 - 21.4) 11.25 (7.1 - 17.5) 
2 – < 25 223 (82.3) 117 (84.8) 
0.524 
≥ 25 48 (17.7) 21 (15.2) 
HOMA2-IR* Min-Max 0.3 - 9.9 0.4 - 6.5 
˂ 0.001 
Median (IQR) 2 (1.3 - 3.2) 1.5 (0.9 - 2.4) 
Normal < 2 140 (51.7) 96 (69.6) 
0.001 
IR ≥ 2 131 (48.3) 42 (30.4) 
Total cholesterol 
(mg/dL) 
Min-Max 73 - 494 107 - 332.7 
˂ 0.001 
Median (IQR) 
161 (132.5 - 
190) 
187 (151.9 - 
216.5) 
< 150 116 (38.0) 30 (21.7) 
0.001 
≥ 150 189 (62.0) 108 (78.3) 
Triglycerides 
(mg/dL) 
Min-Max 38 - 744 32 -846.2 
˂ 0.001 
Median (IQR) 138 (100 - 198) 106 (74.8 - 156.1) 
< 150 168 (55.1) 100 (72.5) 
0.002 < 200 63 (20.7) 18 (13.0) 
≥ 200 74 (24.3) 20 (14.5) 
Min-Max 1.4 - 87.0 19.5 - 90.8 0.001 
124 
HDL* 
Cholesterol 
(mg/dL) 
Median (IQR) 37 (32 - 45.5) 42 (34 - 50.7) 
Optimal  
Male ≥ 40 
Female ≥ 50 
129 (39.7) 63 (45.7) 
0.234 
Risky  
Male < 40 
Female < 50 
196 (60.3) 75 (54.3) 
LDL* 
Cholesterol 
(mg/dL) 
Min-Max 9 - 244 27.6 - 234.4 
˂ 0.001 
Median (IQR) 93 (70.5 - 122) 114 (87.6 - 141.7) 
< 70 mg/dL 74 (24.3) 15 (10.9) 
 0.001 
≥ 70 mg/dL 231 (75.7) 123 (89.1) 
Systolic BP* Min-Max 90 - 200 82 - 219 
˂ 0.001 
Median (IQR) 
140 (128.5 - 
157) 121 (108 - 136) 
Diastolic BP* Min-Max 50 – 117 43 – 101 
˂ 0.001 
Median (IQR) 80 (70 - 86) 64 (57 - 76) 
*FPG = Fasting plasma glucose, *HbA1c = Glycated haemoglobin, *HOMA2-IR = Homeostasis 
model assessment-(2)-Insulin resistance, *HDL = High-density lipoprotein, *LDL = Low-density 
lipoprotein, *BP = Blood pressure. HDL cholesterol: Optimal = Male ≥ 40 Female ≥ 50; Risky = Male 
<40, Female < 50 
Table 32. T2DM and IR cases among cases and controls. 
Study population  
N = 463 
Cases 
n = 325 (%) 
95% CI 
Controls 
n = 138 (%) 
95% CI p 
T2DM participants 213 (65.5) 60.1 - 70.7 38 (27.5) 20.3 - 35.8 ˂ 0.001 
 
T2DM using insulin 74 (34.7) 28.4 - 41.5 1 (2.6) 0.1 - 13.8 
˂ 0.001 T2DM not using 
insulin 
139 (65.3) 58.5 -71.6 37 (97.4) 86.2 - 99.9 
Normoglycemic 
participants 
112 (34.5) 30.2 - 41.2 100 (72.5) 64.2 - 79.7 ˂ 0.001 
 
Normoglycemic with 
IR 
36 (31.3) 23.0 - 40.6 23 (23.0) 15.2 - 32.5 
0.138 
Normoglycemic 
without IR 
76 (68.7) 56.7 - 74.7 77 (77.0) 67.5 - 84.8 
  n = 305 (%)  n = 138 (%)   
 Participants with MS 285 (93.4) 90.1 - 95.9 66 (42.8) 39.3 - 56.5 
˂ 0.001 
 
Participants without 
MS 
20 (6.6) 4.1 - 9.9 72 (52.2) 43.5 - 60.7 
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Figure 18. Diabetes status of cases and 
controls 
Figure 19. Insulin use among cases and 
controls 
  
Figure 20. IR status of normoglycemic cases and controls 
 
 
 
4.2. Logistic Regression 
Controls were selected using systematic random sampling by selecting every fifth 
participant attending to the TB and chest diseases centre, as described in the previous 
chapter. Although ideally, we should have selected a new control group, we were 
unable to select controls for the CHD group from the King Faisal Hospital because the 
patients attending the hospital were uncooperative and it was difficult to convince 
them to participate. In addition, recruitment of patients took place at the same time 
that the study on TB, which recruited patients from a different city 300 kilometres 
apart. Therefore, we used the same controls recruited from the TB and chest diseases 
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centre. We tried to recruit controls of similar gender and age balance than patients 
with CHD but, unfortunately, at the time of analysis, we realized that controls were 
much more older than cases, to a degree that makes it difficult to control for 
confounding, as many other risk factors are associated to age (obesity, hypertension 
etc.) and the sample size was unlikely to be large enough to fully explore these 
associations. Furthermore, the ethnicity of cases and controls was also markedly 
different which worsen the situation. We reworked the analysis by removing factors 
for T2DM that were highly correlated. Fasting plasma glucose, history of T2DM and 
HbA1c were all merged into the presence or absence of T2DM and estimated the 
AOR. 
As described in the previous chapter, many variables had significant correlations and 
we undertook the same approach conducting multivariable backward stepwise 
logistic regression for clusters of variables, to identify the main variables for each 
cluster. The variables with p-values < 0.2 were selected to enter multivariable 
backward stepwise logistic regressions. These included gender, age, nationality, 
marital status, education, occupation, T2DM, T2DM using insulin, family history of 
diabetes, hypertension, taking hypertensive medication, hyperlipidaemia, taking lipid 
lowering therapy, history of gestational diabetes, polycystic ovaries, type of job, 
monthly income, level of stress, overweight among family, overweight as a child, 
smoking, past smoker, number of breakfast meals last week, number of lunch meals 
last week, number of dinner meals last week, participant rating of his/her diet, fast 
food consumption, WHR, BMI, FPG, HbA1c, fasting plasma insulin, total 
cholesterol, triglycerides, LDL Cholesterol, HDL Cholesterol, systolic BP and 
diastolic BP. Multivariable backward stepwise logistic regressions were conducted 
separately for demographic characteristics, medical history, lifestyle and diet, 
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anthropometry and metabolic and clinical characteristics of cases and controls. As 
shown in appendix (14 - 15). For each cluster, the variables remaining statistically 
significant were carried forward into multivariate analysis using backward statistics 
regressions with replacement. We adjusted for age, and gender to obtain AORs.  
The multivariable backward stepwise logistic regression analysis for significant 
variables from the previous logistic regression analysis including T2DM is shown in 
table 33. Cases were more likely to be Saudi (AORs 45.0, 95% CI 1.4 - 18.0, p = 
0.013) and to have T2DM (AORs 3.4, 95% CI 1.0 - 11.1, p = 0.046). The odds of 
being male for patients with CHD was AOR 23.9 (95% CI 4.6 - 124.8, p ˂ 0.001). 
Subjects with CHD were more likely to be aged 40 – 49, 50 - 59, 60 - 69 and ≥ 70 
years old (AORs 40.9, 95% CI 3.4 - 491.6, p = 0.003); (71.7, 95% CI 6.0 - 862.2, p = 
0.001), (43.9, 95% CI 3.6 - 538.2, p = 0.003) and (104.0, 95% CI 6.5 – 1672, p = 
0.001). Cases were less likely to be married or previously married (AOR 0.06, 95% 
CI 0.01 - 0.30, p = 0.001) and to have primary education (AOR 22.8, 95% CI 2.7 - 
196.8, p = 0.004). Cases were more likely to take hypertensive medications (AOR 
8.6, 95% CI 2.3 - 31.8, p = 0.001) and lipid lowering therapy (AOR 21.1, 95% CI 5.7 
- 77.7, p ˂ 0.001) than controls. Cases were less likely to eat fast foods 3 – 4 
times/week (AOR 0.07, 95% CI 0.01 - 0.70, p = 0.024), were more likely to have 
high WHR (AOR 30.6, 95% CI 5.1 - 184.8, p ˂ 0.001) and high diastolic BP (AOR 
1.1, 95% CI 1.1 - 1.2, p ˂ 0.001) than controls. 
The multivariable backward stepwise logistic regression analysis for significant 
variables from the previous logistic regression analysis including metabolic 
syndrome is shown in table 34. The odds of being male for patients with CHD was 
AOR 3.1 (95% CI 1.3 - 7.5, p = 0.012). Subjects with CHD were more likely to be 
aged 40 – 49, 50 - 59, 60 - 69 and ≥ 70 years old (AORs 31.8, 95% CI 4.8 - 209.6, p 
128 
˂ 0.001); (62.0, 95% CI 9.3 - 414.5, p ˂ 0.001), (104.2, 95% CI 14.5 - 751.4, p ˂ 
0.001) and (183.9, 95% CI 23.5 - 1440, p ˂ 0.001). Cases were less likely to be 
married or previously married (AOR 0.2, 95% CI 0.06 - 0.5, p = 0.001) and to have 
primary education (AOR 9.6, 95% CI 2.5 - 36.4, p = 0.001) and more likely to be 
among 5001 – 10000 (SAR) monthly income group (AOR 6.7, 95% CI 1.4 - 31.3, p 
= 0.016). Cases were more likely to have metabolic syndrome (AOR 6.1, 95% CI 2.5 
- 15.0, p ˂ 0.001) and were more likely to have higher level of stress (AOR 10.6, 
95% CI 1.4 - 80.9, p = 0.022) than controls. 
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Table 33. Logistic regression model for factors predicting getting CHD including T2DM  
Variables 
N = 463 
Univariate Multivariate 
Cases 
n = 325 (%) 
Controls 
n = 138 (%) 
P AOR* (95% CI) p 
Gender Female 95 (29.2) 55 (39.9) 
0.025 
1 
Male 230 (70.8) 83 (60.1) 23.867(4.57 - 124.76) ˂ 0.001 
Age group 18 – 39 2 (0.6) 61 (44.6) 
˂ 0.001 
1 
40 – 49 31 (9.5) 29 (21.0) 40.960 (3.41 - 491.58) 0.003 
50 – 59 91 (28.0) 27 (19.6) 71.712 (5.96 - 862.20) 0.001 
60 – 69 103 (31.7) 13 (9.4) 43.905 (3.58 - 538.15) 0.003 
≥ 70 98 (30.2) 8 (5.8) 104.031 (6.47 - 1672) 0.001 
Ethnicity Non-Saudi 42 (12.9) 67 (48.6) 
˂ 0.001 
1 
Saudi 283 (87.1) 71 (51.4) 5.034 (1.41 - 17.98) 0.013 
Marital status Single 29 (8.9) 33 (23.9) 
˂ 0.001 
1 
Married 296 (91.1) 105 (76.1) 0.059 (0.01 - 0.30) 0.001 
Education No education 33 (10.2) 13 (9.4) 
˂ 0.001 
1 
Literacy 73 (22.5) 20 (14.5) 2.064 (0.34 - 12.52) 0.431 
Primary education 122 (37.5) 21 (15.2) 22.830 (2.65 - 196.80) 0.004 
Intermediate 
education 
22 (6.8) 31 (22.5) 0.679 (0.07 - 6.34) 0.735 
Secondary 
education 
57 (17.5) 36 (26.1) 1.964 (0.24 - 15.95) 0.528 
Higher education 18 (5.5) 17 (12.3) 4.007 (0.32 - 50.37) 0.282 
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Type of job Sedentary 307 (94.5) 95 (68.8) 
˂ 0.001 
27.544 (0.55 - 1374) 0.097 
Moderate Physical 
Activity 
16 (4.9) 38 (27.5) 10.737 (0.22 - 530.72) 0.233 
Physically Very 
Demanding 
2 (0.6) 5 (3.6) 1 
Past smoker 
No 207 (63.7) 130 (94.2) 
˂ 0.001 
1 
Yes 118 (36.3) 8 (5.8) 1.926 (0.46 - 8.15) 0.373 
T2DM No 112 (34.5) 100 (72.5) 
˂ 0.001 
1 
Yes 213 (65.5) 38 (27.5) 3.436 (1.02 - 11.11) 0.046 
Takes 
hypertensive 
medication 
No 47 (14.5) 117 (84.8) 
˂ 0.001 
1 
Yes 278 (85.5) 21 (15.2) 8.577 (2.31 - 31.83) 0.001 
Takes lipid 
lowering therapy 
No 52 (16.0) 120 (87.0) 
˂ 0.001 
1 
Yes 270 (83.1) 15 (10.9) 21.103 (5.73 - 77.70) ˂ 0.001 
Don't know 3 (0.9) 3 (2.2) 0.053 (0.00 - 1.08) 0.056 
Level of stress Low 199 (61.2) 110 (79.7) 
˂ 0.001 
1 
Medium 105 (32.3) 25 (18.1) 2.603 (0.77 - 8.77) 0.123 
High 21 (6.5) 3 (2.2) 9.312 (0.34 - 256.88) 0.187 
Fast food 
consumption 
0 ‐ 1 Times/Month 172 (52.9) 51 (37.0) 
˂ 0.001 
1 
2 ‐ 3 Times/Month 73 (22.5) 21 (15.2) 2.103 (0.47 - 9.45) 0.332 
1 ‐ 2 Times/Week 45 (13.8) 30 (21.7) 0.229 (0.05 - 1.02) 0.053 
3 ‐ 4 Times/Week 19 (5.8) 22 (15.9) 0.069 (0.01 - 0.70) 0.024 
≥ 5 Times/Week 16 (4.9) 14 (10.1) 0.476 (0.05 - 4.31) 0.509 
WHR 
 
Male 
case 
Male 
controls 
Female 
case 
Female 
controls 
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Low 
10  
(4.3) 
42 
(50.6) 
3  
(3.2) 
18 
(32.7) 
˂ 0.001 
1 
Moderate 
92 
(40.0) 
35 
(42.2) 
17 
(17.9) 
20 
(36.4) 
2.213 (0.42 - 11.54) 0.346 
High 
128 
(55.7) 
6  
(7.2) 
75 
(78.9) 
17 
(30.9) 
30.572 (5.06 - 184.82) ˂ 0.001 
Systolic BP Median (IQR) 140 (128.5 - 157) 121 (108 - 136) ˂ 0.001 0.976 (0.95 - 1.01) 0.106 
Diastolic BP Median (IQR) 80 (70 - 86) 64 (57 - 76) ˂ 0.001 1.108 (1.05 - 1.17) ˂ 0.001 
Constant    ˂ 0.001 ˂ 0.001 
*AOR = Adjusted Odds Ratio 
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Table 34 Logistic regression model for factors predicting getting CHD including metabolic syndrome. 
Variables 
N = 463 
Univariate Multivariate 
Cases 
n = 325 (%) 
Controls 
n = 138 (%) 
P AOR* (95% CI) p 
Gender Female 95 (29.2) 55 (39.9) 
0.025 
1 
Male 230 (70.8) 83 (60.1) 3.088 (1.28 - 7.47) 0.012 
Age group 18 – 39 2 (0.6) 61 (44.6) 
˂ 0.001 
1 
40 – 49 31 (9.5) 29 (21.0) 31.745 (4.81 - 209.61) ˂ 0.001 
50 – 59 91 (28.0) 27 (19.6) 62.008 (9.28 - 414.46) ˂ 0.001 
60 – 69 103 (31.7) 13 (9.4) 104.198 (14.45 - 751.4) ˂ 0.001 
≥ 70 98 (30.2) 8 (5.8) 183.875 (23.47 - 1440) ˂ 0.001 
Ethnicity Non-Saudi 42 (12.9) 67 (48.6) 
˂ 0.001 
1 
Saudi 283 (87.1) 71 (51.4) 2.017 (0.78 - 5.21) 0.147 
Marital status Single 29 (8.9) 33 (23.9) 
˂ 0.001 
1 
Married 296 (91.1) 105 (76.1) 0.179 (0.06 - 0.51) 0.001 
Education No education 33 (10.2) 13 (9.4) 
˂ 0.001 
1 
Literacy 73 (22.5) 20 (14.5) 3.305 (0.96 - 11.44) 0.059 
Primary education 122 (37.5) 21 (15.2) 9.589 (2.53 - 36.35) 0.001 
Intermediate 
education 
22 (6.8) 31 (22.5) 0.515 (0.11 - 2.38) 0.395 
Secondary 
education 
57 (17.5) 36 (26.1) 1.118 (0.25 - 5.04) 0.884 
Higher education 18 (5.5) 17 (12.3) 1.403 (0.22 - 8.88) 0.719 
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Type of job Sedentary 307 (94.5) 95 (68.8) 
˂ 0.001 
13.404 (0.70 - 255.20) 0.084 
Moderate Physical 
Activity 
16 (4.9) 38 (27.5) 4.275 (0.23 - 79.47) 0.330 
Physically Very 
Demanding 
2 (0.6) 5 (3.6) 1 
Past smoker 
No 207 (63.7) 130 (94.2) 
˂ 0.001 
1 
Yes 118 (36.3) 8 (5.8) 2.677 (0.99 - 7.21) 0.051 
Monthly income 
(SAR) 
≤ 3000 141 (43.4) 92 (66.7) 
˂ 0.001 
1 
3000 – 5000 105 (32.3) 34 (24.6) 1.177 (0.46 - 3.03) 0.735 
5001 – 10000 54 (16.6) 9 (6.5) 6.677 (1.42 - 31.29) 0.016 
≥ 10000 25 (7.7) 3 (2.2) 4.954 (0.77 - 31.76) 0.091 
Metabolic 
syndrome  
Cases n= 305 
No 20 (6.6) 72 (52.2) 
˂ 0.001 
1 
Yes 285 (93.4) 66 (42.8) 6.110 (2.49 - 15.01) ˂ 0.001 
Level of stress Low 199 (61.2) 110 (79.7) 
˂ 0.001 
1 
Medium 105 (32.3) 25 (18.1) 1.869 (0.85 - 4.10) 0.119 
High 21 (6.5) 3 (2.2) 10.635 (1.40 - 80.88) 0.022 
Fast food 
consumption 
0 ‐ 1 Times/Month 172 (52.9) 51 (37.0) 
˂ 0.001 
1 
2 ‐ 3 Times/Month 73 (22.5) 21 (15.2) 1.003 (0.38 - 2.65) 0.995 
1 ‐ 2 Times/Week 45 (13.8) 30 (21.7) 0.557 (0.21 - 1.48) 0.242 
3 ‐ 4 Times/Week 19 (5.8) 22 (15.9) 0.371 (0.09 - 1.51) 0.166 
≥ 5 Times/Week 16 (4.9) 14 (10.1) 0.619 (0.13 - 2.99) 0.551 
Total cholesterol 
(mg/dL) 
< 150 116 (38.0) 30 (21.7) 
 0.001 
1 
≥ 150 189 (62.0) 108 (78.3) 0.422 (0.18 - 1.01) 0.051 
Constant    0.001 ˂ 0.001 
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4.3. Comparison of CHD cases with and without T2DM or IR  
We conducted a sub-analysis for (a) normoglycaemic CHD cases without IR (b) 
euglycaemic CHD cases with IR and (c) CHD cases with T2DM to determine factors 
independently associated with T2DM and IR among patients with CHD. Independent 
variables for these analyses were chosen based on the literature of risk factors for 
CHD. We will call normoglycemic CHD cases without IR as ‘CHD-controls’ (n = 
79); euglycemic CHD cases with IR as ‘CHD-IR’ (n = 37) and CHD diabetic cases 
as CHD-diabetic’ (n = 209).  
The demographic characteristics of CHD-IR and CHD-diabetic cases and CHD-
controls are shown in table 35. CHD-IR cases were more likely to work for the 
governmental sector (12, 32.4%) and to be retired (15, 40.5%) than CHD-controls 
(10, 12.7% and 25, 31.6%, respectively). CHD-controls were more likely to work for 
the private sector (13, 16.5%) or to belong to the non-employed categories (25, 
31.6%) than CHD-IR cases (2, 5.4% and 6, 16.2%, respectively) (p = 0.041).  
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Table 35. Demographic characteristics of CHD-IR cases, CHD-diabetic cases 
and CHD-controls  
Demographic 
characteristics 
N = 463 
CHD-
Controls 
n = 79 (%) 
 CHD-IR 
n = 37 (%) 
P 
 CHD- 
Diabetic 
n = 209 
(%) 
P 
Sex 
Male 58 (73.4) 26 (70.3) 
0.724 
146 (69.9) 
0.553 
Female 21 (26.6) 11 (29.7) 63 (30.1) 
Age 
Min-Max 37 - 95 38 - 98 
0.190 
42 - 90 
0.673 
Median (IQR) 62 (55 - 75) 60 (53 - 64) 
63 (55 - 
70) 
Age 
groups 
18 – 39 1 (1.3) 1 (2.7) 
0.177 
0 (0.0) 
0.207 
40 – 49 10 (12.7) 5 (13.5) 16 (7.7) 
50 – 59 20 (25.3) 9 (24.3) 62 (29.7) 
60 – 69 20 (25.3) 16 (43.2) 67 (32.1) 
≥ 70 28 (35.4) 6 (16.2) 64 (30.6) 
Marital 
status 
Single 4 (5.1) 2 (5.4) 
0.944 
23 (11.0) 
0.099 
With 
partner/married 
64 (81.0) 29 (78.4) 150 (71.8) 
Divorced/separa
ted 
0 (0.0) 0 (0.0) 9 (4.3) 
Widowed 11 (13.9) 6 (16.2) 27 (12.9) 
Education 
No education 14 (17.7) 4 (10.8) 
0.627 
15 (7.2) 
0.169 
Literacy 14 (17.7) 8 (21.6) 51 (24.4) 
Primary 
education 
28 (35.4) 13 (35.1) 81 (38.8) 
Intermediate 
education 
5 (6.3) 2 (5.4) 15 (7.2) 
Secondary 
education 
14 (17.7) 5 (13.5) 38 (18.2) 
Higher 
education 
4 (5.1) 5 (13.5) 9 (4.3) 
Occupatio
n 
Governmental 10 (12.7) 12 (32.4) 
0.041 
43 (20.6) 
0.170 
Private 13 (16.5) 2 (5.4) 24 (11.5) 
Labourer 5 (6.3) 1 (2.7) 3 (1.4) 
Retired 25 (31.6) 15 (40.5) 62 (29.7) 
Non-employed 25 (31.6) 6 (16.2) 74 (35.4) 
Other 1 (1.3) 1 (2.7) 3 (1.4) 
Ethnicity 
Saudi 64 (81.0) 34 (91.9) 
0.131 
185 (88.5) 
0.097 
Non-Saudi 15 (19.0) 3 (8.1) 24 (11.5) 
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The medical histories of CHD-IR, CHD-diabetic cases and CHD-controls are shown 
in table 36. There were clear differences between CHD-diabetic cases and CHD-
controls in terms of family history of diabetes, with 152 (72.7%) of CHD-diabetic 
cases and 33 (41.8%) of CHD-controls having a family history of diabetes (p ˂ 
0.001) (figure 21); with a higher frequency among first degree (133, 63.6% versus  
30, 38.0%, respectively, p ˂ 0.001) and second degree CHD-diabetic cases than 
CHD-controls (65, 31.1% versus 12, 15.2%, respectively, p = 0.006). CHD-diabetic 
cases were more likely to have experienced gestational diabetes than CHD-controls 
(12, 19.0% versus 0, 0.0%, p = 0.035, respectively) (figure 22).  
Table 36. Medical history of CHD-IR cases, CHD-diabetic cases and CHD-
controls  
Medical history 
N = 463 
CHD-
Controls 
n = 79 
(%) 
 CHD-
IR 
n = 37 
(%) 
P 
 CHD- 
Diabetic 
n = 209 
(%) 
P 
Family history 
of diabetes 
Yes 33 (41.8) 21 (56.8) 
0.132 
152 
(72.7) 
˂ 
0.001 
No 46 (58.2) 16 (43.2) 57 (27.3) 
1st 
degree 
Yes 30 (38.0) 18 (48.6) 
0.277 
133 
(63.6) 
˂ 
0.001 
No 49 (62.0) 19 (51.4) 76 (36.4) 
2nd 
degree 
Yes 12 (15.2) 4 (10.8) 
0.524 
65 (31.1) 
0.006 
No 67 (84.8) 33 (89.2) 
144 
(68.9) 
3rd 
degree 
Yes 2 (2.5) 2 (5.4) 
0.445 
10 (4.8) 
0.370 
No 77 (97.5) 35 (94.6) 
199 
(95.2) 
Hypertension 
Yes 61 (77.2) 23 (62.2) 
0.091 
168 
(80.4) 
0.400 
No 18 (22.8) 14 (37.8) 39 (18.7) 
Don’t know 0 (0.0) 0 (0.0) 2 (1.0) 
Takes 
hypertensive 
medication 
Yes 66 (83.5) 29 (78.4) 
0.501 
183 
(87.6) 0.374 
No 13 (16.5) 8 (21.6) 26 (12.4) 
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Hyperlipidaemia  
Yes 62 (78.5) 26 (70.3) 
0.600 
175 
(83.7) 
0.581 
No 13 (16.5) 9 (24.3) 26 (12.4) 
Don’t know 4 (5.1) 2 (5.4) 8 (3.8) 
Takes lipid 
lowering 
therapy 
Yes 64 (81.0) 29 (78.4) 
0.610 
177 
(84.7) 
0.757 
No 14 (17.7) 8 (21.6) 30 (14.4) 
Don’t know 1 (1.3) 0 (0.0) 2 (1.0) 
History of 
gestational 
diabetes 
Yes 0 (0.0) 0 (0.0)) 
0.354 
12 (19.0) 
0.035 
No 20 (95.2) 11 (100) 49 (77.8) 
Don’t know 1 (4.8) 0 (0.0) 2 (3.2) 
Not 
applicable 
58 (73.4) 26 (70.3) 
147 
(70.3) 
History of 
polycystic 
ovaries 
Yes 1 (4.8) 1 (9.1) 
0.639 
7 (11.1) 
0.483 
No 20 (95.2) 10 (90.9) 55 (87.3) 
Don’t know 0 (0.0) 0 (0.0) 1 (1.6) 
Not 
applicable 
58 (73.4) 26 (70.3) 
146 
(69.9) 
 
Figure 21. Family history of diabetes of 
CHD-diabetic cases and CHD-controls 
Figure 22. Gestational diabetes between 
CHD-diabetic and CHD-controls 
   
 
The lifestyle and diet of CHD-diabetic, CHD-IR cases and CHD-controls are shown 
in table 37. CHD-IR cases were more likely to have a higher monthly income ≥ 
10000 SAR (5, 13.5%) than CHD-controls (1, 1.3%) and a monthly income of 
41.8
58.2
72.7
27.3
0
50
100
Yes No
P
E
R
C
E
N
T
A
G
E
 (
%
)
P ˂ 0.001
FAMILY HISTORY OF 
DIABETES
CHD-controls CHD-DM
0
95.2
4.8
19
77.8
3.2
0
50
100
Yes No Don’t know
P
E
R
C
E
N
T
A
G
E
 (
%
)
P = 0.035
HISTORY OF 
GESTATIONAL DIABETES
CHD-controls CHD-DM
138 
between 5001 and 10000 SAR (8, 21.6%) than CHD-controls (14, 17.7%) (p = 
0.027). CHD-diabetic cases in turn were more likely to have a history of overweight 
during childhood than CHD-controls (47, 22.5% versus 8, 10.1%, respectively, p = 
0.038) (figure 23).  
Table 37. Lifestyle and diet of CHD-IR cases, CHD-diabetic cases and CHD-
controls  
Lifestyle and diet 
N = 463 
CHD-
Controls 
n = 79 (%) 
 CHD-IR 
n = 37 (%) 
P 
 CHD- 
Diabetic 
n = 209 (%) 
P 
Type of job 
Sedentary 73 (92.4) 34 (91.9) 
0.644 
200 (95.7) 
0.532 
Moderate 
Physical 
Activity 
5 (6.3) 3 (8.1) 8 (3.8) 
Physically 
Very 
Demanding 
1 (1.3) 0 (0.0) 1 (0.5) 
Monthly 
income 
(SAR) 
≤ 3000 34 (43.0) 16 (43.2) 
0.027 
91 (43.5) 
0.055 
3000 - 5000 30 (38.0) 8 (21.6) 67 (32.1) 
5001 - 10000 14 (17.7) 8 (21.6) 32 (15.3) 
≥ 10000 1 (1.3) 5 (13.5) 19 (9.1) 
Level of 
stress 
Low 51 (64.6) 24 (64.9) 
0.197 
124 (59.3) 
0.582 Medium 24 (30.4) 13 (35.1) 68 (32.5) 
High 4 (5.1) 0 (0.0) 17 (8.1) 
Overweight 
among 
family 
Yes 20 (25.3) 15 (40.5) 
0.096 
78 (37.3) 
0.103 No 59 (74.7) 22 (59.5) 130 (62.2) 
Don’t know 0 (0.0) 0 (0.0) 1 (0.5) 
If yes, who? 
Father 
Yes 1 (1.3) 1 (2.7) 
0.538 
12 (5.7) 
0.067 
No 78 (98.7) 36 (97.3) 197 (94.3) 
Mother 
Yes 4 (5.1) 3 (8.1) 
0.531 
17 (8.1) 
0.371 
No 75 (94.9) 34 (91.9) 192 (91.9) 
Overweight 
as a child 
Yes 8 (10.1) 6 (16.2) 
0.455 
47 (22.5) 
0.038 No 70 (88.6) 31 (83.8) 158 (75.6) 
Don’t know 1 (1.3) 0 (0.0) 4 (1.9) 
Smoking 
Yes 10 (12.7) 6 (16.2) 
0.604 
21 (10.0) 
0.524 
No 69 (87.3) 31 (83.8) 188 (90.0) 
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Cigarettes 
per day 
10 per 
day 
Yes 3 (3.8) 2 (5.4) 
0.696 
4 (1.9) 
0.375 
No 76 (96.2) 35 (94.6) 205 (98.1) 
10–20 
per day 
Yes 7 (8.9) 4 (10.8) 
0.741 
17 (8.1) 
0.842 
No 72 (91.1) 33 (89.2) 192 (91.9) 
Past smoker 
Yes 29 (36.7) 9 (24.3) 
0.185 
80 (38.3) 
0.807 
No 50 (63.3) 28 (75.7) 129 (61.7) 
Number of 
breakfast 
meals last 
week 
Never 2 (2.5) 4 (10.8) 
0.198 
12 (5.7) 
0.335 
1 - 6 10 (12.7) 4 (10.8) 18 (8.6) 
Always 67 (84.8) 29 (78.4) 179 (85.6) 
Number of 
lunch meals 
last week 
Never 1 (1.3) 2 (5.4) 
0.421 
7 (3.3) 
0.539 1 - 6 5 (6.3) 3 (8.1) 17 (8.1) 
Always 73 (92.4) 32 (86.5) 185 (88.5) 
Number of 
dinner 
meals last 
week 
Never 2 (2.5) 0 (0.0) 
0.438 
2 (1.0) 
0.627 1 - 6 5 (6.3) 3 (8.1) 14 (6.7) 
Always 72 (91.1) 34 (91.9) 193 (92.3) 
Participant 
rating of 
his/her diet 
Good 9 (11.4) 1 (2.7) 
0.298 
12 (5.7) 
0.235 Fair 52 (65.8) 27 (73.0) 141 (67.5) 
Poor 18 (22.8) 9 (24.3) 56 (26.8) 
Fast food 
consumption 
0 ‐ 1 
Times/Month 
34 (43.0) 16 (43.2) 
0.185 
122 (58.4) 
0.078 
2 ‐ 3 
Times/Month 
17 (21.5) 14 (37.8) 42 (20.1) 
1 ‐ 2 
Times/Week 
18 (22.8) 3 (8.1) 24 (11.5) 
3 ‐ 4 
Times/Week 
6 (7.6) 3 (8.1) 10 (4.8) 
≥ 5 
Times/Week 
4 (5.1) 1 (2.7) 11 (5.3) 
Food 
portions 
description 
Small 17 (21.5) 4 (10.8) 
0.236 
41 (19.6) 
0.817 Intermediate 40 (50.6) 18 (48.6) 102 (48.8) 
Large 22 (27.8) 15 (40.5) 66 (31.6) 
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Figure 23. History of childhood overweight of CHD-diabetic cases 
and CHD-controls 
 
  
 
 
The anthropometry of CHD-IR and CHD-diabetic male cases and male CHD-
controls are shown in table 38. Male CHD-IR cases had higher median weight than 
male CHD-controls (87 versus 76 Kgs, respectively) with a median difference of 11 
Kgs (p = 0.024) and a higher median waist circumference (112 versus 104, 
respectively), with a median difference of 8 cms (p = 0.028). Moreover, male CHD-
IR cases had higher median WHR than male CHD-controls (1.03 versus 0.99, 
respectively), with median difference of 0.04 (p = 0.007).  
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Table 38. Male anthropometry of CHD-IR cases, CHD-diabetic cases and CHD-controls  
Anthropometry (Male) 
N = 230 
CHD-Controls 
n = 58 (%) 
 CHD-IR 
n = 26 (%) 
P 
CHD-diabetic  
n = 146 (%) 
P 
Height (cm) Median (IQR) 167 (162 - 171) 168 (163 -174) 0.413 166 (161 - 171) 0.676 
Weight (kg) Median (IQR) 76 (68 - 88) 87 (75 - 98) 0.024 77 (71 - 89) 0.196 
BMI (kg/m2) Median (IQR) 27 (24 - 31) 30 (27 - 33) 0.063 28 (25 - 31) 0.159 
BMI groups 
≤ 18.4 0 (0.0) 0 (0.0) 
0.087 
0 (0.0) 
0.500 
18.5 - 24.9 18 (31.0) 3 (11.5) 35 (24.0) 
25 - 29.9 23 (39.7) 10 (38.5) 58 (39.7) 
≥ 30 17 (29.3) 13 (50.0) 53 (36.3) 
Waist (cm) Median (IQR) 104 (94 - 112) 112 (102 - 118) 0.028 107 (100 - 114) 0.052 
Hip (cm) Median (IQR) 104 (98 - 112) 108 (102 - 114) 0.171 106 (101 - 113) 0.140 
WHR Median (IQR) 0.99 (0.95 - 1.02) 1.03 (0.97 - 1.07) 0.007 1.00 (0.97 - 1.04) 0.110 
WHR groups 
Low 2 (3.4) 1 (3.8) 
0.172 
7 (4.8) 
0.473 Moderate 28 (48.3) 7 (26.9) 57 (39.0) 
High 28 (48.3) 18 (69.2) 82 (56.2) 
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The anthropometry data of CHD-IR, CHD-diabetic female cases and female CHD-
controls are shown in table 39. Female CHD-IR cases had higher weight than female 
CHD-controls with medians of (83 versus 67 Kgs, respectively), and a median 
difference of 16 Kgs (p = 0.006), resulting in a higher median BMI (35 versus 29, 
respectively) with a median BMI difference of 6 (p = 0.020); and median waist 
circumference of 119 versus 104 with a median difference of 15 cms (p = 0.038). 
The median BMI for female CHD-diabetic cases were 32 compared to the 29 female 
CHD-controls, with a median difference of 3 (p = 0.032). Female CHD-diabetic 
cases, therefore, were much more likely to be obese than female CHD-controls (38, 
60.3% versus 8, 38.1%, respectively, p = 0.027). 
The metabolic characteristics of CHD-IR and CHD-diabetic cases and CHD-controls 
are shown in table 40. There were 13 cases missing among CHD-controls and 7 
among CHD-T2DM. CHD-diabetic cases had higher median triglycerides than CHD-
controls (151 versus 119 mg/dL, respectively) with a median difference of 32 mg/dL 
(p = 0.003); and a higher proportion being classified as having high triglycerides (60, 
29.7% versus 8, 12.1%, respectively, p = 0.010) (figure 24). 
Moreover, CHD-diabetic cases had a higher median HDL Cholesterol (37 versus 41 
mg/dL, respectively) with a median difference of 4 mg/dL (p = 0.016) and were more 
likely to be classified as having risky HDL Cholesterol than CHD-controls (140, 
69.3% versus 36, 54.5%, respectively, p = 0.001) (figure 25). Furthermore, CHD-
diabetic cases had a lower median LDL Cholesterol (88 versus 101 mg/dL, 
respectively) with a median difference of 13 mg/dL (p = 0.061).  
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Table 39. Female anthropometry of CHD-IR cases, CHD-diabetic cases and CHD-controls  
Anthropometry (Female) 
N = 95 
CHD-Controls 
n = 21 (%) 
 CHD-IR 
n = 11 (%) 
P 
CHD-Diabetic 
n = 63 (%) 
P 
Height (cm) Median (IQR) 152 (149 - 154) 154 (146 - 157) 0.481 151 (147 -158) 0.725 
Weight (kg) Median (IQR) 67 (57 - 80) 83 (71 - 93) 0.006 75 (65 - 84) 0.077 
BMI (kg/m2) Median (IQR) 29 (24 - 33) 35 (30 - 42) 0.020 32 (28 - 36) 0.032 
BMI groups 
≤ 18.4 0 (0.0) 0 (0.0) 
0.052 
0 (0.0) 
0.027 
18.5 - 24.9 7 (33.3) 1 (9.1) 6 (9.5) 
25 - 29.9 6 (28.6) 1 (9.1) 19 (30.2) 
≥ 30 8 (38.1) 9 (81.8) 38 (60.3) 
Waist (cm) Median (IQR) 104 (94 - 110) 119 (109 - 125) 0.038 107 (97 - 114) 0.278 
Hip (cm) Median (IQR) 108 (98 - 118) 124 (102 - 128) 0.074 111 (102 - 122) 0.181 
WHR Median (IQR) 0.95 (0.91 - 0.99) 0.95 (0.95 - 1.08) 0.180 0.95 (0.91 - 0.98) 0.744 
WHR groups 
Low 0 (0.0) 0 (0.0) 
0.288 
3 (4.8) 
0.359 Moderate 5 (23.8) 1 (9.1) 11 (17.5) 
High 16 (76.2) 10 (90.9) 49 (77.8) 
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Table 40. Metabolic characteristics of CHD-IR cases, CHD-diabetic cases and 
CHD-controls  
Metabolic/Clinical 
characteristic 
N = 463 
CHD-
Controls 
n = 66 (%) 
 CHD-IR 
n = 37 (%) 
P 
CHD-Diabetic 
n = 202 (%) 
P 
Missing = 
(13) 
Missing = 
(0) 
 Missing = (7)  
Total 
cholesterol 
(mg/dL)  
Min - Max 87 - 282 91 - 250 
0.507 
73 - 494  
Median 
(IQR) 
166 (128 - 
202) 
165 (147 - 
204) 
159 (133 - 184) 0.465 
< 150 26 (39.4) 10 (27.0) 
0.207 
80 (39.6) 
0.976 
≥ 150 40 (60.6) 27 (73.0) 122 (60.4) 
Triglycerides 
(mg/dL) 
Min-Max 38 - 382 58 - 310 
0.294 
43 - 744   
Median 
(IQR) 
119 (88 - 
153) 
129 (107 - 
170) 
151 (104 - 214) 0.003 
< 150 45 (68.2) 23 (62.2) 
0.792 
100 (49.5) 
0.010 < 200 13 (19.7) 8 (21.6) 42 (20.8) 
≥ 200 8 (12.1) 6 (16.2) 60 (29.7) 
HDL 
Cholesterol 
(mg/dL) 
Min - Max 15 - 87 10 - 63 
0.842 
1.4 - 82  
Median 
(IQR) 
41 (34 - 
49) 
40 (34 - 
51) 
37 (31 - 44) 0.016 
Optimal  
Male ≥ 40 
Female ≥ 
50 
43 (65.2) 17 (45.9) 
0.394 
69 (34.2) 
0.001 
Risky  
Male < 40 
Female < 
50 
36 (54.5) 20 (54.1) 140 (69.3) 
LDL 
Cholesterol 
(mg/dL) 
Min - Max 21 - 209 27 - 182 
0.945 
9 - 244  
Median 
(IQR) 
101 (75 - 
134) 
100 (77 - 
127) 
88 (68 - 115) 0.061 
< 70 14 (21.2) 7 (18.9) 
0.782 
53 (26.2) 
0.413 
≥ 70 52 (78.8) 30 (81.1) 149 (73.8) 
Systolic BP 
Min-Max 108 - 200 100 - 188 
0.960 
90 - 200  
Median 
(IQR) 
138 (127 - 
153) 
140 (122 - 
154) 
140 (130 - 160) 0.174 
Diastolic BP 
Min-Max 50 - 117 59 - 96 
0.231 
55 - 105  
Median 
(IQR) 
80 (70 - 
85) 
80 (74 - 
90) 
78 (70 - 85) 0.834 
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Figure 24. Triglycerides levels of CHD-
diabetic and CHD-controls 
Figure 25. HDL Cholesterol levels of 
CHD-diabetic and CHD-controls 
   
The multivariable backward stepwise logistic regression analysis for significant 
variables from the previous logistic regression analysis is shown in table 41. We 
conducted a logistic regression analysis for the sub-analysis of (a) normoglycaemic 
CHD cases without IR and (b) euglycaemic CHD cases with IR to determine factors 
independently associated with IR. The variables with p < 2 were selected to inter into 
a multivariable backward stepwise logistic regression. Variables selected included 
ethnicity, monthly income, BMI Male, BMI Female and family history of diabetes. 
We adjusted for age and gender to obtain AORs. The AORs for having IR for obese 
subjects (BMI ≥ 30) was 4.793 (95% CI 1.358 - 16.913, p = 0.015) when compared 
with adults with normal weight. 
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Table 41. Logistic regression model for the comparison of CHD-IR cases and 
CHD-controls. 
Variables 
N = 463 
Multivariate 
AOR* (95% CI) p 
Age group 18 – 39 1 
40 – 49 0.557 (0.023 - 13.408) 0.719 
50 – 59 0.781 (0.034 - 18.116) 0.878 
60 – 69 0.955 (0.041 - 22.310) 0.977 
≥ 70 0.274 (0.010 - 7.264) 0.439 
Monthly income 
(SAR) 
≤ 3000 1 
3000 - 5000 0.471 (0.159 - 1.394) 0.174 
5001 - 10000 0.747 (0.212 - 2.632) 0.649 
≥ 10000 10.815 (0.946 - 123.601) 0.055 
BMI groups 
18.5 - 24.9 1 
25 - 29.9 1.644 (0.418 - 6.463) 0.476 
≥ 30 4.793 (1.358 - 16.913) 0.015 
Family history of 
diabetes 
No 1 
Yes 1.695 (0.671 – 4.292) 0.264 
Constant 0.477 0.660 
 
The multivariable backward stepwise logistic regression analysis for significant 
variables from the previous logistic regression analysis is shown in table 42. We also 
conducted a logistic regression analysis to compare (a) normoglycemic CHD cases 
without IR and (b) CHD cases with T2DM to determine factors independently 
associated with T2DM. The significant variables were selected to inter into a 
multivariable backward stepwise logistic regression. These variables included 
education, ethnicity, family history of diabetes, fast food consumption, BMI and 
triglycerides. We adjusted for age and gender to obtain AORs. Cases were more 
likely to be Saudis (AOR 2.778, 95% CI 1.143 - 6.756, p = 0.024) and to belong to 
literacy groups (AOR 3.970, 95% CI 1.328 - 11.870, p = 0.014) and to have primary 
education (AOR 2.812, 95% CI 1.063 - 7.438, p = 0.037). CHD-diabetic cases were 
more likely to have a family history of diabetes (2.710, 95% CI 1.429 - 5.128, p = 
147 
0.002), high triglycerides (AOR 3.724, 95% CI 1.485 - 9.338, p = 0.005) and to 
indicate they consumed fast foods 2 ‐ 3 times/month (AOR 0.341, 95% CI 0.147 - 
0.795, p = 0.013) or 1 ‐ 2 times/week (AOR 0.329, 95% CI 0.132 - 0.817, p = 0.017) 
than controls. 
Table 42. Logistic regression model for the comparison of CHD-diabetic cases 
and CHD-controls. 
Variables 
N = 463 
Multivariate 
AOR* (95% CI) p 
Ethnicity Non-Saudi 1 
Saudi 2.778 (1.143 - 6.756) 0.024 
Education No education 1 
Literacy 3.970 (1.328 - 11.870) 0.014 
Primary education 2.812 (1.063 - 7.438) 0.037 
Intermediate 
education 
2.134 (0.501 - 9.091) 0.305 
Secondary 
education 
2.327 (0.780 - 6.946) 0.130 
Higher education 2.208 (0.439 - 11.093) 0.336 
Family history of 
diabetes 
No 1 
Yes 2.710 (1.429 - 5.128) 0.002 
Fast food 
consumption 
0 ‐ 1 Times/Month 1 
2 ‐ 3 Times/Month 0.341 (0.147 - 0.795) 0.013 
1 ‐ 2 Times/Week 0.329 (0.132 - 0.817) 0.017 
3 ‐ 4 Times/Week 0.513 (0.142 - 1.853) 0.309 
≥ 5 Times/Week 0.548 (0.141 - 2.132) 0.385 
BMI groups 
18.5 - 24.9 1 
25 - 29.9 1.171 (0.537 - 2.555) 0.692 
≥ 30 1.793 (0.789 - 4.073) 0.163 
Triglycerides 
(mg/dL) 
< 150 1 
< 200 1.567 (0.706 - 3.479) 0.270 
≥ 200 3.724 (1.485 - 9.338) 0.005 
Constant 0.692 0.591 
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4.4. WHO Quality of life BREF Questionnaire (WHOQoL-BREF) 
A comparison among CHD-IR cases and CHD-controls according to the 26 questions 
of the WHOQoL-BREF questionnaire for quality of life is shown in table 43. The 
same comparison is shown for CHD-diabetic cases and CHD-controls as shown in 
table 44. CHD-IR cases had lower overall satisfaction scores with bodily appearance 
than CHD-controls, with mean ranks of 45 versus 65, respectively, (p = 0.003). 
CHD-IR cases had lower score of overall perception of satisfaction with themselves 
than CHD-controls with mean rank of 51 versus 62, respectively (p = 0.041). On the 
other hand, CHD-diabetic cases had lower overall perception of quality of life scores 
than CHD-controls. Their mean rank quality of life score was 136 versus 166, 
respectively (p = 0.002). The CHD- diabetic cases had lower overall satisfaction with 
the bodily appearance scores than CHD-controls with mean ranks of 137 versus 164, 
respectively (p = 0.012). CHD-diabetic cases had lower score of overall perception 
of satisfaction with themselves than CHD-controls with mean rank of 138 versus 162, 
respectively (p = 0.015). CHD-diabetic cases had lower score of overall satisfaction 
with access to health services than CHD-controls (141 versus 153, respectively, p = 
0.049) and lower overall satisfaction score with their transport than CHD-controls 
(141 versus 154, respectively, p = 0.027). 
The quality of life profile scoring of CHD-IR cases and CHD-controls is shown in 
table 45, while the scoring of CHD-diabetic cases and CHD-controls is shown in 
table 46. CHD-IR cases had a lower mean (SD) of psychological domains raw score, 
transformed scores 4-20 and transformed scores 0-100 than among CHD-controls. 
The means (SD) for CHD-IR were 22.6 (2.1), 15.0 (1.4) and 60.2 (5.5) respectively, 
while for CHD-controls were 23.8 (2.2), 15.8 (1.5) and 63.4 (5.9), respectively, (p = 
0.006). No other significant results are shown in other different domains. 
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Table 43: Comparison among CHD-IR cases and CHD-controls according to the 26 questions of quality of life. 
CHD 
N = 325 
CHD-Controls 
n = 79 (%) 
CHD-IR 
n = 37 (%) 
p 
Median 
(IQR) 
Mean 
rank 
Median 
(IQR) 
Mean 
rank 
Individual’s overall perception of quality of life. 
Q1. How would you rate your quality of life? 
5 (4 - 5) - 5 (4 - 5) - 0.808 
Individual’s overall perception of health.  
Q2. How satisfied are you with your health? 
4 (4 - 4) - 4 (4 - 4) - 0.322 
Q3. To what extent do you feel that physical pain prevents you from doing what you need 
to do? 
4 (3-5) - 4 (3-5) - 0.940 
Q4. How much do you need any medical treatment to function in your daily life? 1 (1-1) - 1 (1-1) - 0.476 
Q5. How much do you enjoy life? 5 (4 - 5) - 4 (4 - 5) - 0.056 
Q6. To what extent do you feel your life to be meaningful? 5 (5 - 5) - 5 (5 - 5) - 0.166 
Q7. How well are you able to concentrate? 5 (5 - 5) - 5 (5 - 5) - 0.234 
Q8. How safe do you feel in your daily life? 5 (5 - 5) - 5 (5 - 5) - 0.686 
Q9. How healthy is your physical environment? 5 (5 - 5) - 5 (5 - 5) - 0.948 
Q10. Do you have enough energy for everyday life? 4 (3 - 5) - 4 (3 - 5) - 0.640 
Q11. Are you able to accept your bodily appearance? 3 (2 - 5) 65 2 (2 - 3) 45 0.003 
Q12. Have you enough money to meet your needs? 4 (4 - 5) - 5 (3 - 5) - 0.294 
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Q13. How available to you is the information that you need in your day-to-day life? 4 (3 - 5) - 4 (3 - 5) - 0.130 
Q14. To what extent do you have the opportunity for leisure activities?  4 (4 - 5) - 5 (4 - 5) - 0.374 
Q15. How well are you able to get around? 5 (5 - 5) - 5 (5 - 5) - 0.793 
Q16. How satisfied are you with your sleep 5 (3 - 5) - 5 (4 - 5) - 0.716 
Q17. How satisfied are you with your ability to perform your daily living activities? 4 (4 - 5) - 4 (3 - 5) - 0.444 
Q18. How satisfied are you with your capacity for work? 4 (3 - 5) - 4 (3 - 5) - 0.940 
Q19. How satisfied are you with yourself? 5 (4 - 5) 62 5 (4 - 5) 51 0.041 
Q20. How satisfied are you with your personal relationships? 5 (5 - 5) - 5 (5 - 5) - 0.773 
Q21. How satisfied are you with your marriage relationship? 5 (5 - 5) - 5 (5 - 5) - 0.703 
Q22. How satisfied are you with the support you get from your friends? 5 (5 - 5) - 5 (5 - 5) - 0.651 
Q23. How satisfied are you with the conditions of your living place? 5 (5 - 5) - 5 (5 - 5) - 0.297 
Q24. How satisfied are you with your access to health services? 5 (5 - 5) - 5 (5 - 5) - 0.963 
Q25. How satisfied are you with your transport? 5 (5 - 5) - 5 (5 - 5) - 0.717 
Q26. How often do you have negative feelings such as blue mood, despair, anxiety, 
depression? 
5 (3-5) - 5 (3-5) - 0.886 
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Table 44: Comparison among CHD-diabetic cases and CHD-controls according to the 26 questions of quality of life. 
CHD 
N = 325 
CHD-Controls 
n = 79 (%) 
CHD-Diabetic 
n = 209 (%) 
P 
Median 
(IQR) 
Mean 
rank 
Median 
(IQR) 
Mean 
rank 
Individual’s overall perception of quality of life. 
Q1. How would you rate your quality of life? 
5 (4 - 5) 166 5 (4 - 5) 136 0.002 
Individual’s overall perception of health.  
Q2. How satisfied are you with your health? 
4 (4 - 4) - 4 (3 - 4) - 0.284 
Q3. To what extent do you feel that physical pain prevents you from doing what you need 
to do? 
4 (3-5) - 4 (3-5) - 0.766 
Q4. How much do you need any medical treatment to function in your daily life? 1 (1-1) - 1 (1-1) - 0.509 
Q5. How much do you enjoy life? 5 (4 - 5) - 4 (4 - 5) - 0.700 
Q6. To what extent do you feel your life to be meaningful? 5 (5 - 5) - 5 (5 - 5) - 0.501 
Q7. How well are you able to concentrate? 5 (5 - 5) - 5 (4 - 5) - 0.290 
Q8. How safe do you feel in your daily life? 5 (5 - 5) - 5 (5 - 5) - 0.228 
Q9. How healthy is your physical environment? 5 (5 - 5) - 5 (5 - 5) - 0.351 
Q10. Do you have enough energy for everyday life? 4 (3 - 5) - 4 (3 - 5) - 0.630 
Q11. Are you able to accept your bodily appearance? 3 (2 - 5) 164 3 (2 - 4) 137 0.012 
Q12. Have you enough money to meet your needs? 4 (4 - 5) - 4 (3 - 5) - 0.853 
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Q13. How available to you is the information that you need in your day-to-day life? 4 (3 - 5) - 4 (3 - 4) - 0.079 
Q14. To what extent do you have the opportunity for leisure activities?  4 (4 - 5) - 5 (4 - 5) - 0.919 
Q15. How well are you able to get around? 5 (5 - 5) - 5 (5 - 5) - 0.098 
Q16. How satisfied are you with your sleep 5 (3 - 5) - 5 (3 - 5) - 0.595 
Q17. How satisfied are you with your ability to perform your daily living activities? 4 (4 - 5) - 4 (4 - 4)  - 0.160 
Q18. How satisfied are you with your capacity for work? 4 (3 - 5) - 4 (3 - 4) - 0.329 
Q19. How satisfied are you with yourself? 5 (4 - 5) 161 5 (4 - 5) 138 0.015 
Q20. How satisfied are you with your personal relationships? 5 (5 - 5) - 5 (5 - 5) - 0.505 
Q21. How satisfied are you with your marriage relationship? 5 (5 - 5) - 5 (5 - 5) - 0.474 
Q22. How satisfied are you with the support you get from your friends? 5 (5 - 5) - 5 (5 - 5) - 0.375 
Q23. How satisfied are you with the conditions of your living place? 5 (5 - 5) - 5 (5 - 5) - 0.124 
Q24. How satisfied are you with your access to health services? 5 (5 - 5) 153 5 (5 - 5) 141 0.049 
Q25. How satisfied are you with your transport? 5 (5 - 5) 154 5 (5 - 5) 141 0.027 
Q26. How often do you have negative feelings such as blue mood, despair, anxiety, 
depression? 
5 (3-5) - 5 (3-5) - 0.239 
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Table 45. The quality of life profile scoring of CHD-IR cases and CHD-controls 
Domains 
N = 325 
CHD-controls  
n = 79 
CHD-IR  
n = 37 
t p Raw score 
Transformed scores 
Raw score 
Transformed scores 
4-20 0-100 4-20 0-100 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Mean  
(SD) 
Physical health 27.7 (3.1) 15.8 (1.7) 63.4 (7.0) 27.7 (3.0) 15.8 (1.7) 63.4 (6.9) 0.007 0.994 
Psychological 23.8 (2.2) 15.8 (1.5) 63.4 (5.9) 22.6 (2.1) 15.0 (1.4) 60.2 (5.5) 2.791 0.006 
Social relationships 14.2 (2.0) 19.0 (2.6) 75.8 (10.5) 14.4 (1.3) 19.2 (1.7) 76.7 (6.8) 0.460 0.647 
Environment 36.5 (2.7) 18.3 (1.4) 73.1 (5.5) 37.2 (3.2) 18.6 (1.6) 74.3 (6.3) 1.081 0.282 
 
Table 46. The quality of life profile scoring of CHD-diabetic cases and CHD-controls  
Domains 
N = 325 
CHD-controls  
n = 79 
CHD-diabetic  
n = 209 
t p Raw score 
Transformed scores 
Raw score 
Transformed scores 
4-20 0-100 4-20 0-100 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Mean  
(SD) 
Physical health 27.7 (3.1) 15.8 (1.7) 63.4 (7.0) 27.4 (2.9) 15.7 (1.7) 62.7 (6.7) 0.788 0.431 
Psychological 23.8 (2.2) 15.8 (1.5) 63.4 (5.9) 23.2 (2.1) 15.5 (1.4) 62.0 (5.5) 1.912 0.057 
Social relationships 14.2 (2.0) 19.0 (2.6) 75.8 (10.5) 14.0 (2.2) 18.7 (2.9) 74.7 (11.6) 0.750 0.454 
Environment 36.5 (2.7) 18.3 (1.4) 73.1 (5.5) 35.7 (3.8) 17.9 (1.9) 71.4 (7.6) 1.783 0.076 
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5. Chapter 5 - General Discussion and conclusion 
5.1. TB Discussion  
Low- and Middle-Income Countries have witnessed a rapidly increasing incidence 
and prevalence of T2DM in recent decades. This increase has occurred while the 
global incidence of TB has declined steadily over several decades, although at a 
much lower rate than predicted by the WHO (312), and this condition still remains 
the main cause of infectious death in many countries. These two situations have 
resulted in both conditions increasingly being encountered as co-morbidities in the 
world.  
The TB prevalence in the Middle East is low compared to other areas of the world as 
for example, by 2010 the UAE reported 6.2 cases per 100,000 population, while 
Saudi Arabia and Iran had reported 23 cases per 100,000 population (203, 313).  
Although these rates are relatively low in the Middle East, TB is often concentrated 
in specific population groups, notably migrants from Asia and Africa and the elderly.   
Countries in the Middle East have also experienced major increases in T2DM. These 
increases are historically recent, as lifestyle patterns have mainly change since the 
discovery of petroleum, which in Saudi Arabia occurred in 1938, followed by an 
exponential increase in oil production in the 1970s. Increased wealth in Saudi Arabia 
was accompanied by increasing obesity, sedentary habits and T2DM. Saudi Arabia is 
nowadays home to a population with the highest prevalence of risk factors for T2DM 
such as obesity (56) and the IDF classifying Saudi Arabia as one of the ten countries 
with the highest estimated T2DM prevalence in the world. T2DM increases 
continued unabated in recent years, with a 2011 estimated prevalence of 16.2%, 
which is expected to reach 20.8% by 2030 (54, 55).  
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The country, therefore, increasingly has patients with T2DM and populations, 
including migrants from places with a high prevalence of TB are, particularly, at risk 
of having both co-morbidities. A systematic review of the prevalence of T2DM and 
TB co-morbidity in Middle Eastern countries (314) reported that the prevalence of 
both conditions varied across the region, from as low as 4.2% in Iran to as high as 
60% in Yemen (31, 189). African-based studies in comparison, have reported that the 
proportion of patients with TB that have T2DM at the time of diagnosis is generally 
lower, ranging from 3.4% to 16.4% of TB cases (203).  
In our study, 29% of TB cases had T2DM. This high proportion is comparable to 
studies from areas with a high prevalence of T2DM, such as Mexico (29.3%), 
Taiwan (29.5%) and Kerala-India (44%), but is higher than in other areas closer to 
the Middle East Region with low T2DM but high TB prevalence, such as Ethiopia 
(8.3%) and Uganda (8.5%) (31). 
The association of T2DM and TB is not limited to LMICs.  While the prevalence of 
TB is generally low in industrialized high-income countries, the association of TB-
T2DM is generally lower, although with wide geographical variations. A cohort in 
Barcelona of 5849 patients with TB recruited between 2000 and 2013 reported that 
4% to 7.2% had T2DM (215). This proportion was lower than in Japan, where 13.1 
of patients with TB had T2DM, which was attributed to TB mostly occurring among 
the elderly population; and in the UK (16%) and the USA (12%), where obesity rates 
are higher than Japan and Spain (315). In these settings, T2DM still increases the risk 
of TB. Although this association is weaker than in low income countries. In a UK 
case-control study, the AORs for TB among patients with a history of T2DM was 3.8 
(p < 0.05) (216). However, further case-control studies in Denmark, Australia and 
the USA, have reported that T2DM only modestly increased the risk of TB (203).  
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In TB endemic regions there is great concern regarding the increased risk of TB that 
occurs due to T2DM. Bi-directional associations have been reported in the literature 
between hyperglycaemia and TB (316, 317). TB is an infection that triggers a major 
inflammatory process that is recognised to trigger hyperglycaemia, and it is possible 
the presence of inflammation has led to an over-diagnosis of T2DM. This is also the 
case with other conditions, such as pregnancy that can cause transient stress-related 
hyperglycaemia and other infections. The stress-related hyperglycaemia associated 
with TB could be caused by an increase in IR, which occurs through a complex 
interaction involving cytokines, growth hormones, catecholamine and cortisol (318-
320). This IR can lead to hyperglycaemia through two pathways, the first being 
through hepatic glucose being overproduced via the inability to suppress 
gluconeogenesis, and the second is due to insulin-mediated defects in the uptake of 
glucose. Stress-related hyperglycaemia also leads to blood glucose levels being 
further increased as it enhances the inflammatory response (318). Individuals with 
both hyperglycaemia and TB who receive anti-TB treatment often have a 
substantially decreased FPG when the TB is cured. Conversely, TB can worsen a 
pre-existing T2DM and TB treatment outcome is poor in the presence of 
hyperglycaemia. Transient hyperglycaemia can be present in a significant number of 
individuals that already have T2DM and, therefore, this distinction is difficult at the 
time individuals presents to the clinic with a new episode of TB. Studies have 
recently indicated that after anti-TB treatment for 6 months 38% of these individuals 
still have hyperglycaemia, which indicates in 60% hyperglycaemia was related to the 
inflammatory process, while 38% had an underlying T2DM (321)  
The majority of studies regarding T2DM and TB are observational, with few studies 
being prospective cohorts. Most cohort studies are retrospective and based on patient 
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medical records, making it difficult to infer the directionality of the association. 
Although the majority of data indicate that T2DM precedes TB in a substantial 
number of patients, not all cases presenting with hypaerglacaemia will have the 
lifelong glucose abnormalities of T2DM (220). Several cross-sectional studies have 
supported the view that T2DM increases susceptibility to TB and patients with TB 
and diabetes have a median 7 years since their T2DM diagnosis and have 
experienced other complications of T2DM before the development of TB (196, 219, 
221).  
Another possible view is that TB may increase the risk of developing T2DM, 
although this theory is uncommonly considered in literature at present (221). A 
number of studies have revealed that on the early phase of TB, IGT and/or induced 
hyperglycaemia occur (222). This incidence can be significant as  20 - 50% of 
individuals with IGT go on develop to T2DM, which is usually seen to occur after 3 
to 5 years (222, 223). Establishing the real contribution of T2DM to TB is not 
straightforward as it can be sporadic hyperglycaemia associated to inflammation, 
which may reverse after TB treatment (222, 223) or TB may results as a result of 
reduced resistance to TB due to the underlying T2DM. Hyperglycaemia may also 
present itself as a side effect of treatment with Isoniazid and Rifampicin (224). 
A Tanzanian study reported that upon enrolment, patients with TB that had glucose 
levels that were consistent to T2DM, newly diagnosed T2DM patients account for 50 
- 80% (based on the type of screening test) of the study group. A further study in 
Mwanza, Tanzania gave similar findings with 77% of individuals with T2DM were 
newly diagnosed T2DM cases. Studies in China and India however, have reported 
different results with over 50% of cases being diagnosed with T2DM before they the 
TB diagnosis (321-323). The majority of the individuals that were recently diagnosed 
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with T2DM had experienced a moderate increase in glycaemic levels. At the time of 
TB diagnosis, the majority of patients recently diagnosed as T2DM and pre-DM had 
reverted to normal glucose and were considered to have transient hyperglycaemia 
(321). In Iran, a third of the patients newly diagnosed to have TB had high levels of 
HbA1c, which after three months of anti-TB treatment had returned to normal (324). 
Transient hyperglycaemia is likely caused by a number of factors, which could 
reflect the inflammation that is caused by TB, the predisposition of the patient and 
the hyperglycaemic effect that is caused by anti-TB treatment (325). This reverse 
causality may occur when the diagnoses of the diseases are made close together. The 
high occurrence of transient hyperglycaemia found in patients with TB gives rise to 
the notion of reverse causality between T2DM and TB, which also highlights the 
importance of further T2DM screening being implemented later into the treatment of 
TB. Moreover, there is also a need to address whether transient hyperglycaemia that 
is observed in patients diagnosed with TB would result in a greater risk of 
developing T2DM later in life (326). 
5.1.1. Summary of this thesis findings 
This study was carried out among patients formerly treated for TB. A high 
proportion of the cases were non-Saudi citizens, with the majority originating from 
Somalia, Yemen, Ethiopia, Pakistan, Sudan, Chad, Bangladesh, Eritrea and the 
Philippines. A high frequency of patients formerly treated for TB and controls 
without TB had T2DM, with no difference among cases and controls at the 
univariate analysis. Patients with T2DM, those with TB were more likely to be using 
insulin (20.4%) than controls without TB (6.1%). An important issue in the 
univariate analysis, however, was that cases were younger than controls. As T2DM 
and its risk factors increase with age, it was considered that this was likely a 
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significant confounding factor and, therefore, its interpretation needs to be 
interpreted with caution, and the multivariate analysis conducted was controlled by 
age. The results of the final multivariable backward stepwise logistic regression 
including T2DM indicate that cases were more likely to be non-Saudis, to have 
T2DM and that they had a poorer diet than controls. Cases were more likely to eat 
fast foods 1 – 2 times/week or 2 – 3 times/month, less likely to be obese, to have 
higher total cholesterol and a lower level of risky HDL Cholesterol than controls. On 
the other hand, when we replaced variables for T2DM and replaced them with the 
more comprehensive definition of metabolic syndrome, the multivariable backward 
stepwise logistic regression results indicated cases were more likely to be non-Saudis 
and had a poorer diet than controls. Cases were also less likely to be obese and to 
have higher total cholesterol than controls. 
TB-T2DM and TB-IR cases were also compared with TB-controls to identify risk 
factors for T2DM or IR. Both male and female patients with T2DM had higher BMI 
and were much more likely to be obese, had higher cholesterol and triglycerides. 
Moreover, patients with T2DM had higher LDL cholesterol and more likely to have 
experienced haemoptysis than patients without T2DM. Female cases with T2DM 
were more likely to have experienced gestational diabetes. Similarly, the comparison 
of TB-IR and TB-controls indicated patients with IR were more likely to have 
experienced heart problems, to have been overweight during childhood, total 
cholesterol and females had higher median BMI. These characteristics replicate well 
established risk factors for both T2DM and IR among the general population and 
their association to TB is still unclear. 
Although many studies have reported the increased prevalence of T2DM among 
patients with TB at the time of making the diagnosis of TB, there are very few 
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studies examining whether patients formerly treated for TB continue to have T2DM 
several months after treatment when the inflammatory processes associated with TB 
have subsided. Patients with TB often have IFG, for example, in West Africa 1.9% 
of patients with TB had T2DM and 5% had IFG (26). In Sri Lanka, 7.1% of patients 
with TB had T2DM and 20% had IFG (27). Although IFG could reflect a 
predisposition to T2DM, IFG is also likely due to the pro-inflammatory responses to 
TB, the effect of medications or the ‘stress/transient hyperglycaemia’ phenomenon 
(9).  
We measured IR with the HOMA2-IR method which describes the balance of insulin 
levels in the context of fasting glucose conditions. The HOMA-IR is extensively 
used as a regular measurement tool in clinical practice and epidemiological research 
and is one of the more popular fasting indices (327). Although the 
hyperinsulinaemic-euglycaemic clamp technique is still considered the gold-standard 
for IR diagnosis and is still the diagnostic tool of preference in some clinical settings, 
it was not a viable option in this study, as study subjects were investigated in out-
patient departments and the tool is time consuming. One significant disadvantage of 
the HOMA-IR is that it does not have a standardized limit to categorize individuals 
that have IR. Prior studies have indicated that IR appears between HOMA-IR levels 
of 1.55 - 3.8 (328), which is a large range. In this study we used a cut-off ≥ 2, as this 
is the cut-off used in most publications. Using this cut-off, in participants without 
T2DM, the prevalence of IR among euglycaemic patients with former TB was 22%. 
This prevalence rates fall between the 20% to 40% IR rates reported in the general 
population of Saudi Arabia (327) and, therefore, we found no evidence that IR is 
more or less frequent among patients who formerly had TB. 
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A prospective cohort study in patients with TB in South Africa suggested a gradual 
decrease in IR after initiation of TB treatment. Moreover, when confounding 
variables were considered, the study reported that HOMA-IR was not associated with 
the diagnosis of TB. These findings thus suggest IR in a significant proportion of the 
patients could be due to the ‘stress/transient’ hyperglycaemia that is present early in 
the diagnosis of TB and that is eventually resolved once treatment for TB progresses 
(329-331). 
IR has long been linked to the ageing process, (332, 333), as it is generally linked to 
an increase in fat mass and body weight, particularly in the centre of the body (334), 
along with a greater prevalence of chronic lifestyle-associated diseases such as 
metabolic syndrome (335). Generally, an increased anthropometrical measurement 
gives a greater risk of IR; (336) with a positive correlation between the waist-to-hip 
ratio (337) and the BMI (338). 
Studies in the past have also suggested that undernutrition does not only occur in TB 
patients due to the disease itself, but rather to a number of other factors such as 
reduced health-seeking behaviour, extreme poverty and food insecurity (339, 340). 
Indeed, several studies have suggested that epigenetics may play a critical role in the 
Middle East populations, explaining the higher prevalence of both T2DM and IR. A 
recent study suggested epigenetic changes in these populations share many of the 
characteristics reported in European populations, but that some novel mechanisms 
are unique to Arab populations; suggesting that the underlying mechanisms in the 
region might depend on their genetic background and local environmental pressures 
(341). We have written in reverse causality the directionality of association between 
T2DM and TB. 
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5.1.2. Recommendations for clinical practice 
Clinical practice recommendations include the application of bi-directional (TB and 
T2DM) screening in healthcare facilities along with the monitoring patients with TB 
upon commencing treatment for the presence of hyperglycaemia. Although not 
considered in this thesis, patients with T2DM have poorer response to TB treatment 
and newly diagnosed patients with TB and T2DM should be followed closely to 
monitor treatment response. Patients with clinical symptoms of T2DM, biochemical 
or anthropometrical markers should also be referred for nutritional support in a 
timely manner, preferably at the intensive treatment phase of TB.  
Future avenues of research include assessing how IR prevalence changes in cohort 
studies to describe changes in T2DM and IR prevalence and to identify individuals 
with overt T2DM that require long term management. Furthermore, patients with 
established T2DM could be compared to patients who have transient hyperglycaemia 
to explore how to differentiate both conditions at the time of TB diagnosis. Finally, 
patients with transient hyperglycaemia may go on to develop over T2DM, as 
observed among women with gestational diabetes, and should be followed over time.   
5.1.3. Limitations  
The study has significant limitations. These include the lack of standardised HOMA-
IR reference values, along with potential reliability issues surrounding the 
measurement of fasting insulin. Although the former are limitations shared with 
other studies, the latter was due to logistical constrains when conducting the study, as 
it was not possible to obtain external quality assurance to confirm insulin 
measurements were correct. Although laboratories in Saudi Arabia undergo rigorous 
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quality control procedures, it would have been ideal to replicate a subset of tests in a 
second quality-assured laboratory to confirm the reliability of the measurements. 
There are also limitations during the study implementation, as one city had very few 
patients with TB and patients were recruited in two cities 300 kilometres apart, 
which limited the supervision to alternative weeks. There may have been compliance 
issues with the requirement of participants’ interview, sample collection and 
transport which the PhD candidate could not oversee all the time.  
A further limitation is that patients were enrolled several months after the initial TB 
diagnosis, which could have generated recall bias and lost to follow up, especially 
among non-Saudi patients who may have left the country. Ideally, patients should 
have been enrolled at the time of their TB diagnosis for prospective follow up as 
cohorts with and without T2DM or IR. 
With regards to selection biases and methodological limitations, it was clear the 
choice of controls was not adequate, as controls were older than TB cases and very 
different to patients with CHD. These substantial different likely precluded 
correcting these differences by the use of logistic regression s, and this is 
acknowledged as a major limitation of this thesis. 
Lastly, the sample size of the study should have been bigger. Although the data 
collected met the original samples size estimations, we did not expect to find the high 
prevalence of T2DM and IR among controls and, therefore, the study is likely to be 
underpowered. The high prevalence of T2DM in cases with TB resulted in a small 
sample size of the group with TB and IR and, therefore, we were unable to conduct a 
logistic regression analysis. It is thus likely the study did not identify metabolic 
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anomalies that might be present at a low frequency among patient populations with a 
lower prevalence of T2DM among the general population. 
5.1.4. Strengths 
The study provided baseline information, which will help Saudi Arabia to strengthen 
the TB control programme and increase the knowledge toward exploring the 
prevalence of euglycaemic IR among TB patients, its role as a risk factor for TB and 
the severity of clinical presentation, which are poorly established in Saudi Arabia. A 
further strength is the high response rate, as most eligible patients accepted to 
participate. Further, a team of trained interviewers interviewed the participants at a 
mutually convenient location either in their own homes or the healthcare facilities to 
meet participant satisfaction. Despite the hot weather, blood sample transportation 
was within two hours of collection by a reporter using a box and container with ice 
under safety precautions and samples were processed in fully accredited, a high-
quality laboratory in King Fahad Hospital. 
The availability of data and adequacy for testing the hypothesis is integral to the 
validity of a retrospective case-control study. A key strength of the data collection 
was using the ministry of health TB databases to complete missing information and 
to verify data collected at the time of the interview that referred to the time of TB 
diagnosis.  
5.1.5. Conclusion 
The results of this study suggest that the frequency of T2DM and IR in patients with 
TB was very high with more than a quarter of patients having T2DM. However, the 
frequency of IR was not higher among patients with TB than among individuals 
without TB, reflecting the very high prevalence of IR among the general population. 
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Patients with a history of TB had lower HDL cholesterol; were more likely to be 
prediabetic and to be non-Saudi. Patients with TB and T2DM or IR shared the same 
characteristics as patients with T2DM and IR without TB. Patients with IR were 
more likely to have experienced CVDs and to be obese or overweight and report 
poor diet habits, while the lack of exercise and active lifestyles were nearly non-
existent. There is a need for early identification programs, in particular within 
vulnerable and young populations to enable IR reversal and to prevent future 
complications associated with IR and T2DM. 
5.2. CHD Discussion 
CHD is nowadays recognised a public health problem in Saudi Arabia, with a 
significant number of research studies published between 1985 and 2015 (342). 
Cardiovascular diseases are associated with a higher mortality among patients with 
T2DM and cardiac complications are usually the result of dyslipidaemia, with 
elevated triglycerides and LDL cholesterol and a decrease in HDL cholesterol. It has 
long been recommended (e.g. by the ADA, 1999) that lipid profiles should be 
monitored regularly in patients with T2DM, as this is a major contributor to coronary 
artery disease, because impaired lipid homeostasis and lipid peroxidation worsen as 
glycaemic control deteriorates (343).  
The city directorate of King Abdul Aziz for Technology and Science has 
acknowledged that the lifestyle of the Saudi Arabian residents is facing a transition, 
with an increase in unhealthy diets, fast food consumption and sedentary lifestyles. 
These changes have been attributed to socioeconomic changes with the population 
having a rapid process of urbanisation and environment factors (344). Numerous 
studies have reported risk factors for CHD associated with lifestyle changes in Saudi 
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Arabia (345, 346). Among these, obesity and T2DM are prominent. In King Faisal 
hospital (2011), 30% of patients with CHD had T2DM and 70% of females and 64% 
of males were obese and these are often markers of unhealthy lifestyles (258). A 
study in four Middle East countries of 840 participants (374 in Israel, 120 in 
Lebanon, 150 from the UAE and 196 in Saudi Arabia) with established CVD 
reported that nearly half were former or current smokers (46%), obese (38.6%), 
around a third had dyslipidaemia (34.1%), half had T2DM (52.3%) and the majority 
had hypertension (80.2%) (347, 348). The Eastern Mediterranean region has a high 
prevalence of smoking (25.4%) which is nearly as high as regions with the highest 
smoking rates in the world (Western Pacific, 25.8%; Europe 27.3%) (349) and higher 
than the global average of 22.7%. In the region, males smoke more (40%) than 
females (6.8%) (350). A 2016 WHO report indicated 12.2% of adults in the Saudi 
population were smokers (351), highlighting that patients with CHD have higher 
smoking rates than the general population.  
The lack of exercise is a major risk factor worldwide, with 23% of adults undertaking 
less moderate to vigorous physical activity than the recommended 150 minutes per 
week. The Eastern Mediterranean Region has very low figures of physical activity, 
with only 27.5% of men and 38.7% of women being physically active. The least 
physically active population in the region is Saudi Arabia, while the most active is 
Jordan (350). A Saudi Health Information Survey reported that 75.1% of women and 
46% of men reported having no or very low physical activity (352) and a 2016 
systematic review confirmed that 53.2% to 98.1% of Saudi women reported no 
physical activity (353). 
Diet is also a major risk factor for CHD including low fibre, vegetable and fruit 
intake along with a high intake of processed foods, saturated fats, sugar and salt. 
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Countries in the Middle East and North African region have the highest sodium 
intake. The population also has an inadequate fruit and vegetable intake and in Saudi 
Arabia only 7.3% of 15 - 64 year olds consume the recommended daily five fruit and 
vegetable servings (351). 
The Eastern Mediterranean region has the third highest prevalence of obesity in the 
world, with 14.6% of males and 23.6% of females classed as overweight. The Gulf 
countries have the highest rates of obesity within this region (351). Although 
currently Qatar has the highest prevalence of obesity estimated at 67.5% of women 
and 38.2% of men, some projections indicate that Saudi Arabia may overtake this in 
the near future (354) and a systematic review indicated that although between 6% to 
29% Saudi female university students had obesity, this figure increased to 21% to 
71% among women participating in national surveys or attending primary care 
centres (351).  
The prevalence of hypertension is also high within the Eastern Mediterranean Region 
(350) with Somalia having the highest prevalence along with Morocco (25.3%), 
while the UAE has the lowest prevalence (14.7%), although a screening program in 
Abu Dhabi indicated 23% of adults had hypertension. In Saudi Arabia, 17.7% of men 
and 12.5% of women have hypertension (350, 351).  
The 2008 WHO dyslipidaemia report, is the latest available to date (355). The global 
prevalence of total cholesterol ≥ 5 mmol/l among adults ≥ 25 years old was 40.2% 
for women and 37.3% for men (355). The Eastern Mediterranean region had the third 
highest hypercholesterolaemia with 36.2% of men and 40.4% of women, with most 
of the Gulf countries having a prevalence ≥ 50%. The prevalence of dyslipidaemia 
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among Saudi was 36.4% for women and 42.1% for men. It is, however, likely these 
frequencies are much higher ten years later. (355).  
Over 75% of T2DM patients die from CVD-related diseases, which is double the 
figure of patients without T2DM (356). Our findings, therefore, confirm the high 
prevalence of comorbidity in patients with stable CHD.  
This study also confirms that patients with CHD are more likely to have IR. Former 
studies have examined the association between atherosclerosis and IR. For example, 
Karrowni et al. reported a series of 1073 non-diabetic patients examined using 
angiography after myocardial infarction found an independent link between multi-
vessel CHD and IR (357). Granér et al. found that patients that exhibited a higher 
degree of IR also exhibited more extensive and severe forms of CHD than 
individuals that displayed lower levels of IR (358). Baseline fasting hyperinsulinemia 
is a predictor of coronary atherosclerosis among non-diabetic patients (359). 
Hyperinsulinemia, has been identified in numerous large-scale population based 
reports as a predictor of CHD (360). However, not all studies have found this 
association. In a study of 986 consecutive patients examined with elective coronary 
angiography, there were no HOMA-IR differences (361) and other studies have 
reported negative associations between ≥ 50% stenosis of the coronary arteries and 
fasting insulinaemia (362). 
5.2.1. Summary of findings 
Our study found in the univariate analysis, that a high proportion of patients with 
stable CHD had T2DM than controls, and that patients with CHD and T2DM were 
more likely to be using insulin than controls who had only T2DM. Moreover, 
euglycemic patients with CHD were more likely to have IR than controls. The 
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regression analysis including T2DM show that cases were more likely to be Saudi, 
male and to have T2DM. Subjects with CHD were more likely to be over 40 years 
old, were less likely to be married or previously married or to have primary 
education. Cases were more likely to be taking hypertensive medications and lipid 
lowering therapy than controls. Cases were less likely to eat fast foods 3 – 4 
times/week, but more likely to have high WHR and diastolic BP than controls.  
When the diagnosis of T2DM was included into metabolic syndrome, and thus 
excluded as a single factor, the logistic regression indicated cases were more likely to 
be male and more likely to be aged over 40 years old and to have a salary range 
between SAR 5001 and 10000 per month and less likely to be married and to have 
primary education. Cases were also more likely to have metabolic syndrome and to 
report higher levels of stress than controls. 
Patients with CHD with T2DM were compared to patients with normoglycemic 
patients with CHD without IR (the latter used as CHD controls) to examine risk 
factors for T2DM and IR. Patients with CHD and T2DM were more likely to have 
experienced gestational diabetes, to have a family history of T2DM, to have been 
overweight during childhood and to have higher triglycerides, HDL Cholesterol and 
lower LDL Cholesterol than CHD-controls. Female patients with CHD and T2DM 
also had higher BMI and were more likely to be obese.  
The factors associated with T2DM among patients with CHD were similar to the risk 
factors for T2DM reported in the literature, and in reports of risk factors for T2DM 
in Saudi Arabia. The only different factor was the low LDL concentrations. This may 
be due to the retrospective enrolment of patients with patients being more aware of 
their T2DM and being more careful with medications after a CHD diagnosis, 
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resulting in stricter adherence, lifestyle changes and better pharmacological 
management.  
The comparison of euglycemic patients with CHD with and without IR showed that 
patients with IR had higher anthropometric measurements than patients without IR, 
with males having higher weight, waist circumference and WHR and females higher 
weight, BMI and waist circumference.  
The logistic regression analysis indicated, after adjusting for age and gender, 
independent risk factors for T2DM among patients with CHD were being Saudi, to 
have literacy and primary education, a family history of T2DM, high triglycerides 
and to consumed fast foods 2 ‐ 3 times/month or 1 ‐ 2 times/week. The only 
statistically significant factor for IR was obesity (BMI ≥ 30).  
The WHOQoL-BREF quality of life questionnaire indicated patients with CHD and 
T2DM or IR had lower satisfaction scores. Patients with T2DM had lower scores for 
perception of quality of life, bodily appearance, perception of satisfaction with 
themselves, overall satisfaction with access to health services and with transport 
arrangements than controls. Patients with IR had lower scores for bodily appearance, 
satisfaction with themselves and low score in the psychological domains than 
controls.  
Our findings, therefore, confirm that both T2DM have a strong correlation with CHD 
in Saudi Arabia; that patients with CHD and T2DM or IR have similar risk factors to 
those reported in the literature. Among patients with CHD, patients with IR and 
T2DM have a lower quality of life.   
Although all patients enrolled in this study had stable CHD had known their 
diagnosis and were under clinical management for CHD, a large proportion still had 
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anthropometric indices above normal levels reported the consumption of fast foods, a 
lack of exercise and had abnormal lipid profiles. 
5.2.2. Recommendations for future studies 
There is a growing risk of CHD developing further in the population in the following 
decades and, therefore, short and long-term strategies are needed to reduce CHD risk 
and enhance quality of life. Metabolic syndrome is a major factor for CHD and 
reducing its prevalence should be a key foundation to reduce CHD 
incidence. Moreover, efforts should be made by Saudi Arabia to adopt nationwide 
programs to promote the primary prevention of CHD. There should be a great 
emphasis on early interventions as this can provide the basis that educates children to 
develop healthier lifestyles, implemented through targeting parents to start this at 
home, as well as teachers at schools. A longitudinal study may be required to 
demonstrate how lifestyle modifications can have an effect on reducing the risk of 
CHD by reducing weight, controlling T2DM and hypertension, quitting smoking, 
promoting physical activity and also making efforts to manage metabolic syndrome 
in lowering the CHD risk. Future research into the exact status of the Saudi 
population and what strategies and measures can be revised and used to remedy 
current issues and improve the health status of the nation. Studies are also required to 
assess national and community scale findings on how chronic diseases contribute as 
CHD risk factors and how to combat these issues by creating strategies to encourage 
the public to change behavioural habits and improve the framework for health 
education. 
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5.2.3. Limitations 
The study has significant limitations. These include the same lack of standardised 
HOMA-IR reference values and the limitations described above in the enrolment of 
patients with TB apply to patients with CHDs, as discussed in previous sections. 
We also used a single elevated reading for fasting glucose as the basis of defining 
whether an individual had T2DM, which could have resulted in incorrect 
classification of the patient who had a randomly high fasting glucose on a given day. 
At the baseline, the study did not involve an oral glucose tolerance test, which could 
mean that some T2DM cases were missed; particularly the patients with impaired 
fasting glucose results.  
Controls were selected using systematic random sampling by selecting every fifth 
participant attending to the TB and chest diseases centre. We used the same controls 
recruited from the TB and chest diseases centre for CHD group which caused major 
limitations to compare the groups. With regards to selection biases and 
methodological choices, as we used the same controls recruited from the TB and 
chest diseases centre for CHD group, controls were much younger than the CHD 
group. Furthermore, because we have controls from a different city, patients had 
different types of diseases that patients attending King Fasial Hospital in Taif and, 
therefore, we were unable to correct these differences by logistic regression. 
The controls were also older than TB cases as TB disease that affects your adults 
who are also  younger than CHD group. Patients with CHD disease are usually older 
and, therefore, the controls were poorly matched to TB and CHD cases. Furthermore, 
usually, patients attending the TB and chest diseases centre are healthier than patients 
attending the hospitals as they are come to the centre for occupational health checks or 
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with mild respiratory tract infections, while patients attending the hospitals usually 
have moderate to severe health problems. Therefore, these differences may have had 
a direct effect on the prevalent risk factors for IR and T2DM identifies in this 
dissertation. 
5.2.4. Strengths 
The findings of this study are based on a sample of adults who have a well-
characterised CHD status. The study provided baseline information, which will help 
Saudi Arabia to strengthen the CHD control programme and increase the knowledge 
toward exploring the prevalence of euglycaemic IR among CHD patients and its role 
as a risk factor for CHD and the quality of life. A further strength is the high 
response rate as most eligible patients accepted to participate. Further, a team of 
trained interviewers interviewed the participants at a mutually convenient location 
either in their own homes or the healthcare facilities to meet participant satisfaction. 
Despite the hot weather, blood sample transportation was within two hours of 
collection by a reporter using a box and container with ice under safety precautions 
and samples were processed in fully accredited, a high-quality laboratory in King 
Faisal Hospital. 
5.2.5. Conclusion 
This study confirms an association between T2DM and CHD. CHD were more likely 
to have T2DM, high FPG, to be male, aged above 50 years old and Saudi and to have 
primary education, hypertension and to take lipid lowering medications. Cases were 
more likely to have high WHR and diastolic BP. Patients with CHD and T2DM or IR 
had lower quality of life and satisfaction scores than controls. There is a need for 
further health education to promote disease awareness to minimise the occurrence of 
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T2DM complications. Prospective long-term follow up studies should be conducted 
to demonstrate an association between IR and CHD.  
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GLOSSARY OF TERMS 
List of acronyms used in the application.  
Blood  Pressure (mmHg) (BP) 
Body mass index  (BMI) 
B-type Natriuretic Peptide  (BNP) 
Chronic kidney disease (CKD) 
Coronary heart disease  (CHD) 
Diabetes mellitus  (DM) 
Directly observed treatment short course  (DOTS) 
Disease Control and Prevention  (CDC) 
Ethylene diamine tetra acetic-acid  (EDTA) 
Fasting insulin  (FI) 
Fasting Plasma Glucose  (FPG) 
Gestational diabetes mellitus  (GDM) 
Glucose  (G) 
Haemoglobin A1c  (HA1c) 
Health care workers  (HCWs) 
Hepatitis B virus  (HBV) 
Hepatitis C virus  (HCV) 
High sensitivity C - reactive protein  (Hs-CRP) 
High-density lipoprotein  (HDL) 
Human immunodeficiency virus  (HIV) 
Impaired glucose tolerance IGT 
Impaired fasting glucose IFG 
Insulin resistance  (IR) 
Low-density lipoprotein  (LDL) 
Metabolic syndrome  (MS) 
Ministry of Health (MOH) 
Muscle–brain  (MB) 
Myeloperoxidase  (MPO) 
Myocardial infarction  (MI) 
Room temperature  (RT) 
Saudi Arabia  (SA) 
Standard deviations  (SD) 
The American Diabetes Association  (ADA) 
The homeostatic model assessment  (HOMA) 
Triglycerides  (TG) 
Tuberculosis  (TB) 
Turbidimetric Inhibition Immunoassay  (TINIA) 
Type 2 diabetes Mellitus  (T2DM) 
Waist to hip ratio  (WHR) 
World Health Organization  (WHO) 
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SECTION A 
STUDY OUTLINE 
 
A.1 
LAY SUMMARY: Please use simple language which is understandable to a non-
scientific/non-academic audience.  Sufficient detail of the protocol must be given to 
allow the Committee to make an informed decision without reference to other 
documents.  Please spell out all acronyms.  (max 300 words) 
Many studies have shown that patients with myocardial infarction (MI) or heart attacks or 
Tuberculosis (TB) are more likely to have Diabetes Mellitus (DM). It is likely the 
presence of Insulin Resistance (IR) with normal glucose is also a risk factor for these 
conditions.  
 
IR is a physiological condition characterised by reduced cell sensitivity to insulin leading 
to hyperglycaemia and DM.  Both DM and IR have increased considerably worldwide 
over recent decades and the prevalence of DM globally is 8.5% (2014) and in Saudi 
Arabia is 23.7%. 
 
TB is the second most frequent cause of death due to an infectious disease, causing 1.5 
million deaths and 9.6 million cases worldwide in 2014. The Saudi National TB 
programme reports that TB is more common among foreigners (26 cases/100,000 
individuals) than Saudi nationals (11 cases/100,000 individuals), and visitors from high 
TB burden countries going to Mecca are thought to be the most common source of 
infection. 
 
Coronary heart disease (CHD) is the leading cause of death and the presence of DM 
doubles the risk of CHD. In 2012, three out of 10 of the 56 million deaths occurring 
worldwide were due to CHD, amounting to 17.5 million individuals. On one national 
survey between the year of 1995 and 2000, the overall prevalence of CHD in Saudi Arabia 
was 5.5% among 17232 asymptomatic individuals identified through household visits 
(364). 
 
This study will aim to describe the prevalence of DM and IR in Saudi Arabia among 
patients with (a) TB from Jeddah city, (b) CHD from Taif city and (c) apparently healthy 
controls to investigate the association of IR with TB and CHD. 
 
A.2  
IMPORTANCE OF THE RESEARCH: Please state the intended value of the 
research and explain how this research fits in with national/international research 
priorities. (max 300 words) 
IR is a physiological condition characterised by the reduced cell sensitivity to insulin 
leading to hyperglycaemia and is a sign of DM, which is highly prevalent in Saudi Arabia. 
DM has increased considerably worldwide over recent decades and the prevalence in 
Saudi Arabia is 23.7% among adults.  
 
In one community-based study, a national epidemiological health survey, examine Saudi 
population from selected households in all Saudi Arabia regions (eastern, western, 
southern, northern and central) shows that the overall (crude) prevalence of DM in the age 
group of 30-70 years of selected households between 1995 to 2000 was 23.7% (95% CI 
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23.1-24.3) p<0.0001. Out of 16917 Saudi subjects 4004 subjects (23.7%) were diagnosed 
to have DM. The prevalence of male was 26.2% while the prevalence in female was 
21.5% (p<0.00001). The calculated age adjusted prevalence of DM of year 2000 were 
22.4% for Male and 21.5% for female. IR also occurs in individuals with normal glucose 
(euglycaemic), who despite having a low sensitivity are able to maintain normal glucose 
levels by compensating the lack of sensitivity by increasing the amount of insulin secreted 
by the pancreas.  IR in euglycaemic patients often goes undetected, therefore, euglycaemic 
patients with IR may be at increased risk of communicable and non-communicable 
diseases, such as TB and CHD and may increase the clinical severity of the disease.   
 
TB is the second most frequent cause of death due to infectious diseases, causing 1.5 
million deaths and 9.6 million cases worldwide (2014). The Saudi National TB 
programme reports that TB is more common in foreigners (26 cases/100,000 individuals) 
than Saudi nationals (11 cases/100,000 individuals), and visitors to Mecca are a common 
source of infection. Although DM is a known risk factor of TB, the prevalence of 
euglycaemic IR among cases and its role as a risk factor for TB and severity of clinical 
presentation are poorly established in Saudi Arabia.  
CHD is the leading cause of death worldwide due to non-communicable diseases and DM 
doubles the risk of CHD. In 2012, 17.5 million of the 56 million deaths occurring were 
due to CHD. Individuals with CHD and DM have a higher mortality than individuals 
without DM.  Although there has been extensive research of the link between CHD and 
DM, the link between CHD in euglycaemic patients with IR and its role in the severity to 
the CHD remains ambiguous and has not been studied in Saudi Arabia. 
  
A.3 
DUPLICATION OF RESEARCH: Indicate what steps have been taken to ensure 
this work has not already been carried out.  If this project or a similar one has been 
done before what is the value of repeating it?  
(max 300 words) 
A search of the databases Medline, PubMed, Web of Science and Scopus was 
performed with the keywords “Tuberculosis”, “Prevalence”, “Insulin resistance”, “Insulin 
sensitivity” and/or “Saudi Arabia”. Several studies have reported the risk of TB among 
DM patients is particularly high in certain populations, such as among Hispanic 
populations in the USA, perhaps because latent TB infection is more common in these 
populations. (365-367) A meta-analysis showed that diabetic patients were 3·1 times 
(95% CI 2·27–4·26) more likely to have TB than controls, with higher effect sizes in non-
North American populations (368). The evidence of an association between IR in 
euglycaemic patients and TB is very scanty.  One study reported a strong influence on the 
number of TB patients in Mexico (369). There are however no published studies 
addressing the association of IR and TB in euglycaemic patients in Saudi populations.  
 
A search of Medline, PubMed, Web of Science and Scopus was 
performed using the keywords “Coronary Heart Disease”, “Insulin resistance”, “Insulin 
sensitivity” “Saudi Arabia”. CHD risk factors reported include age, smoking, drinking 
alcohol, body mass index (BMI), dietary factors, lack of physical activity, waist 
circumference, waist to hip ratio (WHR), overweight, obesity, hypertension, 
hyperlipidemia, and diabetes (370). IR, inflammation and activation of the endothelial 
system are associated with CHD (371, 372). Numerous studies have demonstrated that 
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DM and IR are independent risk factors for CHD. To date, extensive studies have been 
carried out to investigate the roles of hyperglycemia in mortality of CHD, stroke and other 
CHD in adults (373, 374). However, no study has investigated the influence of IR in 
euglycaemic individuals among CHD Saudi patients.  
A.4 
OBJECTIVES: List the major objectives of the study.  These must be clearly stated 
and achievable by the proposed design and methods 
7. To describe the prevalence of DM and IR among patients with TB in Jeddah city, 
Saudi Arabia.  
8. To describe the prevalence of DM and IR among patients with CHD in Taif city, 
Saudi Arabia.  
9. To explore whether IR is a risk factor for TB. 
10. To explore whether IR is a risk factor for CHD. 
11. To describe whether the severity of the clinical presentation of TB varies among 
patients with and without IR and/or DM.  
12. To describe whether the quality of life of patients with CHD varies among 
patients with and without IR and/or DM. 
 
A.5  
METHODOLOGY: Please include the methodology for each objective (if 
different) and justify the rationale behind the use of the chosen methodology. Please 
use simple language which is understandable to a non-scientific/non-academic 
audience and spell out all acronyms.   
 
Methodology 
Study location 
This study will be based in Taif and Jeddah city.  Taif is located in the western region of 
Saudi Arabia in the Mecca Province at an elevation of ~1,800 m above sea level, with a 
total area of eight hundred hectares and an estimated 2014 population of 1,109,846 
inhabitants. Jeddah is the largest city in Mecca Province, the largest seaport on the Red 
Sea, located in the western region of Saudi Arabia with total population currently at 3.4 
million people. Jeddah is the principal gateway to Mecca and Medina.  
 
The study will enrol ambulatory patients attending the King Faisal Hospital in Taif and 
tuberculosis and chest diseases centre in Jeddah.  King Faisal Hospital is one of the main 
referral hospitals in the region with a bed capacity of 500 for general patients and 300 for 
Obstetrics and Gynaecology. This referral hospital has many specialties in various 
disciplines and departments and is accredited by the Saudi Central Board for 
Accreditation of Healthcare Institutions (CBAHI). King Faisal Hospital was selected 
because the majority of patients with CHD are referred to this hospital. The hospital 
belongs to the Saudi Arabia (SA) Ministry of Health (MOH), which will facilitate the 
agreement between the LSTM and the MOH. 
 
Tuberculosis and chest diseases centre is located in Jeddah and consists of five clinics for 
diagnosis, treatment and patient’s follow-up. There are five doctors headed by the Medical 
Director. The centre also consists of X-rays, pharmacy, nursing department, infection 
control and quality and health education department. The blood samples send to the 
Madain Al-Fahad Health Centre laboratory. The centre provides therapeutic services for 
patients with newly diagnosed TB and follows patients undergoing TB treatment and until 
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they are fully cured.  The centre provides epidemiological surveillance for Jeddah city, 
examines and diagnoses suspected cases of TB and initiates treatment, checking and 
examining contacts of TB patients, doing annual statistical reports for TB and home visits 
for patients who do not complete treatment. In addition, it provides outreach services and 
education for patients and their families. The centre offers nutritious aid program to the 
patients. It was selected because all TB patients in the city are referred to this centre with 
an estimated 350 new TB patients per year.  The centre belongs to the Saudi MOH, which 
will facilitate the agreement between the LSTM and the MOH.  
 
Objective 1: To describe the prevalence of DM and IR among patients with TB in 
Jeddah city, Saudi Arabia.  
Study design: this will be a cross-sectional survey of patients’ ≥18 years old registered at 
Tuberculosis and Chest Diseases Centre in Jeddah city.  Patients will be eligible to 
participate in the study if they have a diagnosis of bacteriologically confirmed pulmonary 
TB and have received treatment for at least two months since diagnosis.  Only cases 
considered to be new TB cases (this is, who have not received treatment before) will be 
eligible. A bacteriologically confirmed case will be defined as any adult whose sputum 
had acid-fast bacilli in smear microscopy or who had a positive TB culture. In addition, 
only patients who have responded well to the intensive phase of treatment (first 2 months) 
will be selected, to avoid patients with drug-resistance TB who may have a continued 
inflammation process. Patients will be selected during the continuation phase of treatment 
(i.e. after receiving at least two months of treatment) because the inflammation associated 
with the disease in these first two months would result in IR.  We will, therefore, select 
confirmed patients who have received treatment for at least two months. Participants will 
be initially identified from tuberculosis and chest diseases centre treatment registers and 
should include the following inclusion and exclusion criteria: 
Inclusion criteria  
6- Patients with bacteriologically confirmed pulmonary TB. 
7- Patients aged ≥ 18 and residing in Jeddah city. 
8- Registered at TB and chest diseases centre in Jeddah city and still attending the 
clinic for treatment.  
9- Patients have received at least 2 months of anti-TB treatment and is considered to 
be responding clinically to the treatment. 
10- Patients accept to participate when approached at the DOTS clinic. 
Exclusion criteria   
6- Patients with missing contact information and those deported from the country. 
7- Clinical presentation is predominantly Extra-pulmonary TB. 
8- Coexistence of a malignancy. 
9- Known to be pregnant. 
10- Known HIV infection 
Once participants have identified, received counselling and guidance, agreed to participate 
and signed the consent form, a team of trained interviewers will interview them at a 
mutually convenient location either in their own homes or the healthcare facilities. Field 
assistants will use structured questionnaires using Arabic and/or English. Data collected 
will consist of general demographic details such as gender, age, socio-economic status, 
ethnic group and medical history.  
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At a convenient time, patients will be asked to provide blood samples after fasting for 12 
hours.  A phlebotomist will collect 10 ml of venous blood in three different blood tubes as 
follows: 2 ml in EDTA tube, 4 ml in Lithium Heparin tube and 4 ml in a tube with sodium 
fluoride anticoagulant. The samples will be collected at phlebotomy area of the 
Tuberculosis and Chest Diseases Centre in Jeddah city and will be send to the Madain Al-
Fahad Health Centre laboratory in Jeddah for processing. The blood samples will be used 
to do the following tests: Fasting Plasma Glucose (FPG), Fasting plasma insulin, 
Haemoglobin A1c and lipid profile including LDL, HDL and TG. If the patient is not 
fasting instructions will be given to returning to the clinic the next day after fasting for 12 
hours from 8 PM until 8 AM.  
 HA1c Lipid profile Glucose and insulin 
Blood volume  2 ml 4 ml 4 ml 
Type of tube EDTA Lithium Heparin Sodium fluoride 
 
Patients will be classified as having normal glucose values or DM according to their 
glycaemic status using the WHO guidelines to determine the DM diagnostic criteria. 
HOMA will be calculated using the Matthews et al. method to detect IR. The formula of 
IR is as follow: IR = FI×g/22.5, where (FI) is the fasting insulin (μU/mL) and (g) is the 
fasting glucose (mmol/L).  In order to obtain the IR estimate, the sample of venous blood 
will be taken after 12 hours fasting overnight, with the plasma samples either analysed 
immediately or stored at -20. The automated analyser (Hitachi Unicel DxI 600) will be 
used to determine the insulin level and the degree of insulin resistance/sensitivity will be 
measured using HOMA, which is an established index for measuring 
resistance/sensitivity. HOMA-IR estimate will not be estimated in patients using insulin. 
All patients with normal results will be informed of their results via email or phone calls. 
Patients with abnormal results will be asked to attend the clinic to discuss the results with 
the doctor.  
 
Objective 2: To describe the prevalence of DM and IR among patients with CHD.  
Study design: this will be a cross-sectional survey of patients ≥18 years old registered at 
the cardiology department the King Faisal Hospital in Taif city.  Patients will be eligible 
for selection into the study if have documented CHD and are medically stable. A stable 
CHD will be defined as an adult with an established pattern of angina pectoris, a history of 
confirmed myocardial infarction (MI), or the presence of plaque documented by 
catheterization. Only patients with stable CHD will be enrolled, as patients with acute 
coronary syndrome would have an increase in hormones, which will affect lipids, glucose 
and IR. Participants should be eligible if they have the following inclusion and exclusion 
criteria: 
 
Inclusion Criteria  
5- Patient with stable CHD attending the outpatient clinic. 
6- Patients aged ≥18 and residing in Taif city. 
7- Registered at Taif King Faisal Hospital, cardiology department, and still attending 
the clinic for treatment.  
8- Patients accept to participate. 
Exclusion Criteria 
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6- Patients with missing contact information and those deported from the country. 
7- Known renal disease. 
8- Known hepatic disease. 
9- Smoking more than 20 cigarettes per day. 
10- Known to be pregnant. 
 
Angina pectoris will be defined as a syndrome characterized by paroxysmal, constricting 
pain below the sternum, most easily precipitated by exertion or excitement and caused by 
ischemia of the heart muscle, usually due to a coronary artery disease, as arteriosclerosis. 
Confirmed MI will be defined according to the following criteria: at least 30 min of 
ischemic chest pain, ECG evidence of MI, a high level to more than 2 SD above the upper 
limit of the normal range of serum creatinine kinase and more than 4% of MB isoenzyme 
fraction. 
 
Once participants have been identified, received counselling and guidance, agreed to 
participate and signed the consent form, a team of interviewers will interview the 
participant at a mutually convenient location in either their own homes or the healthcare 
facilities. Field assistants will use structured questionnaires in lay Arabic and/or English. 
Data collected will consist of general demographic details such as gender, age, socio-
economic status, ethnic group, medical history, medication, physical activity, smoking 
habits, other diseases and family history of cardiac diseases and diabetes.  
 
Patients will be examined to measure height and weight, waist and hip circumference and 
waist-to-hip ratio (WHR). The blood pressure will be recorded twice from the right arm in 
a seated position using a mercury sphygmomanometer after 15 to 30 minutes of rest in 5-
minute intervals. Patients will be asked to fast for 12 hours and to provide three venous 
blood samples as described for TB patients and to conduct the same tests. The samples 
will be send to the King Faisal General Hospital laboratory in Taif for processing. HOMA 
will be calculated to detect IR in all participants. Patients will be classified as above into 
normal, euglycaemia with IR or DM. All patients will receive their results using the same 
procedures as described for TB patients. 
 
Objective 3: To explore whether IR is a risk factor for TB. 
Study design: This will be a case-control study in which the cases will be patients with 
TB. The control group will be patients without TB. Cases will be enrolled from patients 
participating in the cross-sectional survey first (objective 1) and will be the same patients 
attending spontaneously to tuberculosis and chest diseases centre with confirmed TB.  
Controls will be individuals attending to the same centre who were treated for other 
conditions and were deemed not to have TB. Controls will undergo the same tests as cases 
and both groups will be examined to establish if they have IR. The questionnaire for this 
objective will include a comprehensive list of factors associated with risk of TB and/or IR 
such as lifestyle, physical activity, diet, BMI, medical history and others. We will obtain 
anthropometric measurements (by a nurse of the same gender) including height (cm), 
weight (kg) and waist and hip circumference (cm). BMI will be calculated as weight 
(kg)/height² (m²). Participants should be eligible if they have the following inclusion and 
exclusion criteria: 
Inclusion criteria: 
5- Patients participating in the survey for objective 1. 
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6- Controls will be adults attending the TB Centre without TB. 
7- Participant aged ≥18 and residing in Jeddah city. 
8- Patients accept to participate. 
Exclusion criteria: 
2- Same as objective 1. 
 
According to the HOMA measurement and glucose testing, participants will be classified 
as having IR with and without DM. The prevalence of DM among TB patients in Saudi 
Arabia is reported in the literature to be between 14% and 26%. These data were 
summarized from 11 studies ranging from 1989 to 2009 with a mean age of 47 ±13 years 
(189). We expect the prevalence of IR among TB patients to be 35%.  Of these, 15% will 
have DM. We expect the prevalence of IR among control group without TB to be 20% i.e. 
5% with IR and without hyperglycaemia and 15% with DM. In that case 20/100 compared 
to 5/100 means that, the IR is a risk factor for TB.   
 
Laboratory tests: Participants will be asked to fast for 12 hours from 8 PM until 8 AM to 
provide blood samples. Patients will be asked if they are fasting.  Those who say they 
have not fasted will be asked to come back the next day after fasting. If the patient does 
not attend we will contact him/her by phone or email to encourage him/her to attend. The 
phlebotomist at tuberculosis and chest diseases centre phlebotomy area will collect blood 
between 8-10 AM under safety precautions using a vacutainer blood-collection system or 
a large syringe to collect approximately 10 ml of blood. 
 
The phlebotomist will split 10 ml of the sample into three tubes containing anticoagulants. 
Blood samples will be transported within two hours of collection by a reporter using a 
container with ice under safety precautions. The samples will be processed by two-
laboratory technicians in the Madain Al-Fahad Health Centre in Jeddah one from hormone 
department for insulin estimation and one from chemistry department for the glucose, 
HA1c and lipid profile including LDL, HDL and TG. If the sample is unlabelled or 
improperly labelled, collected in a wrong tube or the sample volume is not sufficient for 
the requirement of test protocol, the sample will be rejected and we will contact the 
patient to come again for blood collection in a convenient day to him/her after fasting.  
FPG analysis: Four ml of venous blood collected in a tube with Sodium Fluoride 
anticoagulant will be used for glucose determination based on the enzymatic reference 
method with Hexokinase using an automated chemistry analyser (Dimension Rxl Max). 
Insulin test: The blood sample collected in a Sodium Fluoride anticoagulant tube will be 
used for measuring insulin based on the chemiluminescence principle using an automated 
analyser (Hitachi Unicel DxI 600).  
HA1c test:  Two ml blood in an EDTA-containing tube will be used to measure HA1c 
based on the Turbidimetric Inhibition Immunoassay (TINIA) principle using an automated 
chemistry analyser (Dimension Rxl Max). 
Lipid profile: The four ml of blood collected in the Lithium Heparin tube will be used to 
establish the lipid profile including LDL, HDL and TG determination based on the 
enzymatic colorimetric method using an automated chemistry analyser (Dimension Rxl 
Max). 
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Objective 4: To explore whether IR is a risk factor for CHD. 
Study design: This will be a second case-control study in which the cases will be CHD 
patients, which is similar to the design described for objective three.  Cases will be 
enrolled from patients participating in the cross-sectional survey second objective and will 
be the same patients attending the King Faisal Hospital who were confirmed to have 
CHD.  The controls will be adults attending the outpatients department of the hospital who 
were treated for other conditions and were deemed not to have CHD. The questionnaire 
will include a comprehensive list of possible risk factors for IR and CHD such as lifestyle, 
physical activity, diet, BMI, medical history and others. We will obtain the same 
anthropometric measurements as described in objective three. Participants should be 
eligible if they have the following inclusion and exclusion criteria: 
Inclusion criteria: 
5- Cases will be participants in the survey for objective 2 attending the King 
Faisal Hospital. 
6- Controls will be adults attending the outpatients department without CHD. 
7- Participant aged ≥18 and residing in Taif city. 
8- Patients accept to participate. 
 
Exclusion criteria: 
2- Same as objective 2. 
 
Diabetic adults are two to four times more likely to have CHD than those without DM. 
The American Diabetes Association (ADA) recognizes DM to be one of the six main 
CHD risk factors. The major risk factors for CHD are uncontrolled hypertension, 
triglyceride, and cholesterol and/or poor glycaemic control, lack of physical activity, 
obesity, and smoking. Subjects with euglycamia IR or DM in combination with one or 
more of these risk factors are more likely to get CHD. To determine whether euglycaemic 
IR is a risk factor for CHD, we will enrol all the cases from the cross-sectional survey 
second objective and controls without CHD.  The prevalence of Metabolic syndrome 
(MS), as a surrogate of IR, in an adult Saudi population is 39.3% (307).  
 
A cohort study in a Saudi population confirm a clear association of MS with CHD as 6.7% 
of CHD patients had MS, compared to 4.6% without MS. A study among Saudi diabetic 
patients also evaluated risk factors for CHD. Concluding that the risk of CHD among 
diabetic patients was between 15–30%. We expect the prevalence of IR among adults 
CHD patients to be 35% i.e. 20% with IR and without hyperglycaemia and 15 % with 
DM. We expect the prevalence of IR among adults control group without CHD to be 20% 
i.e. 5% with IR and 15% with DM. In that case 20/100 compared to 5/100 means that, the 
IR is a risk factor for CHD.  
 
Laboratory tests: All Laboratory tests will be the same as those stated in objective 3. 
Specimens will be collected in King Faisal General Hospital phlebotomy area to be send 
to the king Faisl hospital Labortory.  
 
Objectives (5): To describe whether the severity of the clinical presentation of TB 
varies among patients with and without IR and/or DM.  
Study design: This will be a three arm retrospective case-control study. Cases will be 
patients diagnosed with TB patients who have DM, euglycaemic TB patients who have IR 
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and controls will be patients with TB without IR or DM. Participants should be eligible if 
they have the following inclusion and exclusion criteria: 
Inclusion criteria: 
4- Patients participating in the survey for objectives 1 and in the case-control for 
objective 3.  
5- Cases will be patients diagnosed with TB who have DM and euglycaemic TB 
patients who have IR. 
6- Controls will patients with TB without IR or DM. 
Exclusion criteria: 
2- Same as objective 1 and 3. 
 
Data will be collected retrospectively from the medical records (treatment register) of 
patients enrolled into first objective at the tuberculosis and chest diseases centre in Jeddah. 
TB disease severity will be assessed using a scoring system modified from previously 
published studies (36, 309) . A score of disease severity will be used as described by Gil-
Santana (2016) which includes the presence of each TB related symptom (cough, fever, 
dyspnoea, night sweats, weight loss, haemoptysis and Chest X-ray cavitations). The scores 
for cases will range from 0-9 where zero is absence of any symptom and nine is presence 
of all symptoms. Using the score, patients will be classed as having mild TB; or severe 
disease. Patients with a score of ≤4 will be classed as mild TB; and a score ≥5 will be 
classed as severe disease. Data will be extracted from the patient medical record using a 
structured form including age, gender and symptoms at presentation. Variables that are 
missing will be completed by interviewing the patients. The TB disease severity for the 
control group will be assessed using the same scoring system. 
Objectives (6): To describe whether the quality of life of patients with CHD varies 
among patients with and without IR and/or DM.  
Study design: This will be a three arm retrospective case-control study. Cases will be 
patients with stable CHD who have DM, euglycaemic stable CHD patients who have IR 
and controls will be patients with stable CHD without IR or DM. Participants should be 
eligible if they have the following inclusion and exclusion criteria: 
Inclusion criteria: 
4- Patients participating in the survey for objectives 2 and in the case-control for 
objective 4 
5- Cases will be patients with stable CHD who have DM and euglycaemic stable 
CHD patients who have IR. 
6- Controls will be patients with CHD without IR or DM. 
Exclusion criteria: 
2- Same as objective 2 and 4. 
 
Patients will be enrolled among participants to previous studies to apply a questionnaire to 
assess their quality of life.  The scoring system that we are going to use to assess the 
quality of life is the WHOQOL-BREF, an abbreviated version of the World Health 
Organization quality of life assessment (WHOQOL-100) developed by the WHOQOL 
group (310) along with regular laboratory parameters.  
 
The World Health Organisation Quality Of Life (WHOQOL) 100 assessment was 
established in order to attempt to cross-culturally over the WHOQOL group’s 15 
international centres identify quality of life, as identified by Orley & Kuyken, 1994; 
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WHOQOL Group 1994a, 1994b, 1995; Szabo, 1996.  This assessment provides detailed 
information regarding each individual aspect of the quality of life. However, in some 
cases it may not be practical to use, as the WHOQOL-100 can be too long-winded. 
Therefore, a field trial form known as WHOQOL-BREF was formulated in order to offer 
a shorter quality of life assessment that uses domain-level profiles from pilot WHOQOL 
assessment data as well as all data available from the WHOQOL-100 field trial system. 
The WHOQOL assessment tool allows for comprehensive epidemiological research on 
quality of life for comprehending diseases and methods that can be developed for 
treatment on a particular population group. 
 
WHOQOL-BREF scoring 
There are four domain scores that can be derived from the profile that is produced from 
the WHOQOL-BREF quality of life assessment. A further examination on two more items 
is also done separately and these are in the form of two questions; the 1st question will 
identify the overall perception that an individual has on the quality of life and the 2nd 
question will look at the view of the individual’s health. These four scores will indicate 
how an individual perceives their quality of life for each specific domain. The scores for 
each domain will ascend positively so that a high score will represent a high quality of 
life. The total domain score will be identified by using the mean score from each 
particular domain, and these scores will be multiplied by four so that it is possible to 
compare them with WHOQOL-100 scores. Cleaning and checking data, calculating each 
individual score, computing the domain scores and the procedure for translating the raw 
scores to converted scores can be found on the WHO website. 
 
The anthropometric data will all be gathered including the BMI, age, heart rate, diastolic 
and systolic blood pressure, risk factors (hypertension, status of DM, physical activity, 
smoking, family history and hypercholesterolemia) as well as the laboratory parameters.  
Coronary score has shown a positive correlation with blood glucose and HbA1c, while 
lipid metabolism also plays a role in coronary atherosclerosis genesis. Therefore, we will 
incorporate the following tests in our study, and these are fasting plasma insulin, fasting 
plasma glucose, haemoglobin A1c and also lipid profiling, which will include TG, HDL 
and LDL. 
 
A.6 
PARTICIPANTS: Please state the number of research participants to be 
recruited.  If you are unable to give precise figures, please give estimates. 
A.6.2
  
ELIGIBILITY CRITERIA 
Objective 1 
PARTICIPANTS:  
A.6.1  
AGE/SEX 
Neonates 
(<28 
days) 
Infants 
(1-11 
months) 
Young 
children 
(1-9 
years) 
Adolescents 
(10-18 years) 
Adults 
(>18years) 
Males N/A N/A N/A N/A 90 
Females N/A N/A N/A N/A 85 
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   Inclusion Criteria 
  
Exclusion Criteria 
1- Patients with bacteriologically 
confirmed pulmonary TB. 
2- Patients aged ≥ 18 and residing in 
Jeddah city. 
3- Registered at the TB and chest 
diseases centre in Jeddah and still 
attending the clinic for treatment.  
4- Patients have received at least 2 
months of anti-TB treatment and is 
consider to be responding clinically to 
the treatment. 
5- Patients accept to participate when 
approached at the DOTS clinic. 
1- Patients with missing contact 
information and those deported from 
the country. 
2- Clinical presentation is predominantly 
Extra-pulmonary TB. 
3- Coexistence of a malignancy. 
4- Known to be pregnant. 
5- Known HIV infection 
 
Objective 2 
PARTICIPANTS: 
A.6.1  
AGE/SEX 
Neonates 
(<28 
days) 
Infants 
(1-11 
months) 
Young 
children 
(1-9 
years) 
Adolescents 
(10-18 years) 
Adults 
(>18years) 
Males N/A N/A N/A N/A 147 
Females N/A N/A N/A N/A 200 
Inclusion Criteria Exclusion Criteria 
1- Patient with stable CHD 
attending the outpatient clinic. 
2- Patients aged ≥18 and residing in 
Taif city. 
3- Registered at Taif King Faisal 
Hospital, cardiology department, 
and still attending the clinic for 
treatment.  
4- Patients accept to participate. 
 
1- Patients with missing contact 
information and those deported from 
the country. 
2- Known renal disease. 
3- Known hepatic disease. 
4- Smoking more than 20 cigarettes per 
day. 
5- Known to be pregnant. 
 
Objective 3 
PARTICIPANTS:  
A.6.1  
AGE/SEX 
Neonates 
(<28 
days) 
Infants 
(1-11 
months) 
Young 
children 
(1-9 
years) 
Adolescents 
(10-18 
years) 
Adults 
(>18years) 
Males N/A N/A N/A N/A 70 
Females N/A N/A N/A N/A 70 
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Inclusion Criteria Exclusion Criteria 
1- Patients participating in the 
survey for objective 1. 
2- Controls will be adults attending 
the TB Centre without TB. 
3- Participant aged ≥18 and residing 
in Jeddah city. 
4- Patients accept to participate. 
1- Same as objective 1. 
Objective 4 
PARTICIPANTS:  
A.6.1  
AGE/SEX 
Neonates 
(<28 
days) 
Infants 
(1-11 
months) 
Young 
children 
(1-9 
years) 
Adolescents 
(10-18 
years) 
Adults 
(>18years) 
Males N/A N/A N/A N/A 70 
Females N/A N/A N/A N/A 70 
Inclusion Criteria Exclusion Criteria 
1- Cases will be participants in the 
survey for objective 2 attending 
the King Faisal General 
Hospital. 
2- Controls will be adults attending 
the outpatients department 
without CHD. 
3- Participant aged ≥18 and residing 
in Taif city. 
4- Patients accept to participate. 
1- Same as objective 2. 
 
Objective 5 
PARTICIPANTS:  
A.6.1  
AGE/SEX 
Neonates 
(<28 
days) 
Infants 
(1-11 
months) 
Young 
children 
(1-9 
years) 
Adolescents 
(10-18 years) 
Adults 
(>18years) 
Males N/A N/A N/A N/A 70 
Females N/A N/A N/A N/A 70 
Inclusion Criteria Exclusion Criteria 
1. Patients participating in the survey 
for objectives 1 and in the case-
control for objective 3.  
2. Cases will be patients diagnosed 
with TB who have DM and 
1. Same exclusion criteria as objectives 1 
and 3 
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euglycaemic TB patients who have 
IR. 
3. Controls will patients with TB 
without IR or DM. 
4.  
Objective 6 
PARTICIPANTS: Please state the number of research participants to be recruited.  If you 
are unable to give precise figures, please give estimates. 
A.6.1  
AGE/SEX 
Neonates 
(<28 
days) 
Infants 
(1-11 
months) 
Young 
children 
(1-9 
years) 
Adolescents 
(10-18 years) 
Adults 
(>18years) 
Males N/A N/A N/A N/A 70 
Females N/A N/A N/A N/A 70 
Inclusion Criteria Exclusion Criteria 
1. Patients participating in the survey 
for objectives 2 and in the case-
control for objective 4. 
2. Cases will be patients with stable 
CHD who have DM and 
euglycaemic stable CHD patients 
who have IR. 
3. Controls will be patients with CHD 
without IR or DM. 
1. Same exclusion criteria as objective 2 
and 4.     
 
 
Justification for eligibility criteria – if you are excluding a particular group you should 
justify their exclusion. 
 
Excluded patients for TB study groups. 
Malignancy: Recent evidence has confirmed the proposed synergistic relationship 
between IR/DM and malignancy co-morbidities. Although the pathways and mechanisms 
for these associations are still uncertain, it is becoming clear that hyperinsulinemia and 
hyperglycemia are important regulators of not only the development of malignancy but 
also of treatment outcome.  
 
Pregnant women:  Glucose intolerance during pregnancy is defined as gestational 
diabetes mellitus, which is due to endocrine changes that effect the normal physiological 
metabolism of glucose leading to the development of IR. As very few women will be 
pregnant, we would not be able to analyse this subgroup with a statistical power.   
 
Known HIV infection:  Metabolic abnormalities of HIV-associated lipodystrophy 
syndrome are well established, which are characterised by IR, Type 2 diabetes Mellitus 
(T2DM) and dyslipidemia Including this type of participants may confound our findings 
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and we would not have sufficient participants with these characteristics to compensate for 
their confounding effect. We have therefore decided it is better to exclude them. 
 
Excluded patients for CHD study groups. 
Patients with chronic kidney and liver disease: these patients have an extremely high risk 
of developing CHD. Including them would overestimate our findings. In addition, heavy 
cigarette smoking (>20/day) is a major risk factor of CHD.  Pregnant women:  For the same 
reasons stated as for TB above. 
 
A.6.3 
VULNERABLE GROUPS: Please identify vulnerable groups that will be 
included in this study. Also state how you will minimise any harm to each group 
identified.   
Very few vulnerable groups are included. Non Saudi adults who have recently migrated to 
Saudi Arabia may lose their employment if they are found to have a TB. Unfortunately, 
according to the Saudi law, these cases initiate treatment and are deported to their country 
directly.  As deportation would happen before enrolment, they will not be included in the 
study. Non Saudis who develop TB long after arriving in Saudi Arabia receive the same 
treatment as Saudi patients.   
A.6.4
  
RECRUITMENT PROCESS: Please detail the procedures for how you will be 
approaching each group of participants to take part in the project.   Where will 
recruitment take place?  Who will be responsible for recruitment of participants? 
Objective 1: Participants will be identified from the TB and chest diseases centre in 
Jeddah. The principal investigator/ research assistants will identify patients who meet the 
study’s selection criteria. Patients will be selected during the continuation phase of TB 
treatment (i.e. after receiving at least two months of treatment).  We will, therefore, select 
confirmed patients who have received treatment for at least two months. After identifying 
the patients, the purpose and procedure of the study will be explained to them. Once 
participants have been identified, received counselling and guidance, agreed to participate 
and signed the consent form, a team of trained interviewers will interview them at a 
mutually convenient location either in their own homes or the healthcare facilities. Field 
assistants will use structured questionnaires in lay Arabic and/or English. 
 
Objective 2: The recruitment will take place in King Faisal Hospital in Taif. The principal 
investigator/ research assistants will identify patients who meet the study’s selection criteria 
at the cardiology department of the hospital. After identifying the patients, the purpose 
and procedure of the study will be explained to them. Once participants have identified, 
received counselling and guidance, agreed to participate and signed the consent form, a 
team of interviewers will interview the participant at a mutually convenient location in 
either their own homes or the healthcare facilities. Field assistants will use structured 
questionnaires in lay Arabic and/or English.  
 
Objective 3: The recruitment will take place in the TB and chest diseases centre in Jeddah 
as described above. The controls will be individuals attending the centre who were treated 
for other conditions and were deemed not to have TB. As Saudi Arabia is a low TB 
burden country and we expect a low number of TB cases have the inclusion and exclusion 
criteria, therefore, we will select all patients for cases group until the desired sample size 
is achieved. Controls will be selected using systematic sampling by selecting every 5th 
 214 
patient starting from first patient attending to the TB and chest diseases centre until the 
desired sample size is achieved. Five patients will be enrol daily five days a week.  In case 
any participant refuses to participate, a consecutive patient will be recruited for his/her 
replacement. Participants will be asked to fast for 12 hours from 8 PM until 8 AM to 
provide blood samples. The next day, patients will be asked if have fasted. Those who say 
they have not fasted will be asked to come back the next day after fasting. If the patients 
do not attend we will contact them by phone or email to encourage them to attend. The 
phlebotomist at TB and chest diseases centre phlebotomy area will collect blood between 
8-10 AM. 
 
Objective 4: The recruitment will take place in King Faisal General Hospital in Taif’s 
cardiology department.  Cases will be enrolled from patients participating in the survey 
(objective 2).  Controls will be selected from adults attending the outpatient’s department 
who are being treated for other conditions that were not deemed to be CHD. Controls will 
be selected using systematic sampling as described in objective 3 above.   
  
Objective (5): Participants will be identified from the same patients enrolled into the third 
objective at the TB and chest diseases centre in Jeddah. The physician at the TB clinic will 
identify patients who meet the study’s selection criteria. The data will be collected 
retrospectively from the medical records (treatment register) of enrolled patients. 
  
Objective (6): Participants will be identified from the same patients enrolled into 
objective 4 at King Faisal Hospital. The data will be collected retrospectively from the 
medical records of enrolled patients. 
A.7  
OUTCOMES: What is the primary outcome measure for the study?      
What are the secondary outcome measures? (if any) 
Objective 1: prevalence of DM and IR among patients with TB. 
Objective 2: prevalence of DM and IR among patients with CHD. 
Objective 3: proportion of patients with and without TB with IR/DM. 
Objective 4: proportion of patients with and without CHD with IR/DM.  
Objective 5: severity score of the clinical presentation of TB among patients with and without 
IR and/or diabetes.  
Objective 6: quality of life scores of patients with CHD with and without IR and/or diabetes.  
 
A.8  
MAJOR METHODS OF ANALYSIS: What are the major methods you intend to 
use to analyse the data?   
First and Second objectives: 
Bacteriologically confirmed pulmonary TB patients and patient with stable CHD will be 
classified as having normal glucose values or DM according to their glycaemic status 
using the WHO guidelines to determine the DM diagnostic criteria. Furthermore, IR status 
will be classified according the HOMA calculation using the Matthews et al. formula. The 
formula of IR is as follow: IR = FI×g/22.5, where (FI) is the fasting insulin (μU/mL) and 
(g) is the fasting glucose (mmol/L). The cut-off point for IR will be 2.6.  
➢ Diabetic patient will be defined as the patient of abnormal fasting blood glucose level 
(FPG) (≥126 mg/dl [7.0 mmol/L]) and abnormal Haemoglobin A1c level (HA1c 
≥6.5%). 
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➢ Euglycaemic participant with (FPG < 125 mg/dl [6.9 mmol/L]) will be defined as 
having increase IR if the HOMA-IR > 2.6. 
➢ Participant with FPG is < 110 mg/dl (6.1 mmol/L), Haemoglobin A1c level (HA1c 
≥6.5%) and HOMA ≤ 2.6 will be defined as not having DM or IR. 
 
Third and fourth objectives: 
The outcome measure is to describe the association of T2DM and IR with the following 
assumed risk factors: age, sex, BMI, BP, LDL, HDL and TG. History of DM in the family, 
smoking, dietary habits and physical activity will also be included. Data analysis for this 
study would be conducted through chi-square test to compare between the patient with IR 
and without IR relative to demographic characteristics. In addition, SPSS software will be 
used to input and analyse the collected data. Then multiple Logistic regression analyses 
will be conducted to analyse the significant factors associated with the dependent variable. 
The association between Independent variables will be selected on the basis of the 
literature of diabetes risk factors and will be analysed using the logistic regression analysis. 
Univariate and a multivariate will be conducted, results will be presented as crude and 
adjusted odds ratios with associated 95% CI. Mean ± standard deviation is used to define 
the normal and continuous distributed data. Continuous and ordinal data with outliers or 
skew distribution are defined by the first, median and third quartiles. The coronary score 
is used with continuous variables using simple associations via the Spearman correlation 
coefficient, and the dichotomous variables were calculated using the point bi-serial 
correlation coefficients. The significance level will be set at 0.05. This mixed method 
approach is likely to produce authentic result and cater to the limitations of quantitative 
analysis as mentioned above. 
 
Fifth objective: 
The outcome measure is to describe whether the severity of the clinical presentation of TB 
varies among patients with and without IR and/or DM. Data will be collected 
retrospectively from the medical records (treatment register). TB disease severity will be 
assessed using a scoring system modified from previously published studies. The scores 
for cases will range from 0-9 where zero is absence of any symptom and nine is presence 
of all symptoms. Using the score, patients will be classed as having mild TB; or severe 
disease. . Patients with a score of ≤4 will be classed as mild TB; and a score ≥5 will be 
classed as severe disease. 
 
Sixth objective: 
The outcome measure is to describe whether the quality of life of patients with CHD 
varies among patients with and without IR and/or DM. The scoring system that we are 
going to use to assess the quality of life is the WHOQOL-BREF, an abbreviated version 
of the world health organization quality of life assessment (WHOQOL-100) developed by 
the WHOQOL group along with regular laboratory parameters which include fasting 
plasma insulin, fasting plasma glucose, haemoglobin A1c and also lipid profiling, which 
will include TG, HDL and LDL. 
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A.9 
SAMPLE SIZE: Please justify your choice of sample size (as described in A.6.1). 
Please ensure that the sample size calculation is based on the primary outcome 
measure as detailed in A7. 
The sample size for objective 1: The sample size was calculated using the standard 
formula for estimating a single population proportion. I used the epi info programme; 
sample size calculation for population survey.  I provided the population size which is the 
total number of people attending to the Tuberculosis and Chest Diseases Centre in Jeddah 
city every year, the expected frequency of the diabetes and IR which is 35%, confidence 
limit of 5%. For the cross-sectional survey, we assume that there are 350 adults available 
and the expected prevalence of DM and IR is 35%. To do a survey with an 80% power and 
95% confidence limit we required a sample size of 175 adults. 
 
The sample size of the cross-section survey for CHD group: The sample size was 
calculated using the standard formula for estimating a single population proportion. I used 
the epi info programme; sample size calculation for population survey.  I provided the 
population size which is the total number of people attending to the King Faisal General 
Hospital. For the cross-sectional survey, we assume that there are more than 45,000 adults 
available for the study and the expected prevalence of DM and IR is 35%. To do a survey 
with an 80% power and 95% confidence limit we required a sample size of 347 adults. 
 
The sample size of the case control study for TB group:  I used the epi info programme; 
sample size calculation for unmatched case-control.  I used a power of 80%, a ratio of 1 
case and 1 control and the proportion (percentage) of TB cases with DM being 35% 
compared to a 20% of controls having DM. I estimated that 140 cases and an equal number 
of controls should be recruited to achieve 80% power to detect an odds ratio of 2.0 at the 
5% significance level if 10% or more of the general population were exposed to the risk 
factor. 
The sample size of the case control study for CHD group:  The sample size was based 
on the confidence interval, the power and the ratio of cases and controls and percentage of 
cases and controls expected to be exposed to the risk factor. I used a power of 80%, a ratio 
of 1 case and 1 control and the proportion of CHD cases having DM of 35% compared to 
20% of controls having DM. An estimated 140 cases and an equal number of controls 
should achieve 80% power to detect an odds ratio of 2.0 at the 5% significance level if 
10% or more of the general population were exposed to the risk factor. 
 
A.10 
QUALITY ASSURANCE: Quality assurance is more than just for data analysis – 
it should include procedures in design and data collection.  What procedures are in 
place to ensure the quality of the data? What consideration has been given to 
methods of analysis to ensure efficiency of data use?   
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Project QA activities will be as follow:  
The researcher will follow the advice of supervisors to ensure that all research stages and 
methodologies employed are suitable before beginning. Training and pretesting of the 
questionnaire will be conducted at the King Faisal Hospital in Taif city and Tuberculosis 
and Chest Diseases Centre in Jeddah city. The pre-test result will be first discussed and 
necessary corrections will made on the questionnaire before the actual data collection 
commenced. To ensure the quality of data, questionnaires will thoroughly checked for 
completeness and consistency by study supervisors and principal investigator. 
Manufacturer’s control standard for calibration of autoanalyzer will be used to maintain 
the quality of following measurements: Fasting Plasma Glucose (FPG), Fasting Plasma 
Insulin, Haemoglobin A1c and Lipid Profile including LDL, HDL and TG. The records of 
Internal and external quality control for AFB smear microscopy test and culture will be 
also ensured.  
 
SECTION B 
PROCEDURES AND PATIENT CARE 
B.1 PROCEDURES 
Please detail any clinical or other research procedures to 
which participants will be subjected. 
Tuberculosis 
Procedure To be carried out 
by: 
Who is the person employed 
by? 
Patient diagnosis and follow 
up. Dr. Ali Asghar 
Saudi Arabia, Ministry of 
Health; Jeddah Health Affairs 
Identification of patients in the 
register and completion of 
questionnaires.  
Clinic nurse 
Saudi Arabia, Ministry of 
Health; Jeddah Health Affairs 
Blood collection and 
completion of questionnaires. 
Mosa Mohammad 
Atwady 
Saudi Arabia, Ministry of 
Health; Jeddah Health Affairs 
To transfer of samples from 
the Tuberculosis and chest 
diseases centre to Madain Al-
fahad Health Centre in 
Jeddah. 
Health care driver  
Saudi Arabia, Ministry of 
Health; Jeddah Health Affairs 
 
Coronary Heart Disease 
Procedure 
To be carried out 
by: 
Who is the person employed 
by? 
Patient diagnosis and follow 
up. 
Dr. Mohammed 
Mougrabi 
Saudi Arabia, Ministry of 
Health; Taif Health Affairs 
Patient diagnosis and follow 
up. Dr. Syied Sadeq 
Saudi Arabia, Ministry of 
Health; Taif Health Affairs 
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Identify the patients in the 
register and fill the 
questionnaires. 
Clinic nurse 
Saudi Arabia, Ministry of 
Health; Taif Health Affairs 
Collection of blood at King 
Faisal Hospital phlebotomy 
area 
Phlebotomist  
Saudi Arabia, Ministry of 
Health; Taif Health Affairs 
Insulin measurements  Laboratory 
specialist  
Saudi Arabia, Ministry of 
Health; Taif Health Affairs 
Fasting Plasma Glucose 
(FPG), Haemoglobin A1c and 
lipid profile including LDL, 
HDL and TG. 
Dr. Ashrf Ali 
Khan  
Saudi Arabia, Ministry of 
Health; Taif Health Affairs 
Coordination between Taif 
Health Affairs and Laboratory Alaa Salem Abed 
Saudi Arabia, Ministry of 
Health; Taif Health Affairs 
 
 
B.2       
STANDARD PATIENT CARE: Please explain if the procedures 
outlined in B.1 are part of the normal clinical work of the staff who will 
perform the procedure.  If not applicable to your study, please write a 
sentence stating that this is not a clinical study. 
This is not a clinical study and we are going to follow the same routine diagnostic 
procedure. In addition to that, the blood collection will take place in the phlebotomy 
department which collect blood as a daily routine procedure. 
 
B.3  
END OF TRIAL TREATMENT: For intervention trials, what steps will be taken 
to make successful interventions or treatment available to all trial participants at the 
end of the trial?  If not applicable to your study, please write a sentence stating that 
this is not a clinical study. 
Not applicable.  This is not a clinical trial. 
 
 
B.4 TRAINING 
Please indicate the basis on which the persons identified in B.1 
are thought to be competent to carry out these procedures.  List 
any training of staff which will be required prior to 
commencement of the study. 
Tuberculosis 
Staff Member Experience/competencies Training Required 
The researcher Currently PhD student at LSTM Not required 
Dr. Ali Asghar Physician at the TB clinic Not required 
Clinic nurse 
Staff in the tuberculosis and 
chest diseases centre 
Questionnaire filling 
training 
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Mosa Mohammad 
Atwady 
Staff in the tuberculosis and 
chest diseases centre Not required 
Health care driver  
Staff in the tuberculosis and 
chest diseases centre Not required 
Coronary Heart Disease 
Staff Member Experience/competencies Training Required 
The researcher Currently PhD student at LSTM Not required 
Dr. Syied Sadeq Staff at the CVD clinic Not required 
Clinic nurse 
Staff at the King Faisal Hospital 
in the CVD clinic 
Questionnaire filling 
training 
Phlebotomist  
Staff at the King Faisal Hospital 
phlebotomy department. Not required 
Laboratory specialist  
Staff at the King Faisal Hospital 
laboratory department. Not required 
Dr. Ashrf Ali Khan  
Staff at the King Faisal Hospital 
laboratory department. Not required 
Alaa Salem  Abed 
Coordination between Taif 
Health Affairs and Laboratories  Not required 
 
SECTION C 
RISKS AND CONSEQUENCES 
 
C.1 
ADVERSE EFFECTS, DISCOMFORT OR RISKS: Outline the 
potential adverse effects, discomfort or risks that may result from the study 
for participants, investigators and members of the public and how you will 
minimise them. 
Tuberculosis 
C.1.1 
Participants 
Potential adverse effects, discomfort or risks 
There will be no serious adverse effects in participating in this study; 
however, there will be an interview, which may be discomforting. 
Patients will also be required to dedicate some time for the interview to 
take place.  
 
The participants should give blood sample. Blood collecting procedure 
may cause some minor adverse effect in some cases as the followings: 
 
Hematoma: This may cause pain and discomfort leading to 
complications in drawing more blood from that particular site.  
 
Pain: There is a risk that during collection a needle may pierce the nerve. 
The participant will complain of an electric shock sensation going up 
their arm.  
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Steps to be taken to minimise adverse effects, discomfort and risks  
The interview: There will be an appropriate room with comfortable 
chairs provided and we will also ensure that the interviewer will adhere to 
academic principles by confirming that the participant is fully aware of the 
importance and the purpose of this study. The languages used in the 
interview will be Arabic and/or English, and the questions will be 
structured in a manner that will be clear and easy for the participant to 
understand. The participant will be free to cycle between topic areas or 
questions going back or skipping forward to any particular area.  
 
Hematoma: If haematoma is observed, the tourniquet and needle must 
be removed and pressure should be applied to the site for at least 3 
minutes. The site is then checked for the haematoma to see if it has 
stopped and a gauze or bandage is taped to the area for a minimum of 
half an hour, the patient is also informed about the haematoma. 
 
Pain: if this occurs remove the needle immediately from the arm of the 
participant and apply pressure to the site of the piercing. Check with the 
patient whether the sensation has stopped and if this is the case ask the 
participant if they are willing to allow for another site to be used. The 
participant should be told that the reason they felt this pain was because 
the needle had touched a nerve.  
C.1.2 
Investigators 
Potential adverse effects, discomfort or risks 
Health care workers (HCWs) exposure to air-borne pathogens as they 
will be dealing with TB patients, blood-borne pathogens from needle 
sticks, sharps injuries are primarily associated with HCWs transmission 
of hepatitis B virus (HBV), hepatitis C virus (HCV), and human 
immunodeficiency virus (HIV). 
Steps to be taken to minimise adverse effects, discomfort and risks 
The staff will be encouraged to follow the TB infection-control 
measures by the Centres for Disease Control and Prevention (CDC) 
and the local infection control guidelines precautions for preventing 
transmission of blood-born and air born infections. Laboratory 
workers are responsible for their own safety and that of their co-
workers. 
C.1.3 
Members of 
the public 
Potential adverse effects, discomfort or risks 
The study will be conducted in a health care centre and there is no public 
will be involved in this research. 
Steps to be taken to minimise adverse effects, discomfort and risks 
No special precautions are required. 
 
 
Coronary Heart Disease 
C.1.1 
Participants 
Potential adverse effects, discomfort or risks 
Same as Tuberculosis group. 
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Steps to be taken to minimise adverse effects, discomfort and risks  
Same as Tuberculosis group. 
C.1.2 
Investigators 
Potential adverse effects, discomfort or risks 
Same as Tuberculosis group. 
Steps to be taken to minimise adverse effects, discomfort and risks 
Same as Tuberculosis group. 
C.1.3 
Members of 
the public 
Potential adverse effects, discomfort or risks 
Same as Tuberculosis group. 
Steps to be taken to minimise adverse effects, discomfort and risks 
Same as Tuberculosis group. 
 
C.2 
CONSEQUENCES FOR LOCAL HEALTH SERVICES 
 
C.2.1
  
IMPACT ON LOCAL SERVICES: What demands will this research place on 
local health services? 
No extra demand on local health services will be required.  
The interview: using structured questionnaires will require time and effort and will be done 
by the researcher / assistance and it will not affect the working schedule of the local health 
service.  
The blood collection: will be done at the working hours and will not affect the working time 
of the local health service.  
The laboratory tests: most of the procedures that we are going to do are daily work for the 
assistance but will increase the work load. 
C.2.2
  
MINIMISING IMPACT ON LOCAL SERVICES: Detail how the design of the 
research project takes into account the demands described above in C.2.1 
The interview: the research will interview the participants and I will employ a research 
assistant to help in conducting the study. He/she will be employed to interview the 
participants. The assistant will be paid for this work.  
The blood collection: the blood collection will be allocated according to the phlebotomist 
working hours and daily routine work to minimise the impact on his/her activities.  
The laboratory tests: the laboratory assistances will be paid for the work. 
 
SECTION D 
PRIVACY AND INFORMED CONSENT  
 
D.1 
INFORMED CONSENT (please pay particular attention to the guidance notes for this 
section) 
 
D.1.
1   
OBTAINING INFORMED CONSENT: Please give details of how you will obtain informed 
consent.  You must include details of (i) information given to participants, (ii) who will deliver the 
information and (iii) consideration of local circumstances.  Please note that reference of transport 
of samples to another country must be included in the consent forms.  Please also give special 
consideration to whether proxy consent is required (for those lacking capacity to consent, minor 
etc) and give details as to how this would be obtained.  
 
 222 
 
Participants information form for tuberculosis patients 
 
The following information will be given to the participants: 
The purpose of the study, why the participant has been selected, a summary of the study procedure 
such as processes of data collection (e.g. questionnaires), the possible impact the research will 
have on the participant, such as side effects, risks, benefits, discomforts, data sharing, data storage, 
confidentiality, results circulation and voluntary involvement, where the participant can at any 
time withdraw themselves from the study and they will be provided with contact details of the 
appropriate person/researcher for any queries. 
 
The consent form will be distributed to men/women that attend the centre of tuberculosis and chest 
diseases, to invite individuals to take part in the research study on diabetes mellitus and insulin 
resistance as key risk factors for tuberculosis among diabetic and euglycaemic patients in the city 
of Jeddah, Saudi Arabia. 
 
Fareed Almaleki, Liverpool School of Tropical Medicine. 
Determining the association of insulin resistance and diabetes mellitus as key risk factors for 
tuberculosis among diabetic and euglycaemic patients in Saudi Arabia. 
 
The consent form is split into two parts, and these are: 
 
• The research information sheet. 
• The certificate of consent. 
The participant will receive a copy of the consent form. 
 
Introduction:  
I am [The name of the individual providing the consent form]. I work for the centre of tuberculosis 
and chest diseases, Jeddah, and I am acting on behalf of Fareed Almaleki, who studies at the 
Liverpool School of Tropical Medicine, UK. We are performing research on topical diseases and 
their diagnosis, in particular diabetes mellitus, which is highly prevalent in Saudi Arabia. We are 
inviting you to take part in our research study, however, before participating, it is important to 
understand what the study will involve and why the research is being implemented. Please have a 
look carefully at the following information and if there is anything you are unsure of, or if you 
would like any further information do not hesitate to ask any questions. You are also free to 
review this information with your GP or any friends and family, and we would like to emphasise 
that you should only go ahead with the invitation if you are happy to take part in the study. Should 
you agree to participate in this study, we will need to ask you questions regarding your medical 
history enquiring about previous and current diseases.  If you come across any words that you do 
not understand in this document or in the interview, please inform me and we will stop to ensure 
that it is explained to you. If you have any further questions at a later time you can either ask 
myself, the staff or the study doctor, while you will also be provided with the details of the contact 
person/researcher so that you can contact them regarding any queries you may have. 
 
Purpose:  
Diabetes mellitus is a frequent disease, which on a global scale affects more than 415 million 
individuals. We propose in this project that insulin resistance and diabetes are key risk factors for 
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tuberculosis and we will look for this association by studying patients in the city of Jeddah, Saudi 
Arabia. Insulin is a normal hormone that helps to utilise sugars.  If the body does not respond well 
to this hormone, we call it insulin resistance. 
 
Participant Selection:  
This study invites participants above the age of 18 that attend the tuberculosis and chest diseases 
centre. 
 
Voluntary Participation:  
Participation in this study is completely voluntary and it entirely up to you if you wish to 
participate, you will be given 24 hours to decide whether or not to participate. The services at this 
clinic that you currently receive will not be affected whether you decide to participate or not and If 
you do participate you can opt out at any time of the study. 
 
Procedures and Protocol: 
In order to determine if insulin resistance and diabetes increases the risk of tuberculosis, we will 
invite 175 participants. Each participant will be asked for a blood sample (10ml) so that we can 
assess their glucose levels, insulin levels, HA1c and lipid profile, which will include TG, HDL and 
LDL. To calculate IR we will use a mathematical formula, and when the results are available we 
will contact the participants by email or by phone to inform them. The participants will be asked 
to complete a questionnaire which will ask about your lifestyle, as well as weight, physical 
activity, diet and family history. There will be a nurse dedicated to measuring each participant’s 
height (cm), weight (kg), hip and waist circumference (cm) and blood pressure (BP). 
 
Risks and discomfort: 
There will be no serious adverse effects in participating in this study; however there will be an 
interview, which will ask some personal questions. You will also be required to dedicate some 
time for the interview to take place. There will be an appropriate room with comfortable chairs 
provided and we will also ensure that the interviewer will adhere to academic principles by 
confirming that the participant is fully aware of the importance and the purpose of this study. The 
languages used in the interview will be Arabic and/or English, and the questions will be clear and 
easy to understand.   
 
Hematoma: In venepuncture, it is possible for the blood to leak from a vein and out under the 
skin. This may cause pain and discomfort leading to complications in drawing more blood from 
that particular site. If haematoma is observed, the tourniquet and needle must be removed and 
pressure should be applied to the site for at least 3 minutes. The site is then checked for the 
haematoma to see if it has stopped and a gauze or bandage is taped to the area for a minimum of 
half an hour. 
 
Pain: There is a small risk that during blood collection a needle may pierce the nerve. You would 
feel a mild electric sensation. If this occurs we will remove the needle and apply pressure to the 
site of the piercing. The sensation will stop and the participant will be told the reason they felt this 
pain was because the needle had touched a nerve.  
 
Samples to be collected and stored:  
Your blood samples may be used anonymously for future studies and in testing for further 
potential diabetic markers. Signing this consent form means that you will give your permission for 
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us to safely store your blood for anonymous use in other future projects that are considered 
suitable. 
 
Benefits:  
By participating in this study, we will be able to detect whether or not you are diabetic and if you 
are likely to develop diabetes. Should we detect that you are diabetic, we can arrange for you to 
meet a specialist and we will also provide you with a leaflet on diabetes risk awareness.  
 
Incentives:  
There is no financial incentive for taking part in this study 
 
Confidentiality:  
The study will take place within your clinic, therefore it is likely that others within the clinic may 
become aware of your participation and question you regarding this. We would like to assure you 
that the identity and all information collected from individuals participating in this study will be 
kept confidential. Your information that is collected in this study is confidential and will only be 
accessed by research sponsors, ethics committee members and institutional officials. Any data that 
we have on you will be number coded and your name will not be used, the only individuals that 
will know your number will be the researchers and this information will be locked away with a 
key.  
 
Right to Refuse or Withdraw:  
You have the right to refuse to participate in this study and if this is the case your treatment in this 
clinic will not be affected, you will still receive any assistance that you had prior to the study. If at 
any time you wish to withdraw from the study, you may do so without the loss of any rights that 
you have as a patient at this clinic, your treatment will not be affected. 
 
Who to Contact:  
Any questions you have can be asked now or at any time during the study. If you would like to 
enquire about anything at a later date, you can use any of the following contact details: [name, 
address/telephone number/e-mail]. 
Consent Form 
CONFIDENTIAL 
Study Title:  Establishing the association of Diabetes Mellitus and Insulin Resistance as key risk 
factors for Tuberculosis and Coronary Heart Diseases among euglycaemic and diabetic patients in 
Saudi Arabia. 
Principal Investigator: Fareed 
Almaleki 
Study Site: Tuberculosis and chest diseases centre in Jeddah 
 
 Please initial 
box 
1. I confirm I have read and understood the information sheet dated September 
2016, Version 1.0 for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
 
2. I understand that participation in this study is voluntary and I am free to withdraw 
consent at any time, without giving a reason, without any penalties. 
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Signing this declaration does not affect your right to decline to take part in any future study. 
 
                                _____                          
Name of participant   Date   Signature 
 
                                _____                  
Name of person taking consent  Date   Signature  
 
* All data gathered on this form and any information you provide us for the study will be 
confidential and will not be communicated to anyone outside the study team. 
 
When complete: 1 copy for participant; 1 copy (original) for research 
Participants information form for coronary heart disease patients  
 
The following information will be given to the participants: 
The purpose of the study, why the participant has been selected, a summary of the study procedure 
such as processes of data collection (e.g. questionnaires), the possible impact the research will 
have on the participant, such as side effects, risks, benefits, discomforts, data sharing, data storage, 
confidentiality, results circulation and voluntary involvement, where the participant can at any 
time withdraw themselves from the study and they will be provided with contact details of the 
appropriate person/researcher for any queries. 
 
The consent form will be distributed to men/women that attend the King Faisal Hospital, to invite 
individuals to take part in the research study on diabetes mellitus and insulin resistance as key risk 
factors for CHD among euglycaemic and diabetic patients in Saudi Arabia; Taif city. 
 
Fareed Almaleki, Liverpool School of Tropical Medicine 
Determining the association of insulin resistance and diabetes mellitus as key risk factors for 
Coronary Heart Diseases among diabetic and euglycaemic patients in Saudi Arabia. 
 
The consent form is split into two parts, and these are: 
• The research information sheet 
• The certificate of consent 
3. I understand that data collected during the study, may be looked at by individuals 
from LSTM and from regulatory authorities.  I give permission for these 
individuals to have access to my records. 
 
4. I hereby declare that I have not been subjected to any form of coercion in giving 
this consent. 
 
5. I agree to the data about me collected in this study being stored for further use in 
the future. 
 
6. I agree that my blood samples will be transported to Madain Al-Fahad Health 
Centre in Jeddah to be analysed. 
 
7. I agree to gift this blood samples for future research purpose.  
8. I agree to take part in this study.  
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The participant will receive a copy of the consent form. 
 
Introduction:  
I am [The name of the individual providing the consent form]. I work for the King Faisal Hospital, 
Taif, and I am acting on behalf of Fareed Almaleki, who studies at the Liverpool School of 
Tropical Medicine, UK. We are performing research on topical diseases and their diagnosis, in 
particular diabetes mellitus, which is highly prevalent in Saudi Arabia. We are inviting you to take 
part in our research study, however, before participating, it is important to understand what the 
study will involve and why the research is being implemented. Please have a look carefully at the 
following information and if there is anything you are unsure of, or if you would like any further 
information do not hesitate to ask any questions. You are also free to review this information with 
your GP or any friends and family, and we would like to emphasise that you should only go ahead 
with the invitation if you are happy to take part in the study. Should you agree to participate in this 
study, we will need to ask you questions regarding your medical history enquiring about previous 
and current diseases.  If you come across any words that you do not understand in this document 
or in the interview, please inform me and we will stop to ensure that it is explained to you. If you 
have any further questions at a later time you can either ask myself, the staff or the study doctor, 
while you will also be provided with the details of the contact person/researcher so that you can 
contact them regarding any queries you may have. 
 
Purpose:  
Diabetes mellitus is a frequent disease, which on a global scale affects more than 415 million 
individuals. We propose in this project that insulin resistance and diabetes are key risk factors for 
CHD and we will look for this association by studying patients in the city of Taif, Saudi Arabia. 
Insulin is a normal hormone that helps to utilise sugars.  If the body does not respond well to this 
hormone, we call it insulin resistance. 
 
Participant Selection:  
This study invites participants above the age of 18 that attend the King Faisal General Hospital in 
Taif. 
 
Voluntary Participation:  
Participation in this study is completely voluntary and it entirely up to you if you wish to 
participate, you will be given 24 hours to decide whether or not to participate. The services at this 
clinic that you currently receive will not be affected whether you decide to participate or not and If 
you do participate you can opt out at any time of the study. 
 
Procedures and Protocol: 
In order to determine if insulin resistance and diabetes increases the risk of CHD, we will invite 
347 participants. Each participant will be asked for a blood sample (10ml) so that we can assess 
their glucose levels, insulin levels, HA1c and lipid profile, which will include TG, HDL and LDL. 
To calculate IR we will use a mathematical formula, and when the results are available we will 
contact the participants by email or by phone to inform them. The participants will be asked to 
complete a questionnaire which will ask about your lifestyle, as well as weight, physical activity, 
diet and family history. There will be a nurse dedicated to measuring each participant’s height 
(cm), weight (kg), hip and waist circumference (cm) and blood pressure (BP). 
 
Risks and discomfort: 
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There will be no serious adverse effects in participating in this study; however there will be an 
interview, which will ask some personal questions. You will also be required to dedicate some 
time for the interview to take place. There will be an appropriate room with comfortable chairs 
provided and we will also ensure that the interviewer will adhere to academic principles by 
confirming that the participant is fully aware of the importance and the purpose of this study. The 
languages used in the interview will be Arabic and/or English, and the questions will be clear and 
easy to understand.   
Hematoma: In venepuncture, it is possible for the blood to leak from a vein and out under the 
skin. This may cause pain and discomfort leading to complications in drawing more blood from 
that particular site. If haematoma is observed, the tourniquet and needle must be removed and 
pressure should be applied to the site for at least 3 minutes. The site is then checked for the 
haematoma to see if it has stopped and a gauze or bandage is taped to the area for a minimum of 
half an hour. 
 
Pain: There is a small risk that during blood collection a needle may pierce the nerve. You would 
feel a mild electric sensation. If this occurs we will remove the needle and apply pressure to the 
site of the piercing. The sensation will stop and the participant will be told the reason they felt this 
pain was because the needle had touched a nerve.  
 
Samples to be collected and stored:  
Your blood samples may be used anonymously for future studies and in testing for further 
potential diabetic markers. Signing this consent form means that you will give your permission for 
us to safely store your blood for anonymous use in other future projects that are considered 
suitable. 
 
Benefits:  
By participating in this study, we will be able to detect whether or not you are diabetic and if you 
are likely to develop diabetes. Should we detect that you are diabetic, we can arrange for you to 
meet a specialist and we will also provide you with a leaflet on diabetes risk awareness.  
 
Incentives:  
There is no financial incentive for taking part in this study 
 
Confidentiality:  
The study will take place within your clinic, therefore it is likely that others within the clinic may 
become aware of your participation and question you regarding this. We would like to assure you 
that the identity and all information collected from individuals participating in this study will be 
kept confidential. Your information that is collected in this study is confidential and will only be 
accessed by research sponsors, ethics committee members and institutional officials. Any data that 
we have on you will be number coded and your name will not be used, the only individuals that 
will know your number will be the researchers and this information will be locked away with a 
key.  
 
Right to Refuse or Withdraw:  
You have the right to refuse to participate in this study and if this is the case your treatment in this 
clinic will not be affected, you will still receive any assistance that you had prior to the study. If at 
any time you wish to withdraw from the study, you may do so without the loss of any rights that 
you have as a patient at this clinic, your treatment will not be affected. 
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Who to Contact:  
Any questions you have can be asked now or at any time during the study. If you would like to 
enquire about anything at a later date, you can use any of the following contact details: [name, 
address/telephone number/e-mail]. 
Consent Form 
CONFIDENTIAL 
Study Title:  Establishing the association of Diabetes Mellitus and Insulin Resistance as key risk 
factors for Tuberculosis and Coronary Heart Diseases among euglycaemic and diabetic patients in 
Saudi Arabia. 
Principal Investigator: Fareed Almaleki Study Site: King Faisal Hospital in Taif 
 
 
Signing this declaration does not affect your right to decline to take part in any future study. 
 
                                _____                          
Name of participant   Date   Signature 
 
                                _____                  
Name of person taking consent  Date   Signature  
 
* All data gathered on this form and any information you provide us for the study will be 
confidential and will not be communicated to anyone outside the study team. 
 
When complete: 1 copy for participant; 1 copy (original) for research 
 Please initial 
box 
1. I confirm I have read and understood the information sheet dated September 
2016, Version 1.0 for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
 
2. I understand that participation in this study is voluntary and I am free to withdraw 
consent at any time, without giving a reason, without any penalties. 
 
3. I understand that data collected during the study, may be looked at by individuals 
from LSTM and from regulatory authorities.  I give permission for these 
individuals to have access to my records. 
 
4. I hereby declare that I have not been subjected to any form of coercion in giving 
this consent. 
 
5. I agree to the data about me collected in this study being stored for further use in 
the future. 
 
6. I agree that my blood samples will be transported to King Faisal Hospital in Taif 
to be analysed.  
 
7. I agree to gift this blood samples for future research purpose.  
8. I agree to take part in this study.  
D.1.
2   
CONSTRAINTS: Please outline any potential constraints to consent and indicate how you 
will reduce the impact of these constraints. 
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The study will be conducted in Saudi Arabia, the King Faisal Hospital and Tuberculosis and Chest 
Diseases Centre are belong to the Saudi MOH, which will facilitate the agreement between the 
LSTM and the MOH. The participant information sheet and the consent will be available in two 
languages Arabic and English, the interviewer will be trained to do the interview, and the researcher / 
assistance will be available to explain any inquiries about the study. 
 
 
D.2 
ASSISTANCE: Please outline any assistance (financial or otherwise) that will be offered to 
potential participants or individuals in return for their participation in this research. 
There will be no assistance offered to potential participants. We will assign a research assistance to 
help interviewing the participants using Arabic/English language, and to process the sample, we 
will reward him/her financially. 
D.3  
PRIVACY AND CONFIDENTIALITY: Please describe how participant privacy and 
confidentiality will be maintained during data collection, analysis and storage.  Please 
include what will be collected (data, samples etc.) and where and for how long it will be 
stored. 
For the primary research participants, voluntary informed consent will be sought from all willing 
participants in Arabic/English and the participants will be assured that all data will be kept 
confidential. Ethical approval will be sought from the LSTM as well as the Department of Preventive 
Medicine, Ministry of Health, Riyadh, Saudi Arabia. Each participant will be informed about the 
purpose of the study and will also be told that they are free to opt out at any time. In addition to that, 
the confidentiality and anonymity of collected data is guaranteed as all data will be stored in a coded 
format using identification numbers instead of participant names. Interview will be conducted in a 
separate room to maintain privacy. The data sheet containing the key for this code will then be 
password-protected and stored on OneDrive. The researcher will also request verbal consent from 
participants before starting and will strive to avoid inconveniencing the participant, organisation or 
community as much as possible. The participants will also be informed that they can refuse to 
answer any questions and can again opt out of the study at any time. For the secondary research, all 
the texts, data, personal and professional quotes and findings of previous works and cited studies 
would be accurately and appropriately cited along with a full reference to the work to ensure that 
any information is not compromised. The data will not be shared with any third party. These 
extensive measures are likely to cater to the ethical issues of citing secondary work as well. 
D.4 DISSEMINATION: Please outline what plans you have for dissemination of results 
The final analysis will be made and the result will be included in a PhD dissertation and possibly other 
scientific publication. 
 
SECTION E 
MAJOR ETHICAL ISSUES 
E.1  
MAJOR ETHICAL ISSUES 
Outline what you consider to be the major ethical issues involved in this research. 
Please indicate how you plan to deal with these ethical issues. 
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The study will initiate after ethical approval which will be obtained from the LSTM ethical committee 
and Department of Preventive Medicine, Ministry of Health, Riyadh, Saudi Arabia. Permission from 
Saudi Arabia Ministry of Health Preventive Medicine Directorate and from health authorities of the 
study sites will be also received prior to the start of the study. Oral and written information will be 
provided to study participants before informed consent is obtained. Those TB patients and CHD patients 
who will be found to have abnormal results referred to TB and CHD clinics for further investigation 
and appropriate management. 
 
Voluntary consent is concerned with each individual’s ability to exercise the free power of choice 
without the intervention of force, fraud, deceit, or other forms of constraint. This right to exercise choice 
is present throughout the entire research process. Being in this study is up to the patients. If the patient 
doesn’t want to be in this study, he/she will not have to participate. No effect on the routine diagnosis 
or treatment if he/she don’t want to participate or even if he/she change his/her mind later and want to 
stop. For patients not diagnosed before as diabetic but during the study we discover that they are either 
diabetic or having IR, we will arrange a speedy appointment with the endocrinologist to be evaluated 
and managed. The data collection procedures include elements where participants are asked to self-
report; some participants may not provide honest answers. To minimise that, we will try to make the 
participants fell that their input are valued and of a scientific importance. 
 
DECLARATION:   TO BE SIGNED BY MAIN APPLICANT 
Applicants must initial each declaration or tick N/A in the right hand column if 
applicable 
Initial  
(by 
hand) 
N/A 
i) I confirm that the details of this proposal are a true representation of the 
research to be undertaken. 
  
ii) I will ensure that the research does not deviate from the protocol described.   
iii) If significant protocol amendments are required as the research progresses, I 
will submit these to the Liverpool School of Tropical Medicine Research 
Ethics Committee for approval.  
  
iv) Where an appropriate mechanism exists, I undertake to seek additional in-
country Ethical Approval in the country(ies) where the research is to be 
carried out.   
  
v) I agree to abide by the ethical principles underlying the Declaration of 
Helsinki and all relevant LSTM Standard Operating Procedures (SOP) 
relating to research conduct (available on LSTM intranet at 
http://pcwww.liv.ac.uk/lstmintranet/research_management/governance_poli
ces_codes.htm or by contacting the Research Office). 
  
vi) I understand that all conditions apply to any co-applicants, researchers and 
other staff involved in the study, and that it is my responsibility to ensure that 
they abide by them. 
  
For studies over two years in duration 
vii) I will provide the Research Ethics Committee with an annual report. 
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For studies using ‘human tissue’* 
viii) I confirm I will abide by LSTM’s Policies and Standard Operating 
Procedures relating to activities involving human tissue 
* Human tissue is defined in the following link: 
http://www.hta.gov.uk/_db/_documents/List_of_materials_considered_to_be_r
elevant_material_under_the_Human_Tissue_Act_2004.pdf 
  
For studies that involve a clinical trial or participation of humans (the use of 
their data or tissue) 
ix) I confirm that I have completed a sponsorship and indemnity form 
http://pcwww.liv.ac.uk/lstmintranet/research_management/applyingforRG/i
ntro.htm 
  
I expect the project to  
commence on (Date) 
Complete by (date) 
Signed:  Date:  
 
From time to time the committee uses ethics applications for training purposes or to give 
examples to new applicants.  In all cases the applications are anonymised.  If you DO NOT 
consent to your application being used for these purposes please tick the box.      
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Appendix 2: Participant’s information form for tuberculosis patients (English 
and Arabic) 
 
Participant Information Sheets 
Participant’s information form for tuberculosis patients 
The following information was given to the participants: 
The purpose of the study, why the participant has been selected, a summary of the 
study procedure such as processes of data collection (e.g. questionnaires), the 
possible impact the research will have on the participant, such as side effects, risks, 
benefits, discomforts, data sharing, data storage, confidentiality, results circulation 
and voluntary involvement, where the participant can at any time withdraw 
themselves from the study and they will be provided with contact details of the 
appropriate person/researcher for any queries. 
 
The consent forms were distributed to the men/women that attended the centre of 
tuberculosis and chest diseases, to invite individuals to take part in the research study 
on diabetes mellitus and insulin resistance as key risk factors for tuberculosis among 
diabetic and euglycaemic patients in the city of Jeddah, Saudi Arabia. 
 
Fareed Almaleki, Liverpool School of Tropical Medicine. 
Determining the association of insulin resistance and diabetes mellitus as key 
risk factors for tuberculosis among diabetic and euglycaemic patients in Saudi 
Arabia. 
 
The consent form is split into two parts, and these are: 
 
• The research information sheet. 
• The certificate of consent. 
 
The participants then received a copy of the consent form. 
 
Introduction:  
I am [The name of the individual providing the consent form]. I work for the centre 
of tuberculosis and chest diseases, Jeddah, and I am acting on behalf of Fareed 
Almaleki, who studies at the Liverpool School of Tropical Medicine, UK. We are 
performing research on topical diseases and their diagnosis, in particular diabetes 
mellitus, which is highly prevalent in Saudi Arabia. We are inviting you to take part 
in our research study, however, before participating, it is important to understand 
what the study will involve and why the research is being implemented. Please have 
a look carefully at the following information and if there is anything you are unsure 
of, or if you would like any further information do not hesitate to ask any questions. 
You are also free to review this information with your GP or any friends and family, 
and we would like to emphasise that you should only go ahead with the invitation if 
you are happy to take part in the study. Should you agree to participate in this study, 
we will need to ask you questions regarding your medical history enquiring about 
previous and current diseases.  If you come across any words that you do not 
understand in this document or in the interview, please inform me and we will stop to 
ensure that it is explained to you. If you have any further questions at a later time you 
can either ask myself, the staff or the study doctor, while you will also be provided 
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with the details of the contact person/researcher so that you can contact them 
regarding any queries you may have. 
 
Purpose:  
Diabetes mellitus is a frequent disease, which on a global scale affects more than 415 
million individuals. We propose in this project that insulin resistance and diabetes 
are key risk factors for tuberculosis and we will look for this association by studying 
patients in the city of Jeddah, Saudi Arabia. Insulin is a normal hormone that helps to 
utilise sugars.  If the body does not respond well to this hormone, we call it insulin 
resistance. 
 
Participant Selection:  
This study invites participants above the age of 18 that attend the tuberculosis and 
chest diseases centre. 
 
Voluntary Participation:  
Participation in this study is completely voluntary and it entirely up to you if you 
wish to participate, you will be given 24 hours to decide whether or not to 
participate. The services at this clinic that you currently receive will not be affected 
whether you decide to participate or not and If you do participate you can opt out at 
any time of the study. 
 
Procedures and Protocol: 
In order to determine if insulin resistance and diabetes increases the risk of 
tuberculosis, we will invite 175 participants. Each participant will be asked for a 
blood sample (10ml) so that we can assess their glucose levels, insulin levels, HA1c 
and lipid profile, which will include TG, HDL and LDL. To calculate IR we used a 
HOMA calculator, and when the results are available we will contact the participants 
by email or by phone to inform them. The participants will be asked to complete a 
questionnaire which will ask about your lifestyle, as well as weight, physical activity, 
diet and family history. There was a nurse dedicated to measuring each participant’s 
height (cm), weight (kg), hip and waist circumference (cm) and blood pressure (BP). 
 
Risks and discomfort: 
There will be no serious adverse effects in participating in this study; however there 
will be an interview, which asked some personal questions. You will also be required 
to dedicate some time for the interview to take place. There will be an appropriate 
room with comfortable chairs provided and we will also ensure that the interviewer 
will adhere to academic principles by confirming that the participant is fully aware of 
the importance and the purpose of this study. The languages used in the interview will 
be Arabic and/or English, and the questions will be clear and easy to understand.   
 
Hematoma: In venepuncture, it is possible for the blood to leak from a vein and out 
under the skin. This may cause pain and discomfort leading to complications in 
drawing more blood from that particular site. If haematoma is observed, the 
tourniquet and needle must be removed and pressure should be applied to the site for 
at least 3 minutes. The site is then checked for the haematoma to see if it has stopped 
and a gauze or bandage is taped to the area for a minimum of half an hour. 
 
 234 
Pain: There is a small risk that during blood collection a needle may pierce the 
nerve. You would feel a mild electric sensation. If this occurs we will remove the 
needle and apply pressure to the site of the piercing. The sensation will stop and the 
participant will be told the reason they felt this pain was because the needle had 
touched a nerve.  
 
Samples to be collected and stored:  
Your blood samples may be used anonymously for future studies and in testing for 
further potential diabetic markers. Signing this consent form means that you will 
give your permission for us to safely store your blood for anonymous use in other 
future projects that are considered suitable. 
 
Benefits:  
By participating in this study, we will be able to detect whether or not you are 
diabetic and if you are likely to develop diabetes. Should we detect that you are 
diabetic, we can arrange for you to meet a specialist and we will also provide you 
with a leaflet on diabetes risk awareness.  
 
Incentives:  
There is no financial incentive for taking part in this study 
 
Confidentiality:  
The study will take place within your clinic, therefore it is likely that others within 
the clinic may become aware of your participation and question you regarding this. 
We would like to assure you that the identity and all information collected from 
individuals participating in this study will be kept confidential. Your information that 
is collected in this study is confidential and will only be accessed by research 
sponsors, ethics committee members and institutional officials. Any data that we 
have on you will be number coded and your name will not be used, the only 
individuals that will know your number will be the researchers and this information 
will be locked away with a key.  
 
Right to Refuse or Withdraw:  
You have the right to refuse to participate in this study and if this is the case your 
treatment in this clinic will not be affected, you will still receive any assistance that 
you had prior to the study. If at any time you wish to withdraw from the study, you 
may do so without the loss of any rights that you have as a patient at this clinic, your 
treatment will not be affected. 
 
Who to Contact:  
Any questions you have can be asked now or at any time during the study. If you 
would like to enquire about anything at a later date, you can use any of the following 
contact details: [name, address/telephone number/e-mail]. 
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TB Arabic version patient information sheet 
 
 236 
 
 237 
 
  
 238 
Appendix 3: Consent form (English and Arabic) 
Consent form (English) 
CONFIDENTIAL 
Study Title:  Establishing the association of Diabetes Mellitus and Insulin Resistance as key 
risk factors for Tuberculosis and Coronary Heart Diseases among euglycaemic and diabetic 
patients in Saudi Arabia. 
Principal Investigator: Fareed 
Almaleki 
Study Site: Tuberculosis and chest diseases centre in 
Jeddah 
 
 
Signing this declaration does not affect your right to decline to take part in any future 
study. 
 
                                                                  
Name of participant   Date   Signature 
                                                                  
Name of person taking consent  Date   Signature  
* All data gathered on this form and any information you provide us for the study 
will be confidential and will not be communicated to anyone outside the study team. 
 
When complete: 1 copy for participant; 1 copy (original) for research 
  
 Please 
initial 
box 
9. I confirm I have read and understood the information sheet dated September 2016, 
Version 1.0 for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
 
10. I understand that participation in this study is voluntary and I am free to withdraw 
consent at any time, without giving a reason, without any penalties. 
 
11. I give permission for the researcher and his supervisors only to have access to my 
records. 
 
12. I hereby declare that I have not been subjected to any form of coercion in giving this 
consent. 
 
13. I agree to the data about me collected in this study being stored for further use in the 
future. 
 
14. I agree that my blood samples will be transported to Madain Al-Fahad Health Centre 
in Jeddah to be analysed. 
 
15. I agree to gift this blood samples for future research purpose.  
16. I agree to take part in this study.  
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Consent form (Arabic) 
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Appendix 4: Participant’s information form for coronary heart disease patients 
(English and Arabic) 
 
Participant’s information form for coronary heart disease patients  
The following information was given to the participants: 
The purpose of the study, why the participant has been selected, a summary of the 
study procedure such as processes of data collection (e.g. questionnaires), the 
possible impact the research will have on the participant, such as side effects, risks, 
benefits, discomforts, data sharing, data storage, confidentiality, results circulation 
and voluntary involvement, where the participant can at any time withdraw 
themselves from the study and they will be provided with contact details of the 
appropriate person/researcher for any queries. 
 
The consent form was distributed to the men/women that attended the King Faisal 
Hospital, to invite individuals to take part in the research study on diabetes mellitus 
and insulin resistance as key risk factors for CHD among euglycaemic and diabetic 
patients in Saudi Arabia; Taif city. 
 
Fareed Almaleki, Liverpool School of Tropical Medicine 
Determining the association of insulin resistance and diabetes mellitus as key 
risk factors for Coronary Heart Diseases among diabetic and euglycaemic 
patients in Saudi Arabia. 
The consent form is split into two parts, and these are: 
• The research information sheet 
• The certificate of consent 
 
The participants then received a copy of the consent form. 
Introduction:  
I am [The name of the individual providing the consent form]. I work for the King 
Faisal Hospital, Taif, and I am acting on behalf of Fareed Almaleki, who studies at 
the Liverpool School of Tropical Medicine, UK. We are performing research on 
topical diseases and their diagnosis, in particular diabetes mellitus, which is highly 
prevalent in Saudi Arabia. We are inviting you to take part in our research study, 
however, before participating, it is important to understand what the study will 
involve and why the research is being implemented. Please have a look carefully at 
the following information and if there is anything you are unsure of, or if you would 
like any further information do not hesitate to ask any questions. You are also free to 
review this information with your GP or any friends and family, and we would like 
to emphasise that you should only go ahead with the invitation if you are happy to 
take part in the study. Should you agree to participate in this study, we will need to 
ask you questions regarding your medical history enquiring about previous and 
current diseases.  If you come across any words that you do not understand in this 
document or in the interview, please inform me and we will stop to ensure that it is 
explained to you. If you have any further questions at a later time you can either ask 
myself, the staff or the study doctor, while you will also be provided with the details 
of the contact person/researcher so that you can contact them regarding any queries 
you may have. 
 
  
 241 
Purpose:  
Diabetes mellitus is a frequent disease, which on a global scale affects more than 415 
million individuals. We propose in this project that insulin resistance and diabetes 
are key risk factors for CHD and we will look for this association by studying 
patients in the city of Taif, Saudi Arabia. Insulin is a normal hormone that helps to 
utilise sugars.  If the body does not respond well to this hormone, we call it insulin 
resistance. 
 
Participant Selection:  
This study invites participants above the age of 18 that attend the King Faisal 
Hospital in Taif. 
 
Voluntary Participation:  
Participation in this study is completely voluntary and it entirely up to you if you 
wish to participate, you will be given 24 hours to decide whether or not to 
participate. The services at this clinic that you currently receive will not be affected 
whether you decide to participate or not and If you do participate you can opt out at 
any time of the study. 
 
Procedures and Protocol: 
In order to determine if insulin resistance and diabetes increases the risk of CHD, we 
will invite 347 participants. Each participant will be asked for a blood sample (10ml) 
so that we can assess their glucose levels, insulin levels, HA1c and lipid profile, 
which will include TG, HDL and LDL. To calculate IR we will use a HOMA 
calculator, and when the results are available we will contact the participants by 
email or by phone to inform them. The participants will be asked to complete a 
questionnaire which will ask about your lifestyle, as well as weight, physical activity, 
diet and family history. There will be a nurse dedicated to measuring each 
participant’s height (cm), weight (kg), hip and waist circumference (cm) and blood 
pressure (BP). 
 
Risks and discomfort: 
There will be no serious adverse effects in participating in this study; however there 
will be an interview, which will ask some personal questions. You will also be 
required to dedicate some time for the interview to take place. There will be an 
appropriate room with comfortable chairs provided and we will also ensure that the 
interviewer will adhere to academic principles by confirming that the participant is 
fully aware of the importance and the purpose of this study. The languages used in the 
interview will be Arabic and/or English, and the questions will be clear and easy to 
understand.   
Hematoma: In venepuncture, it is possible for the blood to leak from a vein and out 
under the skin. This may cause pain and discomfort leading to complications in 
drawing more blood from that particular site. If haematoma is observed, the 
tourniquet and needle must be removed and pressure should be applied to the site for 
at least 3 minutes. The site is then checked for the haematoma to see if it has stopped 
and a gauze or bandage is taped to the area for a minimum of half an hour. 
Pain: There is a small risk that during blood collection a needle may pierce the 
nerve. You would feel a mild electric sensation. If this occurs we will remove the 
needle and apply pressure to the site of the piercing. The sensation will stop and the 
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participant will be told the reason they felt this pain was because the needle had 
touched a nerve.  
 
Samples to be collected and stored:  
Your blood samples may be used anonymously for future studies and in testing for 
further potential diabetic markers. Signing this consent form means that you will 
give your permission for us to safely store your blood for anonymous use in other 
future projects that are considered suitable. 
 
Benefits:  
By participating in this study, we will be able to detect whether or not you are 
diabetic and if you are likely to develop diabetes. Should we detect that you are 
diabetic, we can arrange for you to meet a specialist and we will also provide you 
with a leaflet on diabetes risk awareness.  
 
Incentives:  
There is no financial incentive for taking part in this study 
 
Confidentiality:  
The study will take place within your clinic, therefore it is likely that others within 
the clinic may become aware of your participation and question you regarding this. 
We would like to assure you that the identity and all information collected from 
individuals participating in this study will be kept confidential. Your information that 
is collected in this study is confidential and will only be accessed by research 
sponsors, ethics committee members and institutional officials. Any data that we 
have on you will be number coded and your name will not be used, the only 
individuals that will know your number will be the researchers and this information 
will be locked away with a key.  
 
Right to Refuse or Withdraw:  
You have the right to refuse to participate in this study and if this is the case your 
treatment in this clinic will not be affected, you will still receive any assistance that 
you had prior to the study. If at any time you wish to withdraw from the study, you 
may do so without the loss of any rights that you have as a patient at this clinic, your 
treatment will not be affected. 
 
Who to Contact:  
Any questions you have can be asked now or at any time during the study. If you 
would like to enquire about anything at a later date, you can use any of the following 
contact details: [name, address/telephone number/e-mail]. 
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CHD Arabic version patient information sheet 
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Appendix 5: Consent forms (English and Arabic) 
 
Consent Form (English) 
CONFIDENTIAL 
Study Title:  Establishing the association of Diabetes Mellitus and Insulin Resistance as 
key risk factors for Tuberculosis and Coronary Heart Diseases among euglycaemic and 
diabetic patients in Saudi Arabia. 
Principal Investigator: Fareed 
Almaleki 
Study Site: King Faisal Hospital in Taif 
 
Signing this declaration does not affect your right to decline to take part in any future 
study. 
 
                                                                  
Name of participant   Date   Signature 
                                                                  
Name of person taking consent  Date   Signature 
 
* All data gathered on this form and any information you provide us for the study 
will be confidential and will not be communicated to anyone outside the study team. 
 
When complete: 1 copy for participant; 1 copy (original) for research. 
  
 Please 
initial 
box 
1. I confirm I have read and understood the information sheet dated 
September 2016, Version 1.0 for the above study. I have had the 
opportunity to consider the information, ask questions and have had 
these answered satisfactorily. 
 
2. I understand that participation in this study is voluntary and I am free to 
withdraw consent at any time, without giving a reason, without any 
penalties. 
 
3. I give permission for the researcher and his supervisors only to have 
access to my records. 
 
4. I hereby declare that I have not been subjected to any form of coercion 
in giving this consent. 
 
5. I agree to the data about me collected in this study being stored for 
further use in the future. 
 
6. I agree that my blood samples will be transported to King Faisal 
Hospital in Taif to be analysed.  
 
7. I agree to gift this blood samples for future research purpose.  
8. I agree to take part in this study.  
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Consent form (Arabic) 
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Appendix 6: Ethical approval (LSTM) 
 
 
 249 
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Appendix 7: Ethical approval (MOH-Saudi Arabia) 
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Appendix 8: TB participants questionnaire 
 
Establishing the association of Diabetes and Insulin Resistance as 
risk factors for Tuberculosis and Coronary Heart Diseases in Saudi 
Arabia. 
 
Tuberculosis Group 
Participant information 
Participant name  
 
Participant 
number 
 
 
Date of birth d d m m y y y y 
 
File number  
 
Mobile number    
Address    
 
 
 
Demographic characteristics 
Age             (Years)  
 
Sex (Male 1, Female 2)  
 
Marital status   (Single=1, with partner/married=2, divorced/separated=3, widowed=4)  
 
Education          (No education=0, Literacy =1, primary=2, Intermediate= 3, secondary=4, higher 
education=5, prefer not to answer=6) 
 
 
Occupation     (Governmental=1, private=2, labourer=3, not employed=4, retired=5, other=6)  
 
Country of origen  
 
Lifestyle 
Describe your job (Sedentary=1 Moderate Physical Activity =2 Physically Very Demanding=3)  
 
Describe your annual income during in the past 3 years (≤ 3000=1 3000-5000=2 5001-10000=3 
≥10000=4) 
 
 
How would you rate your stress level? (Low=1, Medium=2, High=3)  
 
Is anyone in your family overweight? (Yes=1 No=2 Don’t know=3 Prefer not to say =4)  
 
If yes, who?  Father ☐   Mother☐   Sibling☐    Grandfather☐   Other☐  
Where you overweight as a child? (Yes=1 No=2 Don’t know=3)  
 
Do you smoke?  
 
  
 
Diet  
How many of the last seven days have you had breakfast? (1 – 7 Days) 
 
 
How many of the last seven days have you had lunch? (1 – 7 Days) 
 
 
How many of the last seven days have you had dinner? (1 – 7 Days)  
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How would you rate your diet? Good ☐            Fair ☐            Poor ☐  
How often do you eat fast food such as 
burgers, fish and chips, fried chicken or 
pizza? 
0‐1 Times/Month ☐ 
2‐3 Times/Month ☐    
1‐2 Times/Week ☐ 
3‐4 Times/Week ☐ 
5+ Times/Wek ☐ 
Describe your daily food portions?  Small ☐                Intermediate ☐       Large ☐ 
 
 
 
 
Physical activity 
Think about all the vigorous activities that you did in the last 7 days. Vigorous physical 
activities refer to activities that take hard physical effort and make you breathe much harder 
than normal. Think only about those physical activities that you did for at least 10 minutes at a 
time. 
During the last 7 days, on how many days did you do 
vigorous physical activities like heavy lifting, digging, or 
aerobics?  
 
 Days per week 
  
No vigorous physical activities  Skip the next question  
How much time did you usually spend doing vigorous 
physical activities on one of those days? 
 
 Hours per day 
 Minutes per day 
 Don’t know/Not sure  
 
Think about all the moderate activities that you did in the last 7 days. Moderate activities 
refer to activities that take moderate physical effort and make you breathe somewhat harder 
than normal. Think only about those physical activities that you did for at least 10 minutes at a 
time. 
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During the last 7 days, on how many days did you do 
moderate physical activities like carrying light loads?  Do not 
include walking. 
 
 Days per week 
  
No moderate physical activities              Skip the next question 
How much time did you usually spend doing moderate physical 
activities on one of those days? 
 
 
 Hours per day 
 Minutes per day 
 Don’t know/Not sure  
Think about the time you spent walking in the last 7 days.  This includes at work and at home, 
walking to travel from place to place, and any other walking that you have done solely for 
recreation, sport, exercise, or leisure. 
During the last 7 days, on how many days did you walk for at 
least 10 minutes at a time?   
 
 Days per week 
  
No walking              Skip the next question 
How much time did you usually spend walking on one of those 
days? 
 
 
 Hours per day 
 Minutes per day 
 Don’t know/Not sure  
Include time spent at work, at home, while doing course work and during leisure time.  This may 
include time spent sitting at a desk, visiting friends, reading, or sitting or lying down to watch 
television. 
During the last 7 days, how much time did you spend sitting on 
a week day? 
 
 Hours per day 
 Minutes per day 
 Don’t know/Not sure  
 
 
Medical history 
(Yes=1, No=2, Don’t know=3, Not 
applicable = 4) 
Have you been diagnosed with diabetes?  
 
If yes, do you take insulin injection?  
 
Do you have a family history of diabetes?  
 
If yes, is this a relative of First degree ☐   Second degree ☐   Third degree ☐ 
Do you have high blood pressure (hypertension)?  
 
If yes, do you take medication for high blood pressure?  
 
Do you have high levels of cholesterol?  
 
If yes, do you take lipid lowering therapy?  
 
Do you have heart problems?   
 
(For females) Have you had a history of gestational diabetes?  
 
(For females) Do you have polycystic ovaries?  
 
Do you have Cancer/leukemia   
 
Have you had an intestinal bypass or gastrectomy?  
 
Have you had an organ transplant?  
 
Are you HIV positive?  
 
Do you have a weakened immune system or recurrent infections?  
 
Have you been taking steroids?  
 
Are you taking any of the following medicines?   
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Enbrel☐             Humira☐            Cimza☐            Remicade☐            Simponi☐              
Thalomid☐ 
 
 
Symptoms   
(Yes=1, No=2, Don’t 
know=3) 
Have you had recently (last two weeks) any of the following symptoms?  
Chest discomfort  
 
Sputum   
 
Cough  
 
Sputum with blood  
 
Shortness of breath  
 
Fever  
 
Night sweats   
 
Poor appetite  
 
Unexpected weight loss  
 
 
Anthropometry 
Height (cm)                                                                          
 
Body Mass Index (BMI = kg/m2)  
 
Weight (kg)                                                                           
 
Waist/Hip Ratio (WHR)              
 
Waist (cm)                                                                                               
 
Systolic blood pressure (mmHg)       
 
Hip (cm)                                                                                                  
 
Diastolic blood pressure (mmHg)  
 
 
Blood tests measurements  
Fasting plasma glucose level (mg/dL)   
 
Haemoglobin A1c (%)  
 
Fasting plasma insulin level (µU/ml)   
 
HOMA-IR  
 
Total cholesterol (mg/dL)  
 
Triglycerides (mg/dL)  
 
HDL Cholesterol (mg/dL)  
 
LDL Cholesterol (mg/dL)  
 
 
TB results                                                                                                    (Positive, Negative 
and Not done) 
TB Bacteriologically confirmed  
 
Acid fast bacilli smear positive   
 
Chest x-ray cavitation   
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Appendix 9: CHD participants questionnaire 
 
Establishing the association of Diabetes and Insulin Resistance as 
risk factors for Tuberculosis and Coronary Heart Diseases in Saudi 
Arabia. 
 
 
Coronary Heart Disease Group 
Participant information 
Participant name  
 
Participant 
number 
 
 
Date of birth d d m m y y y y 
 
File number  
 
Mobile number    
Address    
 
 
Demographic characteristics 
Age             (Years)   
 
Sex (Male 1, Female 2)  
 
Marital status   (Single=1, with partner/married=2, divorced/separated=3, widowed=4)  
 
Education       (No education=0, Literacy =1, primary=2, Intermediate= 3, secondary=4, higher 
education=5, prefer not to answer=6) 
 
 
Occupation     (Governmental=1, private=2, labourer=3, not employed=4, retired=5, other=6)  
 
Country of origen   
 
  
Lifestyle 
Describe your job (Sedentary=1 Moderate Physical Activity =2 Physically Very Demanding=3)  
 
Describe your annual income during in the past 3 years (≤ 3000=1 3000-5000=2 5001-10000=3 
≥10000=4) 
 
 
On a scale of 1-10, how would you rate your stress level? (Low=1, Medium=2, High=3)  
 
Is anyone in your family overweight? (Yes=1 No=2 Don’t know=3 Prefer not to say =4)  
 
If yes, who?  Father ☐   Mother☐   Sibling☐    Grandfather☐   Other☐  
Where you overweight as a child? (Yes=1 No=2 Don’t know=3)  
 
Do you smoke? (Yes=1 No=2 Prefer not to say =3)  
 
If yes, how many cigarette pre day?    1-10 ☐         11-20 ☐            >21 ☐ 
 
Diet  
How many of the last seven days have you had breakfast? (1 – 7 Days) 
 
 
How many of the last seven days have you had lunch? (1 – 7 Days) 
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How many of the last seven days have you had dinner? (1 – 7 Days)  
 
 
How would you rate your diet? Good☐           Fair☐           Poor☐  
How often do you eat fast food such as 
burgers, fish and chips, fried chicken or 
pizza? 
0‐1 times/month ☐ 
2‐3 times/month ☐    
1‐2 times/week ☐ 
3‐4 times/week ☐ 
5+ times/week ☐ 
Describe your daily food portions?  Small ☐            Intermediate ☐        Large ☐ 
 
 
 
Physical activity 
Vigorous physical activities refer to activities that take hard physical effort and make you 
breathe much harder than normal. Think only about those physical activities that you did for 
at least 10 minutes at a time. 
During the last 7 days, on how many days did you do 
vigorous physical activities like heavy lifting, digging, or 
aerobics?  
 
 Days per week 
  
No vigorous physical activities  Skip the next question  
How much time did you usually spend doing vigorous 
physical activities on one of those days? 
 
 Hours per day 
 Minutes per day 
 Don’t know/Not sure  
 
Moderate activities refer to activities that take moderate physical effort and make you breathe 
somewhat harder than normal. Think only about those physical activities that you did for at 
least 10 minutes at a time. 
During the last 7 days, on how many days did you do 
moderate physical activities like carrying light loads?  Do 
not include walking. 
 
 Days per week 
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No moderate physical activities              Skip the next question 
How much time did you usually spend doing moderate physical 
activities on one of those days? 
 
 
 Hours per day 
 Minutes per day 
 Don’t know/Not sure  
Think about the time you spent walking in the last 7 days.  This includes at work and at 
home, walking to travel from place to place, and any other walking that you have done solely 
for recreation, sport, exercise, or leisure. 
During the last 7 days, on how many days did you walk for 
at least 10 minutes at a time?   
 
 Days per week 
  
No walking              Skip the next question 
How much time did you usually spend walking on one of those 
days? 
 
 
 Hours per day 
 Minutes per day 
 Don’t know/Not sure  
Include time spent at work, at home, while doing course work and during leisure time.  This may 
include time spent sitting at a desk, visiting friends, reading, or sitting or lying down to watch 
television. 
During the last 7 days, how much time did you spend sitting on 
a week day? 
 
 Hours per day 
 Minutes per day 
 Don’t know/Not sure  
 
 
 
Medical history (Yes=1, No=2, Don’t know=3, Not applicable = 4) 
Have you been diagnosed with diabetes?  
 
If yes, do you take insulin injection?  
 
Do you have a family history of diabetes?  
 
If yes, is this a relative of First degree ☐   Second degree ☐   Third degree ☐ 
Do you have high blood pressure (hypertension)?  
 
If yes, do you take medication for high blood pressure?  
 
Do you have high levels of cholesterol?  
If yes, do you take lipid lowering therapy?  
 
(For females) Have you had a history of gestational diabetes?  
 
(For females) Do you have polycystic ovaries?  
 
 
Anthropometric 
Height (cm)                                                                          
 
Body Mass Index (BMI = kg/m2)  
 
Weight (kg)                                                                           
 
Waist/Hip Ratio (WHR)              
 
Waist (cm)                                                                                               
 
Systolic blood pressure (mmHg)       
 
Hip (cm)                                                                                                  
 
Diastolic blood pressure (mmHg)  
 
 
Blood tests measurements  
Fasting plasma glucose level (mg/dL)  
 
 
Haemoglobin A1c (%) 
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Fasting plasma insulin level (µU/ml) 
 
 
HOMA-IR 
 
 
Total cholesterol (mg/dL) 
 
 
Triglycerides (mg/dL) 
 
 
HDL Cholesterol (mg/dL) 
 
 
LDL Cholesterol(mg/dL) 
 
 
 
Diagnosis  
What is the clinical 
diagnosis? 
 
Diagn
osis  
…………………………………………………………………………...…………………………………………
……………………….……………………………...... 
When the patient has 
been diagnosis? 
d d m m y y y y 
 
Is there any surgical 
intervention? 
☐ Yes                                 ☐ No 
If yes, when? d d m m y y y y 
 
 
Current clinical 
condition  
☐ Problem solved surgically. 
☐ Problem solved with medicine. 
☐ 2 and 3 combined. 
 261 
 
 
  
 262 
Appendix 10: English version of the WHO-QoL-BREF (WHOQoL-BREF) 
questionnaire 
 
Establishing the association of Diabetes and Insulin Resistance as 
risk factors for Tuberculosis and Coronary Heart Diseases in Saudi 
Arabia. 
 
English version of the WHO-QoL-BREF (WHOQoL-BREF) questionnaire 
 
 
The following questions ask how you feel about your quality of life, health, or 
other areas of your life. I will read out each question to you, along with the 
response options. Please choose the answer that appears most appropriate. 
If you are unsure about which response to give to a question, the first response 
you think of is often the best one. 
 
 
Please keep in mind your standards, hopes, pleasures and concerns. We ask 
that you think about your life in the last four weeks. 
 
 
  
 
Very poor 
 
 
Poor 
 
Neither 
poor nor 
good 
 
 
Good 
 
 
Very good 
 
1. 
 
How would you rate 
your quality of life? 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
  
 
  
 
Very 
dissatisfie
d 
 
 
Dissatisfied 
 
Neither 
satisfied 
nor 
dissatisfied 
 
 
Satisfied 
 
 
Very 
satisfie
d 
 
2. 
 
How satisfied are you with 
your health? 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
  
The following questions ask about how much you have experienced certain 
things in the last four weeks. 
 
  
 
Not at all 
 
 
A little 
 
A 
moderate 
amount 
 
 
Very much 
 
An 
extreme 
amount 
 3. 
 
To what extent do you feel 
that physical pain prevents 
you fromdoing what you 
need to do? 
 
 
 
5 
 
 
 
4 
 
 
 
3 
 
 
 
2 
 
 
 
1 
 
4. 
 
How much do you need 
any medical treatment to 
function in your daily life? 
 
 
5 
 
 
4 
 
 
3 
 
 
2 
 
 
1 
 
5. 
 
How much do you enjoy life? 
 
1 
 
2 
 
3 
 
4 
 
5 
 6. 
 
To what extent do you feel 
your life to be meaningful? 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
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Not at all 
 
 
A little 
 
A 
moderate 
amount 
 
 
Very much 
 
 
Extremely 
 
7. 
 
How well are you able 
to concentrate? 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
8. 
 
How safe do you feel in 
your daily life? 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
9. 
 
How healthy is your 
physical environment? 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
  
The following questions ask about how completely you experience or were 
able to do certain things in the last four weeks. 
 
Not at all   A little Moderately Mostly Completely 
 
  
 
Not at all 
 
 
A little 
 
 
Moderately 
 
 
Mostly 
 
 
Completely 
 10. 
 
Do you have enough energy 
for everyday life? 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
11. 
 
Are you able to accept 
your bodily appearance? 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
12. 
 
Have you enough money 
to meet your needs? 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
13. 
 
How available to you is 
the information that you 
need in your day-to-day 
life? 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
14. 
 
To what extent do you have 
the opportunity for leisure 
activities? 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
  
 
Very poor 
 
 
Poor 
 
Neither 
poor nor 
good 
 
 
Good 
 
 
Very good 
 15. 
 
How well are you able to 
get around? 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
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Very 
dissatisfie
d 
 
 
Dissatisfied 
 
Neither 
satisfied 
nor 
dissatisfied 
 
 
Satisfied 
 
 
Very 
satisfie
d 
 16. 
 
How satisfied are you with 
your sleep? 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
17. 
 
How satisfied are you 
with your ability to 
perform your daily living 
activities? 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
18. 
 
How satisfied are you 
with your capacity for 
work? 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
19. 
 
How satisfied are you 
with yourself? 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
 
20. 
 
How satisfied are you with 
your personal relationships? 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
21. 
 
How satisfied are you 
with your marriage 
relationship? 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
22. 
 
How satisfied are you with 
the support you get from 
your friends? 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
23. 
 
How satisfied are you with 
the conditions of your living 
place? 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
24. 
 
How satisfied are you with 
your access to health services? 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
25. 
 
How satisfied are you 
with your transport? 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
  
The following question refers to how often you have felt or experienced 
certain things in the last four weeks. 
 
  
 
Never 
 
 
Seldom 
 
 
Quite often 
 
 
Very often 
 
 
Always 
 
26. 
 
How often do you have 
negative feelings such as 
blue mood, despair, 
anxiety, depression? 
 
 
 
5 
 
 
 
4 
 
 
 
3 
 
 
 
2 
 
 
 
1 
 
 
 
 
 
 
 
  
 265 
 
Appendix 11: Arabic version of the WHO-QoL-BREF (WHOQoL-BREF) 
questionnaire 
 
Arabic version of the WHO-QoL-BREF (WHOQoL-BREF) questionnaire 
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Appendix 12: Notification & Medical report of TB case 
 
 
 
 
 269 
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Appendix 13: TB Logistic regression tables 
 
TB Logistic regression tables 
 
Demographic characteristics AOR (95% C.I.) p 
Gender  Male  1 
Female 0.802 (0.439 - 1.465) 0.473 
Age  
18 - 29 1 
30 – 39 1.198 (0.564 - 2.544) 0.639 
40 – 49 0.464 (0.201 - 1.070) 0.072 
≥ 50 0.371 (0.172 - 0.800) 0.011 
Ethnicity Non-Saudi 1 
Saudi 0.287 (0.171 - 0.481) ˂ 0.001 
Marital status Married 1 
Not married 1.100 (0.564 - 2.148) 0.779 
Education Educated 1 
Non-Educated 1.894 (1.037 - 3.458) 0.038 
Occupation Not employed 1 
Employed 1.332 (0.740 - 2.397) 0.339 
 Constant 0.625 0.253 
 
Medical history AOR (95% C.I.) p 
Diabetes No  1 
Yes  3.295 (1.587 - 6.842) 0.001 
Don’t know 0.206 (0.022 - 1.928) 0.166 
Family history of 
diabetes 
No 1 
Yes 0.657 (0.389 - 1.111) 0.117 
Hypertension No 1 
Yes 0.149 (0.021 - 1.047) 0.056 
Don’t know 0.458 (0.060 - 3.502) 0.452 
Takes hypertensive 
medication 
Yes 1 
No  0.343 (0.043 - 2.706) 0.310 
Hyperlipidaemia No 1 
Yes 0.200 (0.047 - 0.856) 0.030 
Don’t know 0.149 (0.019 - 1.166) 0.070 
Takes lipid lowering 
therapy 
No 1 
Yes 0.843 (0.139 - 5.103) 0.853 
Don’t know 2.182 (0.112 - 42.348) 0.606 
Polycystic ovaries Yes 1 
No 44 0.999 
Don’t know 66 0.999 
Not applicable 35 0.999 
 Constant 0.000 0.999 
 
Lifestyle and diet AOR (95% C.I.) p 
Monthly income ≤ 3000 1 
3000 - 5000 1.294 (0.600 - 2.793)  0.511 
5001 - 10000 0.402 (0.104 - 1.558) 0.187 
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≥ 10000 0.000 (0.000) 0.999 
Level of stress Low 1 
Medium 0.867 (0.395 - 1.901) 0.721 
High 3.555 (0.785 - 16.103) 0.100 
Family overweight Yes 1 
No 0.718 (0.293 - 1.757) 0.468 
Don’t know 10 (0.000) 1.000 
Prefer not to say 0.000 (0.000) 1.000 
If yes, who? Father (No) 1 
Father (Yes) 0.455 (0.084 - 2.453) 0.360 
Number of dinner 
meals last week 
Never  1 
1 – 6/per week 93 (0.000) 0.999 
Always 95 (0.000) 0.999 
Participant self-
rating the diet 
quality 
   
Good  1 
Fair 19.127 (8.401 - 43.545) ˂ 0.001 
Poor 30.228 (11.058 - 82.628) ˂ 0.001 
Fast food 
consumption 
0 - 1/Month 1 
2 - 3/Month 2.082 (0.946 - 4.580) 0.068 
1 - 2/Week 2.350 (1.009 - 5.470) 0.048 
3 - 4/Week 0.906 (0.377 - 2.177) 0.825 
≥ 5 /Week 1.461 (0.583 - 3.660) 0.418 
 Constant 0.000 0.999 
 
Anthropometry AOR (95% C.I.) p 
WHR Low 1 
Moderate 1.064 0.615 - 1.840) 0.825 
High 1.006 (0.473 - 2.139) 0.988 
BMI ≤ 18.4 1 
18.5 - 24.9 0.540 (0.244 - 1.197) 0.129 
25 - 29.9 0.179 (0.076 - 0.423) ˂ 0.001 
≥ 30 0.119 (0.047 - 0.301) ˂ 0.001 
 Constant 3.765 0.000 
 
Metabolic/clinical characteristics AOR (95% C.I.) p 
FBG (mg/dL) 
< 110 1 
110 – 125 3.151 (1.086 - 9.138) 0.035 
≥ 126 3.244 (1.132 - 9.294) 0.028 
HA1c (%) 
< 5.7  1 
≥ 5.7 – 6.4  0.518 (0.280 - 0.957) 0.036 
≥ 6.5 0.552 (0.211 - 1.443) 0.226 
Fasting Plasma 
Insulin (µU/ml) 
2 – < 25   
≥ 25 0.660 (0.312 - 1.396) 0.277 
Total cholesterol 
(mg/dL) 
< 150  1 
≥ 150 1.233 (0.553 - 2.751) 0.609 
 272 
 
Triglycerides 
(mg/dL) 
< 150  1 
< 200  0.789 (0.368 - 1.690) 0.542 
≥ 200  0.400 (0.144 - 1.114) 0.080 
LDL (mg/dL) 
< 100  1 
≥ 100  1.371 (0.705 - 2.665) 0.352 
HDL 
Optimal 1 
Risky 0.530 (0.309 - 0.909) 0.021 
Systolic BP  0.987 (0.972 - 1.003) 0.109 
Diastolic BP  0.998 (0.973 -1.025) 0.909 
 Constant 6.827 0.018 
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Appendix 14: CHD Logistic regression tables 
 
CHD Logistic regression tables 
 
Demographic characteristics AOR (95% C.I.) p 
Gender  Female 1 
Male 2.907 (1.302 - 6.492) 0.009 
Age 18 – 39 1 
40 – 49 0.014 (0.002 - 0.084) ˂ 0.001 
50 – 59 0.004 (0.001 - 0.027) ˂ 0.001 
60 – 69 0.002 (0.000 - 0.014) ˂ 0.001 
≥ 70 0.001 (0.000 - 0.009) ˂ 0.001 
Ethnicity Non-Saudi 1 
Saudi 4.480 (2.189 - 9.169) ˂ 0.001 
Marital status Single 1 
With partner/married 3.712 (1.081 - 12.742) 0.037 
Divorced/separated 0.112 (0.003 - 4.451) 0.244 
Widowed 0.577 (0.088 - 3.780) 0.567 
Education No education 1 
Literacy 0.374 (0.122 - 1.152) 0.087 
Primary education 0.123 (0.038 - 0.397) ˂ 0.001 
Intermediate education 1.093 (0.304 - 3.924) 0.892 
Secondary education 0.371 (0.113 - 1.221) 0.103 
Higher education 0.296 (0.066 - 1.321) 0.111 
Occupation Not Employed 1 
Employed 1.109 (0.500 - 2.457) 0.800 
 Constant 26.825 0.001 
 
Medical history AOR (95% C.I.) p 
Diabetes No 1 
Yes 17.103 (1.970 - 148.516) 0.010 
Don't know 60.674 (3.267 - 1126.908) 0.006 
Diabetes using 
insulin 
No 1 
Yes 10.749 (1.187 - 97.306) 0.035 
Family history of 
diabetes 
No   
Yes 1.623 (0.802 - 3.286) 0.178 
Hypertension No 1 
Yes 0.537 (0.138 - 2.092) 0.370 
Don't know 5.657 (0.060 - 537.758) 0.456 
Takes hypertensive 
medication 
No  
Yes 23.567 (6.278 - 88.466) ˂ 0.001 
Hyperlipidaemia No 1 
Yes 0.386 (0.101 - 1.472) 0.163 
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Don't know 0.526 (0.090 - 3.062) 0.475 
Takes lipid 
lowering therapy 
No 1 
Yes 28.625 (7.352 - 111.441) ˂ 0.001 
Don't know 32.977 (2.441 - 445.460) 0.008 
History of 
gestational diabetes 
No 1 
Yes 0.972 (0.130 - 7.297) 0.978 
Polycystic ovaries 
No 1 
Yes 1.872 (0.149 - 23.540) 0.627 
Don’t know 2.175 (0.053 - 88.857) 0.682 
Not applicable 0.451 (0.002 - 83.703) 0.765 
 Constant 0.003 0.016 
 
Lifestyle and diet AOR (95% C.I.) p 
Type of job 
Sedentary 1 
Moderate Physical 
Activity 
16.182 (5.748 - 45.561) ˂ 0.001 
Physically Very 
Demanding 
15.955 (0.776 - 328.266) 0.073 
Monthly 
income 
≤ 3000 1 
3000 - 5000 0.446 (0.202 - 0.982) 0.045 
5001 - 10000 0.167 (0.052 - 0.533) 0.003 
≥ 10000 0.064 (0.007 - 0.547) 0.012 
Level of stress Low 1 
Medium 0.364 (0.165 - 0.803) 0.012 
High 0.102 (0.016 - 0.660) 0.017 
Overweight 
among family 
No 1 
Yes 2.125 (0.919 - 4.915) 0.078 
Don’t know 1.839 (0.000) 1.000 
Prefer not to say 35 (0.000) 0.999 
Overweight as 
a child 
No 1 
Yes 1.165 (0.403 - 3.366) 0.778 
Don’t know 0.000 (0.000) 0.999 
Smoking No   
Yes 1.175 (0.426 - 3.243) 0.756 
Past smoker No 1 
Yes 0.152 (0.056 - 0.408) ˂ 0.001 
Number of 
breakfast 
meals last 
week 
1 3.676 (0.165 - 81.987) 0.411 
2 1.269 (0.106 - 15.185) 0.851 
3 2.222 (0.269 - 18.332) 0.458 
4 8.706 (0.624 - 121.541) 0.108 
5 3.190 (0.213 - 47.757) 0.401 
6 42 (0.000) 1.000 
7 0.461 (0.077 - 2.748) 0.395 
1 32.727 (0.000) 1.000 
2 36 (0.000) 0.999 
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Number of 
lunch meals 
last week 
3 73 (0.000) 0.999 
4 33 (0.000) 0.999 
5 29 (0.000) 0.999 
6 42 (0.000) 0.999 
7 14 (0.000) 0.999 
Number of 
dinner meals 
last week 
1 0.175 (0.003 - 10.809) 0.408 
2 0.048 (0.000 - 6.984) 0.231 
3 3.150 (0.202 - 49.127) 0.413 
4 2.385 (0.093 - 61.355) 0.600 
5 0.673 (0.007 - 64.003) 0.865 
6 0.535 (0.052 - 5.475) 0.598 
   
Participant 
rating of 
his/her diet 
Good 1 
Fair 0.040 (0.017 - 0.096) ˂ 0.001 
Poor 0.012 (0.004 - 0.042) ˂ 0.001 
Fast food 
consumption 
0 ‐ 1 Times/Month 1 
2 ‐ 3 Times/Month 0.760 (0.304 - 1.901) 0.557 
1 ‐ 2 Times/Week 2.847 (1.123 - 7.218) 0.027 
3 ‐ 4 Times/Week 6.221 (2.127 - 18.200) 0.001 
≥ 5 Times/Week 4.466 (1.224 - 16.292) 0.023 
 Constant 0.000 0.999 
 
Anthropometry AOR (95% C.I.) p 
WHR 
Low 1 
Moderate 0.120 (0.058 - 0.245) ˂ 0.001 
High 0.026 (0.012 - 0.057) ˂ 0.001 
BMI 
≤ 18.4 1 
18.5 - 24.9 0.000 (0.000) 0.999 
25 - 29.9 0.000 (0.000) 0.999 
≥ 30 0.000 (0.000) 0.999 
 Constant 161 0.999 
 
 
Metabolic/Clinical characteristic AOR (95% C.I.) p 
FPG (mg/dL) 
< 110 1 
110 – 125 0.368 (0.131 - 1.029) 0.057 
≥ 126  0.222 (0.098 - 0.502) ˂ 0.001 
HA1c (%) 
< 5.7 % 1 
≥ 5.7 – 6.4 1.082 (0.565 - 2.070) 0.813 
≥ 6.5% 0.802 (0.349 - 1.845) 0.604 
Fasting Plasma Insulin (µU/ml) 
2 – < 25   
≥ 25 1.172 (0.583 - 2.357) 0.655 
Total cholesterol (mg/dL) 
< 150 1 
≥ 150 4.185 (2.043 - 8.571) ˂ 0.001 
 276 
 
Triglycerides (mg/dL) 
< 150  1 
< 200  0.439 (0.205 - 0.942) 0.035 
≥ 200  0.638 (0.305 - 1.335) 0.233 
LDL (mg/dL) 
< 70 1 
≥ 70 1.009 (0.438 - 2.321) 0.984 
HDL (mg/dL) 
Optimal 1 
Risky 1.165 (0.664 - 2.044) 0.594 
Systolic BP  0.983 (0.968 - 0.999) 0.034 
Diastolic BP  0.942 (0.916 - 0.968) ˂ 0.001 
 Constant 305.852 0.000 
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Appendix 15: CHD Logistic regression tables for CHD-IR cases and CHD-
controls 
 
CHD-IR cases and CHD-controls 
 
Demographic characteristics AOR (95% C.I.) p 
Gender  Female 1 
Male 0.780 (0.286 - 2.130) 0.628 
Age  
18 – 39 1 
40 – 49 0.813 (0.039 - 16.752) 0.893 
50 – 59 0.671 (0.035 - 12.716) 0.790 
60 – 69 1.232 (0.064 - 23.795) 0.890 
≥ 70 0.334 (0.016 - 7.186) 0.484 
Ethnicity Non-Saudi 1 
Saudi 3.994 (0.949 - 16.809) 0.059 
Occupation Not employed 1 
Employed 1.650 (0.539 – 5.050) 0.380 
 Constant 0.321 0.493 
 
Medical history AOR (95% C.I.) p 
Family history of 
diabetes 
No 1 
Yes 1.718 (0. 771 - 3.831) 0.185 
Hypertension No 1 
Yes 0.515 (0.219 - 1.215) 0.130 
 Constant 0.505 0.035 
 
Lifestyle and diet AOR (95% C.I.) p 
Monthly income ≤ 3000 1 
3000-5000 0.480 (0.152 - 1.520) 0.212 
5001-10000 0.996 (0.290 - 3.421) 0.995 
≥10000 10.620 (1.066 - 105.797) 0.044 
Level of stress Low 1 
Medium 1.129 (0.434 - 2.934) 0.803 
High 0.000 (0.000) 0.999 
Family overweight No 1 
Yes 2.326 (0.831 - 6.536) 0.108 
Overweight as a 
child 
Yes 1 
No 1.258 (0.325 - 4.878) 0.739 
Don’t know 0.000 (0.000)  1.000 
Past smoker No 1 
Yes 0.721 (0.242 - 2.149) 0.557 
Number of 
breakfast meals 
last week 
Never 1 
1 – 6 0.296 (0.032 - 2.717) 0.282 
Always 0.298 (0.045 - 1.959) 0.208 
Fast food 
consumption 
0 - 1/Month 1 
2 - 3/Month 1.596 (0.560 - 4.550) 0.382 
1 - 2/Week 0.473 (0.100 - 2.240) 0.346 
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3 - 4/Week 0.859 (0.149 - 4.946) 0.865 
≥ 5 /Week 0.462 (0.038 - 5.627) 0.545 
 Constant 3.908 0.250 
 
 
Anthropometry (Male) AOR (95% C.I.) p 
WHR Low 1 
Moderate 0.288 (0.020 - 4.163) 0.361 
High 0.637 (0.046 - 8.854) 0.737 
BMI 18.5 - 24.9 1 
25 - 29.9 2.380 (0.533 - 10.626) 0.256 
≥ 30 4.341 (0.963 - 19.562) 0.056 
 Constant 0.365 0.433 
 
 
 
Anthropometry (Female) AOR (95% C.I.) p 
WHR Moderate 1 
High 1.369 (0.094 - 19.861) 0.818 
BMI 18.5 - 24.9 1 
25 - 29.9 1.048 (0.047 - 23.394) 0.976 
≥ 30 6.921 (0.556 - 86.142) 0.133 
 Constant 0.121 0.108 
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Appendix 16: CHD Logistic regression tables for CHD-diabetic cases and CHD-
controls 
CHD-diabetic cases and CHD-controls 
Demographic characteristics AOR (95% C.I.) p 
Gender  Female 1 
Male 0.854 (0.384 - 1.901) 0.700 
Age < 50 1 
50 – 59 2.370 (0.847 - 6.632) 0.100 
60 – 69 2.556 (0.895 - 7.303) 0.080 
≥ 70 2.477 (0.804 - 7.627) 0.114 
Ethnicity Non-Saudi 1 
Saudi 2.213 (0.959 - 5.105) 0.053 
Marital status Single 1 
With partner/married 0.371 (0.114 - 1.209) 0.100 
Divorced/separated 33 (0.000) 0.999 
Widowed 0.414 (0.096 - 1.776) 0.235 
Education No education 1 
Literacy 3.801 (1.328 - 10.882) 0.013 
Primary education 3.121 (1.146 - 8.501) 0.026 
Intermediate education 3.285 (0.798 - 13.525) 0.100 
Secondary education 3.291 (1.047 - 10.342) 0.041 
Higher education 2.875 (0.590 - 14.003) 0.191 
Occupation Not Employed 1 
Employed 1.439 (0.683 – 3.021) 0.338 
 Constant 0.695 0.687 
 
Medical history AOR (95% C.I.) p 
Family history of 
diabetes 
No 1 
Yes 3.610 (2.079 - 6.289) 0.000 
History of gestational 
diabetes 
Yes 1 
No 0.000 (0.000) 0.999 
Don’t know 0.000 (0.000) 0.999 
Not applicable 0.000 (0.000) 0.999 
 Constant 1918 0.999 
 
 
Medical history AOR (95% C.I.) p 
Family history of 
diabetes 
No 1 
Yes 1.541 (0.502 - 4.739) 0.450 
History of 
gestational diabetes 
Without Not  
Yes 1 
No 0.000 (0.000) 0.999 
Don’t know 0.000 (0.000) 0.999 
 Constant 1683 0.999 
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Lifestyle and diet 
AOR (95% C.I.) p 
Overweight 
among family 
No 1 
Yes 1.449 (0.780 – 2.695) 0.241 
Don’t know 44 (0.000) 1.000 
Overweight as a 
child 
No 1 
Yes 2.237 (0.957 – 5.236) 0.063 
Don’t know 0.394 (0.035 - 4.425) 0.451 
Fast food 
consumption 
0 ‐ 1 Times/Month 1 
2 ‐ 3 Times/Month 0.643 (0.321 - 1.288) 0.213 
1 ‐ 2 Times/Week 0.388 (0.187 - 0.807) 0.011 
3 ‐ 4 Times/Week 0.460 (0.153 - 1.381) 0.166 
≥ 5 Times/Week 0.677 (0.195 - 2.354) 0.540 
 Constant 9.241 0.000 
 
Anthropometry (Male) AOR (95% C.I.) p 
WHR 
Low 1 
Moderate 0.545 (0.105 - 2.828) 0.470 
High 0.741 (0.141 - 3.890) 0.723 
BMI 
18.5 - 24.9 1 
25 - 29.9 1.241 (0.574 - 2.680) 0.583 
≥ 30 1.540 (0.686 - 3.457) 0.295 
 Constant 3.057 0.171 
 
Anthropometry (Female) AOR (95% C.I.) p 
WHR 
Low 1 
Moderate 0.000 (0.000) 0.999 
High 0.000 (0.000) 0.999 
BMI 
18.5 - 24.9 1 
25 - 29.9 4.172 (0.954 - 18.239) 0.058 
≥ 30 6.385 (1.604 - 25.414) 0.009 
 Constant 674740571 0.999 
 
 
Metabolic/Clinical characteristic AOR (95% C.I.) p 
Triglycerides (mg/dL) 
< 150 1 
< 200  1.370 (0.658 - 2.854) 0.400 
≥ 200  3.206 (1.376 - 7.471) 0.007 
LDL (mg/dL) 
< 70 1 
≥ 70  0.689 (0.346 - 1.373) 0.290 
HDL (mg/dL) 
Optimal 1 
Risky 1.590 (0.869 - 2.910) 0.132 
Systolic BP  1.009 (0.995 - 1.023) 0.190 
 Constant 0.618 0.658 
 
